Methods and compositions for macrophage polarization
Extracellular vesicles with immunomodulatory components repolarize macrophages from M2 to M1 phenotype, addressing the need for enhanced anti-cancer immune responses by increasing inflammatory cytokines and reducing immunosuppressive cytokines, thus improving cancer treatment.
Patent Information
- Application Number
- JP2024154757
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-02-12
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-28
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for improved immunomodulatory methods and compositions that promote macrophage polarization from an M2 phenotype to an M1 phenotype to enhance anti-cancer immune responses, as M2 macrophages exhibit cancer-promoting activities and M1 macrophages exhibit anti-cancer activities.
Extracellular vesicles, such as exosomes, containing immunomodulatory components like nucleic acids (e.g., inhibitory RNA) selectively repolarize macrophages from an M2 phenotype to an M1 phenotype by targeting genes such as KRAS, HRAS, and STAT3, and can include additional components like immune checkpoint inhibitors.
The extracellular vesicles effectively repolarize macrophages to the M1 phenotype, increasing the production of inflammatory cytokines and chemokines, enhancing tumor cell recognition and attack, and reducing immunosuppressive cytokines, thereby improving cancer treatment outcomes.
Smart Images

Figure 2024166292000035 
Figure 2024166292000036 
Figure 2024166292000037
Abstract
Description
[Technical field]
[0001] The present invention relates to compositions and methods comprising extracellular vesicles carrying gene-targeting nucleic acids, which result in macrophage polarization of tumor-associated macrophages. [Background technology]
[0002] Immunotherapy is the treatment of disease by inducing, enhancing, or suppressing an immune response. Cancer immunotherapy usually has fewer side effects than traditional cancer therapies such as chemotherapy and radiation therapy. In one approach, cancer immunotherapy has been used to stimulate a patient's own macrophages to attack cancer cells. Macrophages exhibit different phenotypes, e.g., macrophages can be cancer-promoting or macrophages can have anti-cancer activity. The M2 phenotype, or "alternatively activated macrophages," typically exhibits cancer-promoting activities, such as suppression of the immune system and production of extracellular matrix and tissue remodeling activities. The M1 phenotype, or "classically activated macrophages," typically exhibits anti-cancer activities, such as phagocytosis of tumor cells and stimulation of adaptive immunity so that tumor cells can be recognized and attacked. Improved immunomodulatory methods and compositions that promote macrophage polarization (i.e., conversion to the M1 phenotype) are needed. Summary of the Invention [Means for solving the problem]
[0003] Embodiments of the present disclosure include extracellular vesicles comprising one or more immunomodulatory component(s) that, upon contact with a macrophage, selectively repolarize the macrophage from an M2 phenotype to an M1 phenotype. In some embodiments, the present disclosure includes extracellular vesicles that are exosomes comprising one or more immunomodulatory components that, upon contact with a macrophage, selectively repolarize the macrophage from an M2 phenotype to an M1 phenotype.
[0004] In some embodiments, the extracellular vesicles, e.g., exosomes, comprise one or more immunomodulatory component(s) that, upon contact with a macrophage, selectively repolarize the macrophage from an M2 phenotype to an M1 phenotype, and the immunomodulatory component(s) is a nucleic acid, e.g., an inhibitory RNA, e.g., an antisense RNA, siRNA, shRNA, miRNA, lncRNA, pri-miRNA or pre-miRNA, or, e.g., an antisense oligonucleotide (ASO), or, e.g., the immunomodulatory component is an antisense oligonucleotide comprising a sequence at least 95% identical to a sequence selected from SEQ ID NOs: 1-6.
[0005] In some embodiments, the extracellular vesicles, e.g., exosomes, comprise one or more immunomodulatory component(s) that selectively repolarize macrophages from an M2 phenotype to an M1 phenotype upon contact with macrophages, and the immunomodulatory (component) is, e.g., a nucleic acid, e.g., an inhibitory RNA, e.g., an antisense RNA, siRNA, shRNA, miRNA, lncRNA, pri-miRNA or pre-miRNA, or, e.g., an antisense oligonucleotide (ASO), or, e.g., the immunomodulatory component is an antisense oligonucleotide comprising a sequence at least 95% identical to a sequence selected from SEQ ID NOs: 1-6. and wherein the at least one gene is selected from the group consisting of KRAS, HRAS, NRAS, HIF1-alpha, HIF1-beta, Sp1, P300, LKB1, AMPK, STAT3, STAT6, n-MYC, c-MYC, HCAR1, A2AB, IDO, TDO, arginase, glutaminase, CEBP / β, Pi3Kγ, and PKM2, e.g., STAT3, STAT6, CEBP / β, Pi3Kγ, KRAS, and HIF1-alpha, e.g., STAT3, e.g., KRAS.
[0006] In some embodiments, the extracellular vesicles, e.g., exosomes, comprise one or more immunomodulatory component(s) that, upon contact with macrophages, selectively repolarize the macrophages from an M2 phenotype to an M1 phenotype, and the immunomodulatory component is an antisense oligonucleotide targeting STAT3.
[0007] In some embodiments, the extracellular vesicles, e.g., exosomes, comprise one or more immunomodulatory component(s) that, upon contact with macrophages, selectively repolarize the macrophages from an M2 phenotype to an M1 phenotype, and the immunomodulatory component is an antisense oligonucleotide targeting KRAS.
[0008] In some embodiments, the extracellular vesicles, e.g., exosomes, comprise one or more immunomodulatory component(s) that selectively repolarize macrophages from an M2 phenotype to an M1 phenotype upon contact with macrophages, the immunomodulatory component being an antibody that selectively binds to KRAS, e.g., wild-type human KRAS, or wild-type human KRAS and mouse KRAS. G12D The inhibitory RNA also targets a target gene, such as an antisense RNA, siRNA, shRNA, miRNA, lncRNA, pri-miRNA, or pre-miRNA.
[0009] In any of the above embodiments, the extracellular vesicles, e.g., exosomes, comprise one or more immunomodulatory component(s), e.g., a nucleic acid, an inhibitory RNA, an antisense RNA, an siRNA, an shRNA, an miRNA, an lncRNA, a pri-miRNA or a pre-miRNA, or an ASO, that selectively repolarize a macrophage from an M2 phenotype to an M1 phenotype upon contact with the macrophage, and the macrophage is a tumor (e.g., a pancreatic tumor) resident macrophage.
[0010] In any of the above embodiments, the extracellular vesicles, e.g., exosomes, comprise one or more immunomodulatory component(s), e.g., a nucleic acid, an inhibitory RNA, an antisense RNA, an siRNA, an shRNA, an miRNA, an lncRNA, a pri-miRNA or a pre-miRNA, or an ASO, that selectively repolarize macrophages from an M2 phenotype to an M1 phenotype upon contact with macrophages, and further comprise an additional immunomodulatory component, e.g., a small molecule drug, an antibody or an active fragment thereof, e.g., an immune checkpoint inhibitor that binds to CTLA-4, PD-1, or PD-L1, or an inhibitor that binds to CSF1-R, or a therapeutic protein or an active fragment thereof.
[0011] In any of the above embodiments, the extracellular vesicles, e.g., exosomes, upon contact with macrophages, contain one or more immune modulating component(s), e.g., a nucleic acid, an inhibitory RNA, an antisense RNA, an siRNA, an shRNA, an miRNA, an lncRNA, a pri-miRNA or a pre-miRNA, or an ASO, that selectively repolarize macrophages from an M2 phenotype to an M1 phenotype, and an additional immune modulating component, e.g., an antibody or an active fragment thereof, e.g., an immune checkpoint inhibitor or CS that binds to CTLA-4, PD-1, or PD-L1. The present invention further includes an inhibitor that binds to F1-R, wherein the antibody or active fragment thereof is at least 95% identical to the CDR of ipilimumab, or at least 95% identical to the CDR of nivolumab, or at least 95% identical to the CDR of cemiplimab, or at least 95% identical to the CDR of pembrolizumab, or at least 95% identical to the CDR of atezolizumab, or at least 95% identical to the CDR of avelumab, or at least 95% identical to the CDR of durvalumab, or at least 95% identical to the CDR of pexidartinib, or PLX748. or at least 95% identical to the CDRs of ipilimumab, nivol ... , cemiplimab, pembrolizumab, atezolizumab, avelumab, durvalumab, pexidartinib, PLX7486, ARRY-382, JNJ-40346527, BLZ945, emactuzumab, AMG820, IMC-CS4 and cabilalizumab, or the antibody or active fragment thereof is at least one antibody selected from the group consisting of ipilimumab, nivolumab, cemiplimab, pembrolizumab, atezolizumab, avelumab, durvalumab, pexidartinib, PLX7486, ARRY-382, JNJ-40346527,At least one antibody that competes for binding with an antibody selected from the group consisting of BLZ945, emactuzumab, AMG820, IMC-CS4, and cabilalizumab.
[0012] The extracellular vesicles, e.g., exosomes, upon contact with macrophages, contain one or more immune modulating component(s), e.g., a nucleic acid, an inhibitory RNA, an antisense RNA, an siRNA, an shRNA, an miRNA, an lncRNA, a pri-miRNA or a pre-miRNA, or an ASO, that selectively repolarize macrophages from an M2 phenotype to an M1 phenotype, and further contain an additional immune modulating component, e.g., an antibody or an active fragment thereof, e.g., an immune checkpoint inhibitor that binds to CTLA-4, PD-1, or PD-L1, or an inhibitor that binds to CSF1-R. wherein the antibody or active fragment thereof is at least 95% identical to the CDRs of ipilimumab, or at least 95% identical to the CDRs of nivolumab, or at least 95% identical to the CDRs of cemiplimab, or at least 95% identical to the CDRs of pembrolizumab, or at least 95% identical to the CDRs of atezolizumab, or at least 95% identical to the CDRs of avelumab, or at least 95% identical to the CDRs of durvalumab, or at least 95% identical to the CDRs of pexidartinib, or at least 95% identical to the CDRs of PLX7486. or the antibody or active fragment thereof comprises a CDR that is identical to, or at least 95% identical to, the CDR of ARRY-382, or at least 95% identical to, the CDR of JNJ-40346527, or at least 95% identical to, the CDR of BLZ945, or at least 95% identical to, the CDR of emactuzumab, or at least 95% identical to, the CDR of AMG820, or at least 95% identical to, the CDR of IMC-CS4, or at least 95% identical to, the CDR of cabilalizumab, or the antibody or active fragment thereof is selected from the group consisting of ipilimumab, nivolumab, cemiplimab, pembrolizumab, or the antibody or active fragment thereof is at least one antibody selected from the group consisting of ipilimumab, nivolumab, cemiplimab, pembrolizumab, atezolizumab, avelumab, durvalumab, pexidartinib, PLX7486, ARRY-382, JNJ-40346527, BLZ945, emactuzumab, AMG820, IMC-CS4 and cabilalizumab.In any of the above embodiments, which is at least one antibody that competes for binding with an antibody selected from the group consisting of AMG820, IMC-CS4, and cabilalizumab, it further comprises PTGFRN or a fragment thereof, and the antibody or fragment thereof may optionally be fused to PTGFRN or a fragment thereof.
[0013] In any of the above aspects, the comparison is determined using an assay selected from the group consisting of an extracellular vesicle uptake assay, a target gene expression assay, a downstream gene expression assay, a cytokine release assay, and a macrophage cell surface protein assay.
[0014] In any of the above aspects, the M2 macrophage is a tumor-associated macrophage selected from the group consisting of M2a, M2b, and M2c macrophages.
[0015] In any of the above aspects, the M1 macrophages exhibit increased secretion of proinflammatory cytokines and chemokines selected from the group consisting of INFγ, IL-12, IL-23, TNFα, IL-6, IL-1, CSCL9, CXCL10 and CXCL11 compared to pre-polarized M2 macrophages, and / or exhibit decreased secretion of immunosuppressive cytokines and chemokines selected from the group consisting of IL-10, TGFβ, PGE2, CCL2, CCL17, CCL18, CCL22 and CCL24 compared to pre-polarized M2 macrophages, and / or express increased tumor associated antigens compared to pre-polarized M2 macrophages, and / or exhibit decreased CD8 + Increases stimulation of T cells and / or natural killer cells.
[0016] In aspects, the present disclosure encompasses pharmaceutical compositions comprising extracellular vesicles, e.g., exosomes, that comprise one or more immunomodulatory component(s) that, upon contact with macrophages, selectively repolarize the macrophages from an M2 phenotype to an M1 phenotype.
[0017] In some aspects, the present disclosure encompasses a method of treating a disease (e.g., cancer such as, for example, pancreatic cancer) in a patient (e.g., a human) in need thereof comprising administering (e.g., via a route selected from the group consisting of intravenous, intraperitoneal, and intratumoral administration) an extracellular vesicle of any of the above aspects, e.g., an exosome comprising one or more immunomodulatory component(s) (e.g., an inhibitory RNA targeting a proto-oncogene (e.g., KRAS)) that, upon contact with a macrophage, selectively repolarizes the macrophage from the M2 phenotype to the M1 phenotype of any of the above aspects; or administering a pharmaceutical composition comprising an extracellular vesicle of any of the above aspects, e.g., an exosome comprising one or more immunomodulatory component(s) that, upon contact with a macrophage, selectively repolarizes the macrophage from the M2 phenotype to the M1 phenotype of any of the above aspects.
[0018] In some aspects, the disclosure encompasses the methods of treatment described above and further includes a second therapy, such as surgery, chemotherapy, radiation therapy, cryotherapy, hormone therapy, or immunotherapy.
[0019] In some aspects, the disclosure encompasses methods of modulating gene expression in macrophages comprising contacting macrophages with extracellular vesicles comprising one or more immunomodulatory components that inhibit at least one gene, thereby increasing macrophage polarization from an M2 to an M1 phenotype compared to contacting the macrophages with an equimolar amount(s) of the immunomodulatory component(s) alone.
[0020] In some embodiments, a method of modulating gene expression in macrophages comprises contacting macrophages in vivo or in vitro with extracellular vesicles comprising one or more immunomodulatory components that inhibit at least one gene, thereby increasing macrophage polarization from an M2 to an M1 phenotype compared to contacting the macrophages with an equimolar amount(s) of the immunomodulatory component(s) alone.
[0021] In some aspects, a method of modulating gene expression in macrophages comprises contacting macrophages in vivo (e.g., by administering the extracellular vesicles to a subject, e.g., a human subject, by a route selected from the group consisting of intravenous, intraperitoneal, and intratumoral administration) with extracellular vesicles comprising one or more immunomodulatory components that inhibit at least one gene, thereby increasing macrophage polarization from an M2 to an M1 phenotype, compared to contacting the macrophages with an equimolar amount(s) of the immunomodulatory component(s) alone.
[0022] In some aspects, the subject of the above disclosed methods of modulating gene expression in macrophages is suffering from a condition selected from cancer (e.g., pancreatic cancer) and fibrosis.
[0023] In some embodiments, the extracellular vesicles used in any of the above disclosed methods of modulating gene expression in macrophages are exosomes and the immunomodulatory component is a nucleic acid, e.g., an inhibitory RNA such as an antisense RNA, siRNA, shRNA, miRNA, lncRNA, pri-miRNA or pre-miRNA.
[0024] In some embodiments, the extracellular vesicle used in any of the above disclosed methods of regulating gene expression in macrophages is an exosome and the immunomodulatory component is a nucleic acid, e.g., an ASO.
[0025] In some embodiments, the extracellular vesicles used in any of the above disclosed methods of regulating gene expression in macrophages are exosomes, the immunomodulatory component is a nucleic acid, e.g., an antisense oligonucleotide comprising a sequence 95% identical to a sequence selected from SEQ ID NOs: 1-6 or an antisense oligonucleotide comprising a sequence selected from SEQ ID NOs: 1-6, and at least one gene is selected from the group consisting of KRAS, HRAS, NRAS, HIF1-alpha, HIF1-beta, Sp1, P300, LKB1, AMPK, STAT3, STAT6, n-MYC, c-MYC, HCAR1, A2AB, IDO, TDO, arginase, glutaminase, CEBP / β, Pi3Kγ, and PKM2, or from STAT3, STAT6, CEBP / β, Pi3Kγ, KRAS, and HIF1-alpha, or is STAT3, or is KRAS, and in the case of KRAS, the immunomodulatory component can optionally be an inhibitory RNA targeting wild-type human KRAS.
[0026] In some aspects, the disclosure provides a method of treating pancreatic cancer in a subject comprising administering to the subject an extracellular vesicle comprising an inhibitory RNA targeting human wild-type KRAS, the treatment increasing the rate of polarization of tumor-resident macrophages from an M2 phenotype to an M1 phenotype by inhibiting the expression of human KRAS. G12D to levels higher than those observed in patients treated with inhibitory RNA targeting
[0027] In some aspects, the disclosure provides the aforementioned method of treating pancreatic cancer in a subject, wherein the percentage of tumor-resident macrophages polarization is determined using an ex vivo assay of tumor-resident macrophages obtained from a tumor sample.
[0028] Provided herein are compositions and methods comprising extracellular vesicles selected, enriched or engineered with one or more immunomodulatory components capable of modifying the activity of macrophages, promoting the switching of macrophages from an M2 to an M1 phenotype (macrophage polarization), and enhancing a patient's immune system in the fight against cancer.
[0029] Thus, in a first aspect, extracellular vesicles are provided herein that contain one or more immune-modulating components, such as nucleic acid molecules that inhibit at least one gene in target cells. In certain embodiments, the target cells are macrophages, and gene inhibition increases macrophage polarization from M2 phenotype to M1 phenotype compared to an equimolar amount of immune-modulating component(s) alone. In certain embodiments, the extracellular vesicles are exosomes. In certain embodiments, the nucleic acid is an inhibitory RNA. In certain embodiments, the inhibitory RNA is an antisense RNA, siRNA, shRNA, miRNA, lncRNA, pri-miRNA or pre-miRNA. In certain embodiments, the at least one gene is selected from the group consisting of KRAS, HRAS, NRAS, HIF1-alpha, HIF1-beta, Sp1, P300, LKB1, AMPK, STAT3, STAT6, n-MYC, c-MYC, HCAR1, A2AB, IDO, TDO, arginase, glutaminase, CEBP / β, Pi3Kγ, and PKM2. In certain embodiments, the gene is KRAS. In certain embodiments, the nucleic acid is an inhibitory RNA targeting wild-type human KRAS. In certain embodiments, the inhibitory RNA also targets mouse Kras G12D In certain embodiments, the macrophages are tumor-resident macrophages. In certain embodiments, the cancer is pancreatic cancer. In certain embodiments, the extracellular vesicles further comprise an additional immunomodulatory component. In certain embodiments, the additional immunomodulatory component is a small molecule drug, an antibody, or a therapeutic protein. In certain embodiments, the antibody is an immune checkpoint inhibitor. In certain aspects, provided herein are pharmaceutical compositions comprising any of the above extracellular vesicles.
[0030] In certain aspects, described herein are methods of treating a disease in a patient in need thereof, comprising administering to the patient an extracellular vesicle or pharmaceutical composition described herein, thereby treating the disease in the patient. In certain embodiments, the disease is cancer. In certain embodiments, the cancer is pancreatic cancer. In some embodiments, the disease is a fibrotic condition. In some embodiments, the fibrotic condition is pulmonary fibrosis, liver fibrosis, or pancreatic fibrosis. In certain embodiments, the liver fibrosis is nonalcoholic steatohepatitis, or NASH. In certain embodiments, the patient is a human. In certain embodiments, the nucleic acid is an inhibitory RNA that targets a proto-oncogene. In certain embodiments, the proto-oncogene is human KRAS. In certain embodiments, the cancer is pancreatic cancer. In certain embodiments, the method further comprises performing at least a second therapy. In certain embodiments, the second therapy comprises surgery, chemotherapy, radiation therapy, cryotherapy, hormone therapy, or immunotherapy.
[0031] In certain embodiments, the M2 macrophages are tumor-associated macrophages selected from the group consisting of M2a, M2b, and M2c macrophages. In certain embodiments, the M1 macrophages exhibit increased secretion of proinflammatory cytokines and chemokines selected from the group consisting of INFγ, IL-12, IL-23, TNFα, IL-6, IL-1, CSCL9, CXCL10, and CXCL11 compared to pre-polarized M2 macrophages. In certain embodiments, the M1 macrophages exhibit decreased secretion of immunosuppressive cytokines and chemokines selected from the group consisting of IL-10, TGFβ, PGE2, CCL2, CCL17, CCL18, CCL22, and CCL24 compared to pre-polarized M2 macrophages. In certain embodiments, the M1 macrophages express increased tumor-associated antigens compared to pre-polarized M2 macrophages. In certain embodiments, the M1 macrophages express increased CD8 + Increases stimulation of T cells and / or natural killer cells.
[0032] In certain aspects, described herein are methods of treating pancreatic cancer in a subject, comprising administering to the subject extracellular vesicles comprising inhibitory RNA targeting human wild-type KRAS, wherein the treatment reduces the rate of polarization of tumor-resident macrophages from an M2 phenotype to an M1 phenotype by increasing the proportion of tumor-resident macrophages that are polarized to an M1 phenotype by increasing the proportion of tumor-resident macrophages that are polarized to an M1 phenotype by increasing the proportion of tumor-resident macrophages that are polarized to an M2 phenotype by increasing the proportion of tumor-resident macrophages that are polarized ... G12D to levels higher than those observed in patients treated with inhibitory RNA targeting In certain embodiments, for example, the following are provided: (Item 1) An extracellular vesicle comprising one or more immunomodulatory component(s), which upon contact with a macrophage selectively repolarizes said macrophage from an M2 phenotype to an M1 phenotype. (Item 2) The extracellular vesicle of item 1, wherein the one or more immunomodulatory component(s) inhibits at least one macrophage target gene. (Item 3) The extracellular vesicle according to item 1 or 2, wherein the extracellular vesicle is an exosome. (Item 4) The extracellular vesicle according to any one of items 1 to 3, wherein the immunomodulatory component is a nucleic acid. (Item 5) The extracellular vesicle of item 4, wherein the nucleic acid is an inhibitory RNA. (Item 6) The extracellular vesicle of item 5, wherein the inhibitory RNA is an antisense RNA, an siRNA, an shRNA, an miRNA, an lncRNA, a pri-miRNA or a pre-miRNA. (Item 7) The extracellular vesicle of item 4, wherein the nucleic acid is an antisense oligonucleotide (ASO). (Item 8) 8. The extracellular vesicle according to any one of items 1 to 7, wherein the immunomodulatory component inhibits at least one gene selected from the group consisting of KRAS, HRAS, NRAS, HIF1-alpha, HIF1-beta, Sp1, P300, LKB1, AMPK, STAT3, STAT6, n-MYC, c-MYC, HCAR1, A2AB, IDO, TDO, arginase, glutaminase, CEBP / β, Pi3Kγ, and PKM2. (Item 9) The extracellular vesicle of item 8, wherein the at least one gene is selected from the group consisting of STAT3, STAT6, CEBP / β, Pi3Kγ, KRAS, and HIF1-alpha. (Item 10) 10. The extracellular vesicle according to item 9, wherein the immunomodulatory component is an antisense oligonucleotide comprising a sequence that is at least 95% identical to a sequence selected from SEQ ID NOs: 1 to 6. (Item 11) 11. The extracellular vesicle according to item 10, wherein the immunomodulatory component is an antisense oligonucleotide comprising a sequence selected from SEQ ID NOs: 1 to 6. (Item 12) The extracellular vesicle of item 9, wherein the at least one gene is STAT3. (Item 13) The extracellular vesicle of item 12, wherein the immunomodulatory component is an antisense oligonucleotide targeting STAT3. (Item 14) The extracellular vesicle of item 9, wherein the at least one gene is KRAS. (Item 15) The extracellular vesicle of item 14, wherein the immunomodulatory component is an inhibitory RNA targeting wild-type human KRAS. (Item 16) The inhibitory RNA is a mouse Kras G12D 16. The extracellular vesicle according to item 15, which also targets (Item 17) 17. The extracellular vesicle according to any one of items 1 to 16, wherein the macrophage is a tumor-resident macrophage. (Item 18) The extracellular vesicle according to item 17, wherein the tumor is a pancreatic tumor. (Item 19) 19. The extracellular vesicle according to any one of items 1 to 18, further comprising an additional immunomodulatory component. (Item 20) 20. The extracellular vesicle of item 19, wherein the additional immunomodulatory component is a small molecule drug, an antibody or an active fragment thereof, or a therapeutic protein or an active fragment thereof. (Item 21) 21. The extracellular vesicle of item 20, wherein the additional immunomodulatory component is an antibody or an active fragment thereof. (Item 22) The extracellular vesicle of item 21, wherein the antibody or active fragment thereof is an immune checkpoint inhibitor that binds to CTLA-4, PD-1, or PD-L1, or an inhibitor that binds to CSF1-R. (Item 23) The antibody or active fragment thereof is at least 95% identical to the CDRs of ipilimumab, or at least 95% identical to the CDRs of nivolumab, or at least 95% identical to the CDRs of cemiplimab, or at least 95% identical to the CDRs of pembrolizumab, or at least 95% identical to the CDRs of atezolizumab, or at least 95% identical to the CDRs of avelumab, or at least 95% identical to the CDRs of durvalumab, or at least 95% identical to the CDRs of pexidartinib, or PLX7. 23. The extracellular vesicle of item 22, comprising a CDR that is at least 95% identical to the CDR of 486, or at least 95% identical to the CDR of ARRY-382, or at least 95% identical to the CDR of JNJ-40346527, or at least 95% identical to the CDR of BLZ945, or at least 95% identical to the CDR of emactuzumab, or at least 95% identical to the CDR of AMG820, or at least 95% identical to the CDR of IMC-CS4, or at least 95% identical to the CDR of cabilalizumab. (Item 24) 24. The extracellular vesicle according to item 23, wherein the antibody or active fragment thereof is at least one antibody selected from the group consisting of ipilimumab, nivolumab, cemiplimab, pembrolizumab, atezolizumab, avelumab, durvalumab, pexidartinib, PLX7486, ARRY-382, JNJ-40346527, BLZ945, emactuzumab, AMG820, IMC-CS4, and cabilalizumab. (Item 25) 23. The extracellular vesicle according to item 22, wherein the antibody or active fragment thereof is at least one antibody that competes for binding with an antibody selected from the group consisting of ipilimumab, nivolumab, cemiplimab, pembrolizumab, atezolizumab, avelumab, durvalumab, pexidartinib, PLX7486, ARRY-382, JNJ-40346527, BLZ945, emactuzumab, AMG820, IMC-CS4, and cabilalizumab. (Item 26) 26. The extracellular vesicle according to any one of items 20 to 25, further comprising PTGFRN or a fragment thereof. (Item 27) The extracellular vesicle of item 26, wherein the antibody or fragment thereof is fused to PTGFRN or a fragment thereof. (Item 28) 28. The extracellular vesicle according to any one of items 1 to 27, wherein the comparison is determined using an assay selected from the group consisting of an extracellular vesicle uptake assay, a target gene expression assay, a downstream gene expression assay, a cytokine release assay and a macrophage cell surface protein assay. (Item 29) The extracellular vesicle according to any one of the preceding items, wherein the M2 macrophage is a tumor-associated macrophage selected from the group consisting of M2a, M2b, and M2c macrophages. (Item 30) The extracellular vesicles according to any one of the preceding items, wherein the M1 macrophages exhibit increased secretion of inflammatory cytokines and chemokines selected from the group consisting of INFγ, IL-12, IL-23, TNFα, IL-6, IL-1, CSCL9, CXCL10 and CXCL11 compared to the M2 macrophages before polarization. (Item 31) The extracellular vesicles according to any one of the preceding items, wherein the M1 macrophages exhibit reduced secretion of immunosuppressive cytokines and chemokines selected from the group consisting of IL-10, TGFβ, PGE2, CCL2, CCL17, CCL18, CCL22 and CCL24 compared to the M2 macrophages before polarization. (Item 32) The extracellular vesicles of any one of the preceding items, wherein the M1 macrophages express increased tumor-associated antigens compared to the M2 macrophages prior to polarization. (Item 33) The M1 macrophages are more likely to express CD8 + The extracellular vesicles according to any one of the preceding items, which increase stimulation of T cells and / or natural killer cells. (Item 34) A pharmaceutical composition comprising the extracellular vesicle according to any one of items 1 to 33. (Item 35) A method for treating a disease in a patient in need thereof, comprising administering to the patient an extracellular vesicle according to any one of items 1 to 33 or a pharmaceutical composition according to item 34, thereby treating the disease in the patient. (Item 36) 36. The method of claim 35, wherein the disease is cancer. (Item 37) 37. The method of item 35 or 36, wherein the patient is a human. (Item 38) 38. The method according to any one of items 35 to 37, wherein the immunomodulatory component is an inhibitory RNA targeting a protooncogene. (Item 39) 39. The method of item 38, wherein the proto-oncogene is human KRAS. (Item 40) 40. The method of claim 39, wherein the cancer is pancreatic cancer. (Item 41) 41. The method of any one of items 35 to 40, further comprising administering at least a second therapy. (Item 42) 42. The method of claim 41, wherein the second therapy comprises surgical therapy, chemotherapy, radiation therapy, cryotherapy, hormone therapy, or immunotherapy. (Item 43) 34. The method according to any one of items 26 to 33, wherein the administering is via a route selected from the group consisting of intravenous, intraperitoneal and intratumoral administration. (Item 44) 1. A method of modulating gene expression in macrophages comprising contacting the macrophages with extracellular vesicles comprising one or more immunomodulatory components that inhibit at least one gene, thereby increasing macrophage polarization from an M2 to an M1 phenotype, compared to contacting the macrophages with an equimolar amount(s) of the immunomodulatory component alone. (Item 45) 45. The method of claim 44, wherein the contacting is ex vivo or in vivo. (Item 46) 46. The method of claim 45, wherein the contacting is in vivo. (Item 47) 47. The method of claim 46, wherein the in vivo contacting comprises administering the extracellular vesicles to a subject. (Item 48) 47. The method of item 46, wherein the administering is via a route selected from the group consisting of intravenous, intraperitoneal, and intratumoral administration. (Item 49) 49. The method according to any one of items 46 to 48, wherein the subject is a human. (Item 50) 50. The method of any one of items 46 to 49, wherein the subject is suffering from a condition selected from cancer and fibrosis. (Item 51) 51. The method of item 50, wherein the condition is pancreatic cancer. (Item 52) 52. The method according to any one of items 44 to 51, wherein the extracellular vesicles are exosomes. (Item 53) 51. The method of any one of items 44 to 50, wherein the immunomodulatory component is a nucleic acid. (Item 54) 54. The method of claim 53, wherein the nucleic acid is an inhibitory RNA. (Item 55) 55. The method of item 54, wherein the inhibitory RNA is an antisense RNA, siRNA, shRNA, miRNA, lncRNA, pri-miRNA or pre-miRNA. (Item 56) 56. The method of claim 55, wherein the nucleic acid is an antisense oligonucleotide (ASO). (Item 57) 57. The method of any one of items 44 to 56, wherein the at least one gene is selected from the group consisting of KRAS, HRAS, NRAS, HIF1-alpha, HIF1-beta, Sp1, P300, LKB1, AMPK, STAT3, STAT6, n-MYC, c-MYC, HCAR1, A2AB, IDO, TDO, arginase, glutaminase, CEBP / β, Pi3Kγ, and PKM2. (Item 58) 58. The method of claim 57, wherein the at least one gene is selected from the group consisting of STAT3, STAT6, CEBP / β, Pi3Kγ, KRAS, and HIF1-alpha. (Item 59) 59. The method of claim 58, wherein the immunomodulatory component is an antisense oligonucleotide comprising a sequence that is at least 95% identical to a sequence selected from SEQ ID NOs: 1-6. (Item 60) 60. The method of claim 59, wherein the immunomodulatory component is an antisense oligonucleotide comprising a sequence selected from SEQ ID NOs: 1 to 6. (Item 61) 59. The method of item 58, wherein the at least one gene is STAT3. (Item 62) 62. The method of claim 61, wherein the immunomodulatory component is an antisense oligonucleotide targeted to STAT3. (Item 63) 59. The method of item 58, wherein the at least one gene is KRAS. (Item 64) 64. The method of claim 63, wherein the immunomodulatory component is an inhibitory RNA targeting wild-type human KRAS. (Item 65) 1. A method of treating pancreatic cancer in a subject, comprising administering to the subject extracellular vesicles comprising inhibitory RNA targeting human wild-type KRAS, wherein the treatment increases the rate of polarization of tumor-resident macrophages from an M2 phenotype to an M1 phenotype by increasing the proportion of tumor-resident macrophages that are polarized to an M1 phenotype by increasing the proportion of tumor-resident macrophages that are polarized to an M1 phenotype by increasing the proportion of tumor-resident macrophages that are polarized to an M2 phenotype by increasing the proportion of tumor-resident macrophages that are polarized ... G12D to levels higher than those observed in patients treated with an inhibitory RNA targeting said method. (Item 66) 66. The method of claim 65, wherein the polarization rate of tumor-resident macrophages is determined using an ex vivo assay of tumor-resident macrophages obtained from a tumor sample. [Brief description of the drawings]
[0033] [Figure 1] Gene expression levels of Stat 3, Stat 6, Cebpβ-1, Pi3Kγ, CEBPβ-2, and Kras are shown following transfection of increasing amounts of siRNA targeting each of the genes. [Diagram 2] Arg1 expression after transfection of increasing amounts of siRNA targeting Stat 3, Stat 6, Cebpβ-1, Pi3Kγ, CEBPβ-2, and Kras, respectively, is shown. Scrambled siRNA-transfected macrophages were used as a control. [Diagram 3] Shown is exosome uptake as determined by total cellular GFP intensity in six macrophage subpopulations (M0, M1, M2a, M2c, M2++, and TAM). [Figure 4] Shown is the uptake of free antisense oligos (Free-ASO) and ASO-loaded exosomes (Exo-ASO) by M2 or M0 macrophages as measured by total fluorescence intensity. [Diagram 5] Figure 5A shows exosome uptake by macrophages in vivo after intraperitoneal injection of 1x10 or 1x10 GFP-containing exosomes in naive mice, and Figure 5B shows the renewal of native exosomes and Exo-ASOs by tumor cells and macrophages in vivo after injection of a single dose of native unlabeled exosomes or Cy5-labeled Exo-ASOs in B16F10 tumor-bearing mice. [Figure 6] Figure 1 shows Stat3 expression in M2 polarized mouse RAW264.7 cells after incubation with either 5 μM free cholesterol-tagged ASO or 1 × 105 or 1 × 106 exosomes loaded with cholesterol-tagged ASO. Five different cholesterol-tagged ASOs targeting STAT3 were tested: ASO4.1, double-stranded MOE chemistry; ASO5.1 and ASO5.2, single-stranded O-methyl chemistry; ASO5.3 and ASO5.4, single-stranded MOE chemistry. Untreated polarized macrophages and polarized macrophages incubated with unmodified exosomes were used as negative controls. Stat3 siRNA-transfected macrophages were used as positive controls. [Figure 7]Figure 1 shows Arg1 transcript levels in M2-polarized mouse RAW264.7 cells after incubation with either 5 μM free cholesterol-tagged ASO or 1 × 105 or 1 × 106 exosomes loaded with cholesterol-tagged ASO. Five different cholesterol-tagged ASOs targeting STAT3 were tested: ASO4.1, double-stranded MOE chemistry; ASO5.1 and ASO5.2, single-stranded O-methyl chemistry; ASO5.3 and ASO5.4, single-stranded MOE chemistry. Untreated polarized macrophages and polarized macrophages incubated with unmodified exosomes were used as negative controls. Stat3 siRNA-transfected macrophages were used as positive controls. [Figure 8] Figure 8A shows STAT3 expression in M2-polarized mouse RAW264.7 cells after incubation with a high (4 μM) dose of ASO or high (4 μM) and low (0.4 μM) doses of Exo-ASO for STAT3. Figure 8B shows KRAS expression in M2-polarized mouse RAW264.7 cells after incubation with a high (4 μM) dose of ASO or Exo-ASO for KRAS. Figure 8C shows C / EBPβ expression in M2-polarized mouse RAW264.7 cells after incubation with a high (4 μM) dose of ASO or Exo-ASO for C / EBPβ. [Figure 9] Figure 9A shows STAT3 transcription levels in primary human macrophages from three separate donors after treatment with different doses of free STAT3 ASO or STAT3 Exo-ASO. The IC50 of each treatment and the fold improvement of STAT3 Exo-ASO compared to free STAT3 ASO are presented. Figure 9B shows CD163 levels in primary human macrophages from three separate donors after treatment with different doses of free STAT3 ASO or STAT3 Exo-ASO. The IC50 of each treatment and the fold improvement of STAT3 Exo-ASO compared to free STAT3 ASO are presented. [Figure 10]Target gene expression in human M2 macrophages after treatment with 4 μM free ASO or Exo-ASO for HIF1α, Pi3Kγ, CEBP / β, STAT6, and STAT3, respectively. Untreated human M2 macrophages and human M2 macrophages treated with 4 μM scrambled Exo ASO were used as controls. [Figure 11] Figure 1 shows CD163 expression in human M2 macrophages after treatment with 4 μM free or Exo-ASO for HIF1α, Pi3Kγ, CEBP / β, STAT6, and STAT3, respectively. Untreated human M2 macrophages and human M2 macrophages treated with 4 μM scrambled Exo ASO were used as controls. [Figure 12] Figure 12A shows induction of IL-12 following treatment with 4 μM free STAT3 ASO, 4 μM STAT3 Exo-ASO, 4 μM scrambled Exo-ASO, native exosomes, or C188-9, a small molecule inhibitor of STAT3, in the presence or absence of LPS. Figure 12B shows induction of IL-23 following treatment with 4 μM free STAT3 ASO, 4 μM STAT3 Exo-ASO, 4 μM scrambled Exo-ASO, native exosomes, or C188-9, a small molecule inhibitor of STAT3, in the presence or absence of LPS. [Figure 13A] Figure 13A shows STAT3 transcription levels following treatment with unmodified exosomes (EV only) and concentration-matched Stat3 Free ASO and Stat3 Exo-ASO. [Figure 13B] Figure 13B shows CD163 transcript levels following treatment with unmodified exosomes (EV only) and concentration-matched Stat3 Free ASO and Stat3 Exo-ASO. [Figure 13C] Figure 13C shows TGFβ transcription levels following treatment with unmodified exosomes (EV only) and concentration-matched Stat3 Free ASO and Stat3 Exo-ASO. [Figure 13D]Figure 13D shows STAT6 transcription levels following treatment with unmodified exosomes (EV only) and concentration-matched Stat3 Free ASO and Stat3 Exo-ASO. [Figure 14] Shown are TGFβ expression levels following treatment with exosomes loaded with ASOs against STAT3 (both MOE and LNA chemistries), STAT6 (MOE chemistry), and CEBP / β (MOE chemistry), respectively. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0034] Macrophage polarization is the process by which macrophages adopt different functional programs in response to signals from their microenvironment. This ability is relevant for their multiple roles in the organism. They are potent effector cells of the innate immune system, but are also important in the clearance of cellular debris, embryonic development and tissue repair.
[0035] Macrophage phenotypes are broadly divided into two groups, M1 (classically activated macrophages) and M2 (alternatively activated macrophages). This broad classification is based on in vitro studies in which cultured macrophages were treated with molecules that stimulate their phenotype to switch to a specific state. M1 macrophages are pro-inflammatory and are important in direct host defense against pathogens, such as phagocytosis and secretion of pro-inflammatory cytokines and microbicidal molecules. M2 macrophages have the exact opposite function, controlling the resolution phase of inflammation and repair of damaged tissue. See, e.g., Wynn, TA, Chawla, A., & Pollard, JW (2013). Origins and Hallmarks of Macrophages: Development, Homeostasis, and Disease. Nature, 496(7446), 445-455; Mills, CD, Kincaid, K., Alt, JM, Heilman, MJ, & Hill, AM (2000). M-1 / M-2 Macrophages and the Th1 / Th2 Paradigm. The Journal of Immunology, 164(12), 6166-6173. Many solid tumors are characterized by myeloid-rich cellular infiltration, often including a type of M2 macrophage known as tumor-associated macrophages (TAM). M2 macrophages (like TAM) express high levels of phosphorylated STAT3 and STAT6, which promote the expression of the metabolic enzyme arginase (Arg1). TAMs mediate many tumor-promoting activities, such as promoting cancer cell motility, metastasis formation, and angiogenesis, and TAM formation depends on microenvironmental factors present in the developing tumor. TAMs produce immunosuppressive cytokines, such as IL-10, TGFβ, PGE2, and very small amounts of NO or ROI, and low levels of inflammatory cytokines (IL-12, IL-1β, TNFα, IL-6). Compared to "classically activated" M1 macrophages, the presentation of tumor-associated antigens by TAMs is reduced, as is the stimulation of antitumor functions of T and NK cells. Unlike M1 macrophages, TAMs cannot lyse tumor cells.https: / / en.wikipedia.org / wiki / Macrophage_polarization-cite_note-Sica2008-31 Therefore, targeting TAMs and other M2 macrophages offers a novel therapeutic strategy against cancer, as demonstrated through the delivery of agents that either alter TAM recruitment and distribution, deplete existing TAMs, or induce reeducation of TAMs from an M2 to an M1 phenotype.
[0036] The exosome therapeutics of the present invention have a selective effect on M2 macrophages to promote tissue-resident microenvironments for treating diseases such as cancer and fibrosis by "repolarizing" abnormal macrophages to the M1 phenotype in the context of these diseases. The exosomes described herein are precisely engineered with various biologically active molecules on the exosome surface or within the exosome lumen to generate candidates involved in the pathway that repolarizes M2 macrophages to the M1 phenotype to treat human diseases.
[0037] Tumor-associated M2 polarized macrophages, or TAMs, can effectively suppress T cell proliferation and effector functions and promote tumor growth. Reversion of TAMs to the M1 phenotype has also been reported using antibodies that deplete macrophages oriented to the CSF-1 receptor. These approaches have shown limited success in clinical trials due to a narrow therapeutic window and lack of specificity by targeting all macrophages and not just abnormal M2 macrophages as intended. Such massive depletion of macrophages would be expected to result in increased infection risk and other safety concerns. The exosomes of the present invention, due to their natural exosome orientation to macrophages, more selectively target M2 macrophages, tipping the balance of function toward the desired M1 phenotype. These exosomes repolarize macrophages, resulting in the production of the desired spectrum of inflammatory cytokines required for anti-tumor immune responses. As shown in the examples below, exosomes reprogrammed immunosuppressive M2 macrophages to the M1 phenotype in vitro.
[0038] In addition to the immune suppression induced in the tumor microenvironment, M2 polarized macrophages secrete large amounts of transforming growth factor beta, or TGFβ, a key cytokine involved in cell signaling that induces fibroblast accumulation leading to collagen deposition and tissue remodeling, ultimately resulting in tissue fibrosis. Reprogramming these M2 macrophages to reduce TGFβ production by targeting key signaling molecules such as STAT3 has been shown to have beneficial activity in preclinical models of pulmonary fibrosis. Although several small molecule approaches targeting STAT3 have been employed, the lack of specificity of inhibition solely within abnormal M2 macrophages has prevented this approach to treatment from becoming viable. Certain exosomes described herein selectively target key pathways in M2 macrophages, enabling them to target STAT3 and other cellular pathways in lung and other tissue fibrosis syndromes.
[0039] Disclosed herein are extracellular vesicles useful for modulating macrophages of the immune system. These extracellular vesicles contain one or more immunomodulatory component(s) that inhibit at least one macrophage target gene upon contact with macrophages, thereby increasing macrophage polarization from M2 phenotype to M1 phenotype, compared to equimolar amount(s) of one or more immunomodulatory component(s) alone. Methods for producing the extracellular vesicles and methods of using these extracellular vesicles to treat cancer and other immune system-related diseases, such as fibrotic conditions, are also provided.
[0040] Before describing the invention in more detail, it is to be understood that the invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the invention will be limited only by the appended claims.
[0041] When a range of values is provided, it is understood that each intervening value between the upper and lower limit of that range, and any other stated or intervening value in that stated range, to one-tenth of the unit of the lower limit, unless the context clearly dictates otherwise, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
[0042] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, representative exemplary methods and materials are described below.
[0043] All publications and patents cited in this specification are herein incorporated by reference to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference, and are incorporated by reference herein to disclose and describe the methods and / or materials in connection with which the publications are cited.
[0044] It should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Similarly, the term "at least one" includes plural referents (i.e., is equivalent to the phrase "one or more" unless the context clearly dictates otherwise). It should be further noted that the claims may be drafted to exclude any element. Thus, this statement is intended to serve as a predicate for use of exclusive terminology such as "solely," "only," and the like in connection with the recitation of claim elements or for the use of a negative limitation.
[0045] The term "about," when used to modify a numerical value, is intended to encompass variations of the stated value that are functionally equivalent to the stated value for purposes of practicing the described technology, as can be readily determined by one of ordinary skill in the art. In certain embodiments, the term "about" includes variations of + / -5%, + / -10%, + / -20%, + / -30%, + / -40%, or + / -50% from the stated value.
[0046] As will be apparent to those skilled in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has distinct components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the invention. Any recited method may be carried out in the order of events recited or in any other order which is logically possible.
[0047] In further describing the invention, the present systems for use in carrying out the present methods will be discussed in more detail, followed by a review of the associated methods.
[0048] As used herein, the term "extracellular vesicles" refers to vesicles derived from cells that contain a membrane that encloses an internal space. Extracellular vesicles include all membrane-bound vesicles that have a diameter smaller than the cell from which they are derived. Typically, extracellular vesicles range in diameter from 20 nm to 1000 nm and can contain a variety of macromolecular cargo, either within the internal space, displayed on the external surface of the extracellular vesicle, and / or across the membrane. The cargo can include nucleic acids, proteins, carbohydrates, lipids, small molecules, and / or combinations thereof. By way of example and without limitation, extracellular vesicles include apoptotic bodies, cell fragments, vesicles derived from cells by direct or indirect manipulation (e.g., by continuous extrusion or treatment with alkaline solutions), vesiculated organelles, and vesicles produced by living cells (e.g., by direct plasma membrane budding or fusion of late endosomes with the plasma membrane). Extracellular vesicles can be derived from living or dead organisms, explanted tissues or organs, and / or cultured cells. Species of extracellular vesicles include exosomes and nanovesicles, for example, as described in co-owned U.S. Pat. No. 10,195,290, incorporated herein by reference for all purposes.
[0049] As used herein, the term "exosome" refers to a small (20-300 nm diameter, more preferably 40-200 nm diameter) cell-derived vesicle that includes a membrane enclosing an internal space and is generated from the cell by direct plasma membrane budding or by fusion with the plasma membrane of a late endosome. Exosomes are a type of extracellular vesicle. Exosomes contain lipids or fatty acids and polypeptides, and optionally include a payload (e.g., a therapeutic agent), a receiver (e.g., a targeting moiety), a polynucleotide (e.g., a nucleic acid, RNA, or DNA), a sugar (e.g., a monosaccharide, a polysaccharide, or a glycan) or other molecule. Exosomes can be derived from producer cells and can be isolated from producer cells based on their size, density, biochemical parameters, or a combination thereof.
[0050] As used herein, the term "nanovesicles" refers to small (20-250 nm diameter, more preferably 30-150 nm diameter) vesicles derived from cells that include a membrane enclosing an internal space and are generated from the cells by direct or indirect manipulation such that the nanovesicles are not produced by the producer cells without manipulation. Suitable manipulations of producer cells include, but are not limited to, continuous extrusion, treatment with alkaline solutions, sonication, or combinations thereof. The production of nanovesicles may, in some instances, result in the destruction of the producer cells. Preferably, the population of nanovesicles is substantially free of vesicles derived from producer cells by direct budding from the plasma membrane or fusion with the plasma membrane of late endosomes. Nanovesicles are a type of extracellular vesicle. Nanovesicles include lipids or fatty acids and polypeptides, and optionally include payloads (e.g., therapeutic agents), receivers (e.g., targeting moieties), polynucleotides (e.g., nucleic acids, RNA, or DNA), sugars (e.g., monosaccharides, polysaccharides, or glycans) or other molecules. Nanovesicles may be isolated from producer cells based on their size, density, biochemical parameters, or a combination thereof once the nanovesicles have been engineered to be derived from the producer cells.
[0051] As used herein, the term "M2 phenotype" refers to a type of cell that exhibits one or more tumor-promoting activities or that is associated with a CD8 +reduced or absent stimulation of T cells and / or natural killer cells; absence of phagocytosis of tumor cells; secretion and / or expression of M2-associated cytokines (e.g., IL-10, TGFβ, PGE2, CCL2, CCL17, CCL18, CCL22, and CCL24); secretion and / or expression of growth factors (e.g., VEGF-A, VEGF-C, EGF, and TGF-β); secretion and / or expression of transferases (e.g., matrix metalloproteinases MMP2, MMP9, cysteine cathepsin proteases); secretion / expression of immunosuppressive factors (e.g., arginase I (ArgI), which sequester the substrate L-arginine from inducible nitric oxide synthase (iNOS)); expression of cell surface markers YM1, FIZZ1, Dectin-1, MGL, M2-associated miRNAs (e.g., miRNA146a, miRNA let 7b, and miR-223) (e.g., Mosser, DM, & Edwards, JP (2008) Exploring the full spectrum of macrophage activation. Nature Reviews Immunology,8(12),958-96;Murray,PJ,Allen,JE,Biswas,SK,Fisher,EA,Gilroy,DW,Goerdt,S.,Wynn,TA(2014).Macrophage activation and polarization: nomenclature and experimental guidelines.Immunity,41(1),14-20;and Liu,YC,Zou,XB,Chai,YF,&Yao,YM(2014).Macrophage polarization in inflammatory diseases.International Journal of Biological Sciences, 10(5), 520-5299 and references cited therein, each of which is incorporated by reference for all purposes), and / or refers to macrophages known to be associated with reduced expression / secretion of M1-associated factors or reduced M1-associated activity listed below, wherein the reference sample comprises a population of M1-activated macrophages.In vitro M1 activation is induced by treatment with TLR ligands, such as bacterial lipopolysaccharide (LPS) typical for gram-negative bacteria and lipoteichoic acid (LTA) typical for gram-positive bacteria, granulocyte-macrophage colony-stimulating factor (GM-CSF) or a combination of LPS and interferon-gamma (IFN-γ). Mills, CD, Kincaid, K., Alt, JM, Heilman, MJ, & Hill, AM (2000) M-1 / M-2 Macrophages and the Th1 / Th2 Paradigm. The Journal of Immunology, 164(12), 6166-6173; Krausgruber, Thomas, et al. “IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses.” Nature immunology 12.3(2011):231-238; and Martinez, FO, & Gordon, S. (2014) The M1. and M2 paradigm of macrophage activation: time for reassessment. F1000 Prime Reports, 6 (March), 1-13, and references cited therein, each of which is incorporated by reference for all purposes.
[0052] As used herein, the term "M1 phenotype" includes, but is not limited to, CD8 +Stimulation of T cells and / or natural killer cells, phagocytosis of tumor cells, secretion and / or expression of M1-associated cytokines (e.g., INFγ, IL-12, IL-23, TNFα, IL-6, IL-1, CCL5, CSCL9, CXCL10, and CXCL11), expression of M1-associated miRNAs (e.g., miRNA155, miR-33) (e.g., Mosser, DM, & Edwards, JP (2008) Exploring the full spectrum of macrophage activation. Nature Reviews Immunology, 8 (12), 958-96; Murray, PJ, Allen, JE, Biswas, SK, Fisher, EA, Gilroy, DW, Goerdt, S., Wynn, TA (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity, 41 (1), 14-20; and Liu, YC, Zou, XB, Chai, YF, & Yao, YM (2014). Macrophage polarization in inflammatory diseases. International Journal of Biological Sciences, 10(5), 520-5299 and references cited therein, each of which is incorporated by reference for all purposes) and / or reduced expression / secretion of M2-associated factors, or anti-tumor activity or markers known to those of skill in the art to be associated with an M1 phenotype, such as reduced M2-associated activities listed above, compared to at least one reference sample, wherein the reference sample comprises a population of M2-associated macrophages.In vitro M2 activation is induced by IL-4 and IL-13 (see, e.g., Liu, YC, Zou, XB, Chai, YF, & Yao, YM (2014) Macrophage polarization in inflammatory diseases. International Journal of Biological Sciences, 10(5), 520-529, incorporated by reference for all purposes).
[0053] The term "macrophage polarization" as used herein refers to a change in macrophages from an M2 to an M1 phenotype and / or an increase in the proportion of a population of macrophages (e.g., tumor-associated macrophages or circulating macrophages) found in a patient that exhibits an M1 phenotype compared to at least one reference sample (e.g., a sample taken prior to the test sample or historical data from the same patient). See, e.g., Mills, CD, Kincaid, K., Alt, JM, Heilman, MJ, & Hill, AM (2000) M-1 / M-2 Macrophages and the Th1 / Th2 Paradigm. The Journal of Immunology, 164(12), 6166-6173; Mosser, DM, & Edwards, JP (2008) Exploring the full spectrum of macrophage activation. Nature Reviews Immunology, 8(12), 958-969; and Xue, J., Schmidt, SV and Schultze, JL (2014), Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation. Immunity, 40(2)L 274-288, which are incorporated by reference for all purposes.
[0054] The term "extracellular vesicle delivery" or "delivery of extracellular vesicles" refers to the administration and localization of extracellular vesicles to a target tissue, cell and / or organ of a subject. In some embodiments, the immunomodulatory component may be delivered to the cytoplasm of the target cell. In other embodiments, the immunomodulatory component is delivered to the membrane of the target cell. In some embodiments, the membrane of the extracellular vesicle fuses with the membrane of the target cell.
[0055] As used herein, the term "producer cell" refers to any cell from which extracellular vesicles can be isolated. A producer cell is a cell that serves as a source for extracellular vesicles. A producer cell can share protein, lipid, sugar, or nucleic acid components with the extracellular vesicles. In some embodiments, a producer cell is a modified or artificial cell. In some embodiments, a producer cell is a cultured or isolated cell. In certain embodiments, a producer cell is a cell line. In some embodiments, a producer cell line is a human embryonic kidney cell line. In some embodiments, a producer cell line is a HEK293SF cell line. In certain embodiments, a producer cell is a primary cell. In some embodiments, a producer cell is an immune cell, such as, for example, a B lymphocyte, a T lymphocyte, a dendritic cell, a mast cell, a macrophage, a natural killer cell (NK cell), an antigen-presenting cell, a T helper cell, or a regulatory T cell (Treg cell).
[0056] As used herein, a "membrane" is a boundary layer that separates an internal space from an external space that contains one or more biological compounds, typically lipids, and optionally polypeptides and / or carbohydrates. In some embodiments, the membrane comprises lipids and fatty acids. In some embodiments, the membrane comprises phospholipids, glycolipids, fatty acids, sphingolipids, phosphoglycerides, sterols, cholesterol, and phosphatidylserine. In some of these embodiments, the membrane further comprises one or more polypeptides and / or one or more polysaccharides, such as glycans. The extracellular vesicle comprises a membrane as defined herein.
[0057] As used herein, the term "immunomodulatory component" refers to a therapeutic agent that acts on a target (e.g., target genes including, by way of example and not limitation, KRAS, HRAS, NRAS, HIF1-alpha, HIF1-beta, Sp1, P300, LKB1, AMPK, STAT3, STAT6, n-MYC, c-MYC, HCAR1, A2AB, IDO, TDO, arginase, glutaminase, CEBP / β, Pi3Kγ, and PKM2) that modifies an immune cell (e.g., a macrophage or other immune cell) upon contact with the agent. Immunomodulatory components that may be introduced into the extracellular vesicles and / or producer cells can include therapeutic agents such as inhibitory nucleic acids (e.g., antisense oligonucleotides (ASOs), siRNAs, miRNAs, antisense RNA, shRNAs, lncRNAs, pri-miRNAs, and pre-miRNAs), agonists, antagonists, antibodies, and / or antigen-binding fragments, modulators of immune checkpoint inhibitors or ligands of immune checkpoint inhibitors, surface antigens and their derivatives, and / or cytokines and their derivatives. In certain embodiments, the immunomodulatory components are inhibitory nucleic acids (e.g., antisense oligonucleotides (ASOs), siRNAs, miRNAs, antisense RNA, shRNAs, lncRNAs, pri-miRNAs, and pre-miRNAs).See, e.g., Weiss, B. (ed.): Antisense Oligodeoxynucleotides and Antisense RNA: Novel Pharmacological and Therapeutic Agents, CRC Press, Boca Raton, FL, 1997, which are incorporated by reference for all purposes; Elbashir S, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) "Duplicates of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells". Nature. 411(6836):494-988; Bartel DP (January 2004) "MicroRNAs: genomics, biogenesis, mechanism, and function". Cell. 116(2):281-97; Paddison, PJ; Caudy, AA; Bernstein, E; Hannon, GJ; Conklin, DS (15 April 2002) "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells”.Genes & Development.16(8):948-58, Ma L, Bajic VB, Zhang Z(June 2013)”On the classification of long non-coding RNAs”.RNA Biology.10(6):925-33, and Ambros V, Bartel B, Bartel. See DP, Burge CB, Carrington JC, Chen X, Dreyfuss G, Eddy SR, Griffiths-Jones S, Marshall M, Matzke M, Ruvkun G, Tuschl T (March 2003). "A uniform system for microRNA annotation". RNA. 9(3):277-9.
[0058] As used herein, the phrase "inhibitory nucleic acid molecule" or "inhibitory nucleic acid" refers to any nucleic acid that, when introduced into a cell, interacts with a target gene, causes the inhibition of the expression or activity of the target gene. Inhibitory nucleic acid molecule, i.e., inhibitory nucleic acid, can be DNA or inhibitory RNA (e.g., siRNA, miRNA, antisense RNA, shRNA, lncRNA, pre-miRNA, or mRNA), and the RNA is single-stranded, double-stranded, or contains both single-stranded and double-stranded regions. In some embodiments, the inhibitory nucleic acid is an antisense oligonucleotide (ASO). ASO can be single-stranded or double-stranded DNA, RNA, or DNA / RNA hybrid. See, for example, Antisense Oligodeoxynucleotides and Antisense RNA: Novel Pharmacological and Therapeutic Agents, CRC Press, Boca Raton, FL, 1997, which is incorporated herein by reference for all purposes. "EXO ASOs" physically associate with extracellular vesicles, such as exosomes, through interactions with the vesicle membrane (e.g., as occurs with cholesterol or fatty acyl derivatized ASOs), or by loading into the vesicle lumen using techniques such as electroporation, or through genetic engineering of producer cells, such as by transfection or transduction to introduce a construct encoding the desired ASO into the producer cells, followed by isolation of the extracellular vesicles from the engineered producer cells.
[0059] The term "receiver" refers to a molecule that guides extracellular vesicles to a target and / or facilitates the interaction of extracellular vesicles with a target of a subject. In some embodiments, the receiver is a polypeptide, also sometimes referred to herein as a "receiver polypeptide." In some embodiments, the receiver can increase the concentration of an immunomodulatory component in a tissue of a subject, such as by directed transport to a target tissue of a subject. Examples of receivers include, but are not limited to, those listed in Table 3.
[0060] The term "target" can refer to a gene whose activity is regulated by the immune modulatory component of the present disclosure (i.e., a target gene). In certain embodiments, the target gene is inhibited by a nucleic acid molecule associated with the extracellular vesicle (i.e., bound to the membrane surface, inserted into the lipid bilayer, or enclosed within the vesicle's encapsulation volume), such as, for example, an inhibitory ASO. Examples of target genes include, but are not limited to, KRAS, HRAS, NRAS, HIF1-alpha, HIF1-beta, Sp1, P300, LKB1, AMPK, STAT3, STAT6, n-MYC, c-MYC, HCAR1, A2AB, IDO, TDO, arginase, glutaminase, CEBP / β, Pi3Kγ, and PKM2. "Target" can also refer to a cell (i.e., a target cell) to which the extracellular vesicles of the present disclosure are directed. In certain embodiments, the target cell is an immune cell (e.g., a macrophage). In certain embodiments, the target cell is a hematopoietic stem cell or a pluripotent stem cell. In certain embodiments, the target cell is a circulating macrophage. In certain embodiments, the target cell is a tumor-resident macrophage (i.e., a macrophage located in the tumor microenvironment, in tumor tissue, or near the tumor surface). Additionally, "target" can also refer to a protein on a target cell whose activity is regulated by contact with the immunomodulatory component of the present disclosure, or a protein that acts as a ligand for binding to the extracellular vesicles of the present disclosure (i.e., a target protein). Thus, in certain embodiments, the target protein is on a target cell and interacts with the extracellular vesicle.
[0061] A "therapeutic agent" or "therapeutic molecule" includes a compound or molecule that, when present in an effective amount, produces a desired therapeutic, pharmacological and / or physiological effect in a subject in need thereof. It includes any compound, e.g., a small molecule drug, or a biologic (e.g., a polypeptide drug or a nucleic acid drug), that, when administered to a subject, has a measurable or transmissible effect on the subject, e.g., it relieves or reduces the symptoms of a disease, disorder, or condition.
[0062] The term "immune checkpoint inhibitor" or "checkpoint inhibitor" as used herein refers to a therapeutic agent that stimulates immune cell activity by reducing immune-suppressive checkpoint pathways that suppress immune cells (e.g., agents that inhibit PD-1 / PD-L1 (such as nivolumab, cemiplimab, and pembrolizumab, which target PD-1, and atezolizumab, avelumab, and durvalumab, which target PD-L1, respectively) and agents that inhibit CTLA-4 / B7-1 / B7-2, such as ipilimumab). See, e.g., Pardoll DM (March 2012) "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12(4):252-64.
[0063] As used herein, the term "antibody" includes immunoglobulins and fragments thereof, whether natural or partially or wholly synthetically produced. The term also encompasses any protein having a binding domain that is homologous to an immunoglobulin binding domain. "Antibody" further includes polypeptides comprising a framework region from an immunoglobulin gene or a fragment thereof that specifically binds and recognizes an antigen. The use of the term antibody is meant to include whole antibodies, polyclonal, monoclonal and recombinant antibodies, fragments thereof, further including single chain antibodies, humanized antibodies, murine antibodies, chimeric, mouse-human, mouse-primate, primate-human monoclonal antibodies, anti-idiotypic antibodies, antibody fragments, such as, for example, scFv, (scFv)2, Fab, Fab', and F(ab')2, F(ab1)2, Fv, dAb, and Fd fragments, diabodies, and antibody-related polypeptides. Antibodies include bispecific and multispecific antibodies, so long as they exhibit the desired biological activity or function. Exemplary antibody compositions include antibodies that inhibit CTLA-4, such as ipilimumab, those that inhibit PD-1, such as nivolumab, cemiplimab, and pembrolizumab, those that inhibit PD-L1, such as atezolizumab, avelumab, durvalumab, and those that inhibit CSFR1, such as pexidartinib, PLX7486, ARRY-382, JNJ-40346527, BLZ945, emactuzumab, AMG820, IMC-CS4, and cabilalizumab. The term "antigen-binding fragment" as used herein refers to fragments of intact immunoglobulins and any portion of a polypeptide that contains an antigen-binding region that has the ability to specifically bind to an antigen. For example, an antigen-binding fragment can be, but is not limited to, a F(ab')2 fragment, a Fab' fragment, a Fab fragment, an Fv fragment, or a scFv fragment. The Fab fragment has one antigen-binding site and contains the variable regions of the light and heavy chains, the constant region of the light chain, and the first constant region CH1 of the heavy chain. The Fab' fragment differs from the Fab fragment in that the Fab' fragment additionally contains the hinge region of the heavy chain containing at least one cysteine residue at the C-terminus of the heavy chain CH1 region.F(ab')2 is produced, whereby the cysteine residues of the Fab' fragments are linked by disulfide bonds at the hinge region. The Fv fragment is the smallest antibody fragment that has only the heavy and light chain variable regions, and recombinant techniques for producing Fv fragments are well known in the art. The two-chain Fv fragment can have a structure in which the heavy chain variable region is linked to the light chain variable region by a non-covalent bond. The single-chain Fv (scFv) fragment can generally have a dimeric structure, such as the two-chain Fv fragment in which the heavy chain variable region is covalently linked to the light chain variable region via a peptide linker, or the heavy and light chain variable regions are directly linked to each other at their C-termini. Antigen-binding fragments can be obtained using proteases (e.g., whole antibodies are digested with papain to obtain Fab fragments and with pepsin to obtain F(ab')2 fragments) and can be prepared by recombinant techniques. The dAb fragment consists of the VH domain. Single chain antibody molecules can include polymers having multiple individual molecules, eg, dimers, trimers, or other polymers.
[0064] The phrase "nucleic acid molecule" refers to a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases. Nucleic acid molecules include chromosomal DNA and self-replicating plasmids, vectors, mRNA, tRNA, siRNA, miRNA, etc. The nucleic acid molecule can be recombinant, and an exogenous polypeptide can be expressed when the nucleic acid is introduced into a cell. The term is described, for example, in Selvam C, Mutisya D, Prakash S, Ranganna K, Thilagavathi R. “Therapeutic potential of chemically modified siRNA: Recent trends," Chem Biol Drug Des. 2017 Nov; 90(5): 665-678, for example, locked nucleic acids (LNA) as described in Petersen M, Wengel J (February 2003) "LNA: a versatile tool for therapeutics and genomics". Trends Biotechnol. 21(2): 74-81, and clinically relevant chemically modified nucleic acids as described in Summerton, J; Weller, D (1997) "Morpholino Antisense Oligomers: Design, Preparation and Properties". Antisense & Nucleic Acid Drug Development. 7(3): 187-195, Goodchild, J (2011). Therapeutic oligonucleotides. Methods in Molecular Biology. 764. pp. 1-15, each of which is incorporated herein by reference for all purposes.
[0065] The term "agonist" refers to a molecule that binds to a receptor and activates the receptor to produce a biological response. Receptors can be activated by either endogenous or exogenous agonists. Non-limiting examples of endogenous agonists include hormones and neurotransmitters. Non-limiting examples of exogenous agonists include various classes of compounds including small molecules, antibodies, synthetic peptides, etc. Agonists can be full, partial, or inverse agonists.
[0066] The term "antagonist" refers to a molecule that, upon binding to a receptor, blocks or suppresses agonist-mediated responses rather than inducing a biological response itself. Many antagonists achieve their efficacy by competing with endogenous ligands or substrates at structurally defined binding sites on the receptor. Non-limiting examples of antagonists include alpha blockers, beta blockers, and calcium channel blockers. Antagonists can be competitive, noncompetitive, or uncompetitive antagonists.
[0067] As used herein, the term "pharmaceutical composition" refers to one or more compounds described herein, such as extracellular vesicles, mixed or suspended with one or more other chemical components, such as pharma- ceutically acceptable carriers and excipients. One purpose of a pharmaceutical composition is to facilitate administration of a preparation of extracellular vesicles to a subject. The term "pharmaceutical acceptable" and grammatical variations thereof refer to compositions, carriers, diluents, and reagents that can be administered to or to a subject without producing undesirable physiological effects to an extent that would prohibit administration of the composition. The term "excipient" or "carrier" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of a compound. The term "pharmaceutical acceptable carrier" or "pharmaceutical acceptable excipient" encompasses any agent approved by a regulatory agency of the U.S. Federal Government for use in animals, including humans, or listed in the U.S. Pharmacopeia, as well as any carrier or diluent that does not cause significant irritation to the subject and does not abrogate the biological activity and properties of the administered compound. Included are generally safe, non-toxic and desirable excipients and carriers that are useful in preparing pharmaceutical compositions.
[0068] As used herein, the terms "isolate", "isolated", and "isolating" or "purify", "purified", and "purifying", as well as "extracted" and "extracting", are used interchangeably and refer to a state of preparation (e.g., a plurality of known or unknown amounts and / or concentrations) of desired extracellular vesicles that have undergone one or more processes of purification, e.g., selection or enrichment of the desired extracellular vesicle preparation. In some embodiments, isolating or purifying as used herein is a process of removing, partially removing (e.g., fractionating) extracellular vesicles from a sample containing producer cells. In some embodiments, an isolated extracellular vesicle composition has no detectable undesirable activity, or alternatively, the level or amount of undesirable activity is below an acceptable level or amount. In other embodiments, an isolated extracellular vesicle composition has an amount and / or concentration of desired extracellular vesicles equal to or greater than an acceptable amount and / or amount. In other embodiments, an isolated extracellular vesicle composition is enriched compared to the starting material (e.g., producer cell preparation) from which the composition is derived. This enrichment can be greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99%, 99.999%, 99.9999%, or 99.9999% compared to the starting material. In some embodiments, the isolated extracellular vesicle preparation is substantially free of residual biological products. In some embodiments, the isolated extracellular vesicle preparation is 100% free, 99% free, 98% free, 97% free, 96% free, or 95% free of any contaminating biological material. Residual biological products can include non-biological materials (including chemicals) or unwanted nucleic acids, proteins, lipids, or metabolites. Substantially free of residual biological products can also mean that the extracellular vesicle composition does not contain detectable producer cells and that only extracellular vesicles are detectable.
[0069] The terms "administration," "administering," and variations thereof refer to the introduction of a composition, such as an extracellular vesicle or an agent, into a subject, including any scheduled simultaneous and sequential introduction consistent with producing a therapeutic effect of one or more additional compositions or agents. The timing of dose administration may be selected to achieve a certain level (e.g., plasma level) of the administered agent in the subject, or to a sudden exposure, for example, to reduce toxicity or prevent desensitization. Methods for achieving these results are described, for example, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Macmillan Publishing Co. 13). th Based on known pharmacokinetic principles as set forth in the Pharmacology of the Invention, Ed., the subject is well known to practitioners in the art. The introduction of the composition or agent into the subject is by any suitable route, including oral, intrapulmonary, intranasal, parenteral (intravenous, intraarterial, intramuscular, intraperitoneal, or subcutaneous), rectal, intralymphatic, intrathecal, periocular, intratumoral, or topical. Administration includes self-administration and administration by another. A suitable route of administration allows the composition or agent to perform its intended function. For example, if the suitable route is intravenous, the composition is administered by introducing the composition or agent into the subject's vein.
[0070] As used herein, the terms "modulate", "modulating", "modify" and / or "modulator" generally refer to the ability to directly or indirectly change, by increasing or decreasing, a particular concentration, level, expression, function or behavior, e.g., promote / stimulate / upregulate or interfere / inhibit / downregulate, such as to act as an antagonist or agonist. In some instances, a modulator can increase and / or decrease a particular concentration, level, activity or function relative to a control, or relative to an average level of activity that would generally be expected, or relative to a control level of activity. The terms "inhibit", "suppress", "modulate" are used herein to describe a change in expression or activity of a target gene compared to a state without the immunomodulatory component(s). Inhibition refers to the absence or substantial absence of expression or activity of a gene. Suppression refers to a decrease in expression or activity of a gene, but not a complete or substantial absence. Modulation refers to any alteration, increase or decrease in expression or activity of a gene.
[0071] The term "sufficient amount" means an amount sufficient to produce a desired effect, for example, an amount sufficient to regulate a subject's condition.
[0072] The term "therapeutically effective amount" is an amount effective to ameliorate symptoms of a disease. Since prevention may be considered a therapy, a therapeutically effective amount may be a "prophylactically effective amount."
[0073] The percent "identity" between a nucleotide sequence and a reference sequence is defined as the percentage of a single nucleotide in a nucleotide sequence that is identical to a single nucleotide in a reference sequence to achieve the maximum percent sequence identity, after aligning the sequences and introducing gaps, if necessary. Alignment for the purpose of determining percent nucleotide sequence identity can be achieved by various means within the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEGALIGN (DNASTAR), CLUSTALW, CLUSTAL OMEGA, or MUSCLE software. Those skilled in the art can determine the appropriate parameters for aligning sequences, including any algorithm required to obtain maximum alignment over the full length of the sequences being compared. For further details of the BLAST algorithm, see Mount, DW (2004) Bioinformatics: Sequence and Genome Analysis (2nd ed.). Cold Spring Harbor Press. ISBN 978-0-87969-712-9.
[0074] The percent "identity" between a polypeptide sequence and a reference sequence is defined as the percentage of amino acid residues in the polypeptide sequence that are identical to the amino acid residues in the reference sequence to achieve the maximum percent sequence identity, after aligning the sequences and introducing gaps, if necessary. Alignment for the purpose of determining percent amino acid sequence identity can be achieved by various means within the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEGALIGN (DNASTAR), CLUSTALW, CLUSTAL OMEGA, or MUSCLE software. Those skilled in the art can determine the appropriate parameters for aligning sequences, including any algorithm required to obtain maximum alignment over the full length of the sequences being compared. For further details of the BLAST algorithm, see Mount, DW (2004). Bioinformatics: Sequence and Genome Analysis (2nd ed.). Cold Spring Harbor Press. ISBN 978-0-87969-712-9.
[0075] As used herein, the term "substantially" or "substantial" refers to, for example, the presence, level, or concentration of an entity in a particular space, the effect of an entity on another entity, or the effect of a treatment. For example, the activity, level, or concentration of an entity is substantially increased if the increase is 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 50-fold, 100-fold, or 1000-fold over baseline. The activity, level, or concentration of an entity is also substantially increased if the increase is 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, or 500% over baseline.
[0076] The term "in vivo" refers to a process that occurs in a living organism.
[0077] As used herein, the term "mammal" includes both human and non-human mammals.
[0078] Abbreviations used in this application include the following: "mRNA" refers to messenger RNA, "miRNA" refers to microRNA, "siRNA" refers to small interfering RNA, "antisense RNA" refers to single-stranded RNA complementary to mRNA, which may additionally contain DNA nucleotides and is often referred to as an antisense oligonucleotide or "ASO," "shRNA" refers to small or short hairpin RNA, "lncRNA" refers to long non-coding RNA, and "dsDNA" refers to double-stranded DNA.
[0079] composition An embodiment of the present disclosure includes a composition capable of regulating the immune system. The composition includes an extracellular vesicle comprising a cell membrane and at least one immunomodulatory component associated with the cell membrane or enclosed within a membrane-bound encapsulation volume. Enclosure within the membrane-bound volume can be achieved using techniques including electroporation, lyophilization, or through engineering producer cells (such as HEK293 cells, Chinese hamster ovary (CHO) cells, and mesenchymal stem cells (MSCs)) to introduce constructs encoding the immunomodulatory component, such as nucleic acids (encoding ASOs) or proteins. Association with the cell membrane includes binding to the inner or outer lipid leaflet of the membrane and transmembrane insertion into the lipid bilayer. In some instances, membrane association may occur with, for example, prostaglandin F2 receptor negative regulator (PTGFRN); basigin; (BSG); immunoglobulin superfamily member 2 (IGSF2); immunoglobulin superfamily member 3 (IGSF3); immunoglobulin superfamily member 8 (IGSF8); integrin beta 1 (ITGB1); integrin alpha-4 (ITGA4); 4F2 cell surface antigen heavy chain (SLC3A2); and classes of ATP transporter proteins (which have been identified to be highly enriched on the surface of exosomes that can provide scaffolding and components of fusion proteins including immunomodulatory components) (ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, This is accomplished using proteins (e.g., scaffold proteins or fragments thereof) such as ATP2B2, ATP2B3, ATP2B4 (described in co-owned U.S. Pat. No. 10,195,290). Such extracellular vesicles and exemplary techniques are described in detail in co-owned U.S. Pat. No. 10,195,290, which is incorporated by reference for all purposes. As described in co-owned U.S. Pat. No. 10,195,290, surface-treated exosomes can be generated by chemical and / or physical methods such as PEG-induced fusion and / or ultrasonic fusion to introduce these scaffold proteins (and fragments thereof) into exosomes or producer cells. Complexes can be generated between exogenous therapeutic proteins and scaffold proteins.Alternatively, fusion proteins can be produced by complexing an exogenous therapeutic protein, such as an immunomodulatory protein, with a scaffold protein using the chemical and / or physical methods described above, and producing engineered exosomes containing the complex or fusion protein on their surface. The native full-length or biologically active fragment of a therapeutic protein can be transported to the surface of the exosome by complexing it to a scaffold protein. Such exosomes can also be obtained from producer cells that contain an exogenous sequence inserted into the genome of the cell. For example, the exogenous sequence can be inserted into a genomic site located at the 3' or 5' end of a genomic sequence encoding PTGFRN, BSG, IGSF2, IGSF3, IGSF8, ITGB1, ITGA4, SLC3A2, or an ATP transporter. For example, the exogenous sequence can be inserted into a genomic sequence encoding PTGFRN, BSG, IGSF2, IGSF3, IGSF8, ITGB1, ITGA4, SLC3A2, or an ATP transporter. Association with a cell membrane includes binding of the immunomodulatory component to an internal or external membrane surface, anchoring the immunomodulatory component within a lipid bilayer, or spreading the immunomodulatory component through a lipid bilayer. The immunomodulatory component may be tethered to a scaffold protein or expressed as a fusion protein with a scaffold protein as described in co-owned U.S. Patent No. 10,195,290.
[0080] Extracellular vesicles In various embodiments, the composition comprises an extracellular vesicle. In certain embodiments, the extracellular vesicle is a cell-derived vesicle comprising a membrane enclosing an internal space, as described in co-owned U.S. Patent No. 10,195,290.
[0081] In various embodiments, the extracellular vesicles can be membrane-bound vesicles that have a smaller diameter than the cell from which they are derived. In some embodiments, the extracellular vesicles can be about 20-100 nm, 20-200 nm, 20-300 nm, 20-400 nm, 20-500 nm, 20-600 nm, 20-700 nm, 20-800 nm, 20-900 nm, 30-100 nm, 30-200 nm, 30-300 nm, 30-400 nm, 30-500 nm, 30-600 nm, 30-700 nm, 30-800 nm, 3 ... and having a longest dimension of about 20-1000 nm, such as 0-900 nm, 40-100 nm, 40-200 nm, 40-300 nm, 40-400 nm, 40-500 nm, 40-600 nm, 40-700 nm, 40-800 nm, 40-900 nm, 50-150 nm, 50-500 nm, 50-750 nm, 100-200 nm, 100-500 nm, or 500-1000 nm.
[0082] In certain embodiments, the extracellular vesicles are exosomes. In certain embodiments, the extracellular vesicles are nanovesicles. In certain embodiments, the extracellular vesicles are apoptotic bodies. In certain embodiments, the extracellular vesicles are cell fragments. In certain embodiments, the extracellular vesicles are vesicles derived from cells by direct or indirect manipulation. In certain embodiments, the extracellular vesicles are vesicle organelles. In various embodiments, the extracellular vesicles are vesicles produced by living cells.
[0083] In some embodiments, the extracellular vesicles are derived from a living organism. In some embodiments, the extracellular vesicles are derived from a dead organism. In some embodiments, the extracellular vesicles are derived from an explanted tissue. In some embodiments, the extracellular vesicles are derived from an explanted organ. In some embodiments, the extracellular vesicles are derived from cultured cells. In some of these embodiments, when the extracellular vesicles are produced in a cell culture system, the extracellular vesicles are further isolated (e.g., by separating the extracellular vesicles from the cultured cells). Separation can be achieved by sedimentation. For example, the extracellular vesicles can be separated at a concentration of 0.5-2.0, 0.6-1.0, 0.7-1.0, 0.8-1.0, 0.9-1.0, 1.0-1.1, 1.1-1.2, 1.2-1.3, 1.4-1.5, 1.0-1.5, 1.5-2.0, and 1.0-2.0 kg / m 3 The specific gravity of the extracellular vesicles may be 0.01 to 0.01. Separation may also be achieved by affinity purification. For example, extracellular vesicles may be purified by binding a population containing extracellular vesicles to a resin, the resin containing multiple ligands that have specific affinity for one or more proteins on the surface of the extracellular vesicles. The proteins may be tetraspanins (e.g., CD63, CD81, CD9), EWI proteins / immunoglobulin superfamily members (e.g., PTGFRN, IGSF8, IGSF3), integrins (e.g., ITGB1, ITGA4), ATP transporter proteins (e.g., ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3, ATP2B4), SLC3A2, BSG, or CD98hc.
[0084] In various embodiments, the extracellular vesicles comprise a lipid or fatty acid and a polypeptide. In certain embodiments, the extracellular vesicles further comprise a sugar. In certain embodiments, the extracellular vesicles further comprise a polynucleotide.
[0085] In various embodiments, the extracellular vesicle membrane includes an internal surface and an external surface and encapsulates an internal space. In some embodiments, the extracellular vesicle further comprises a payload, such as an immunomodulatory moiety as described herein. In certain embodiments, the payload is encapsulated within the internal space. In certain embodiments, the payload is displayed on the external surface of the extracellular vesicle. In certain embodiments, the payload spans the membrane of the extracellular vesicle. In various embodiments, the payload comprises a nucleic acid, a protein, a carbohydrate, a lipid, a small molecule, and / or a combination thereof. Methods for producing extracellular vesicles with a payload include electroporation, lyophilization, and genetic engineering of producer cells from which the extracellular vesicles can be isolated. See, for example, co-owned U.S. Pat. No. 10,195,290 and above. In some embodiments, the extracellular vesicle further comprises a targeting moiety that can be specific for a receiver, i.e., an organ, tissue, or cell, as described in co-owned U.S. Pat. No. 10,195,290. A fusion protein with a targeting moiety is used. For example, the fusion protein can include PTGFRN, BSG, IGSF2, IGSF3, IGSF8, ITGB1, ITGA4, SLC3A2, ATP transporter, or a fragment or variant thereof, and a targeting moiety. The targeting moiety can be used to target exosomes to specific organs, tissues, or cells for exosome-based therapy. In some embodiments, the targeting moiety is an antibody or an antigen-binding fragment thereof. Antibodies and antigen-binding fragments thereof include whole antibodies, polyclonal, monoclonal, and recombinant antibodies, fragments thereof, and further include single chain antibodies, humanized antibodies, murine antibodies, chimeric, mouse-human, mouse-primate, primate-human monoclonal antibodies, anti-idiotypic antibodies, antibody fragments, such as, for example, scFv, (scFv)2, Fab, Fab', and F(ab')2, F(ab1)2, Fv, dAb, and Fd fragments, diabodies, and antibody-related polypeptides. Antibodies and antigen-binding fragments thereof also include bispecific and multispecific antibodies, so long as they exhibit the desired biological activity or function.
[0086] Exosomes In various embodiments, the extracellular vesicles are exosomes. In certain embodiments, exosomes are small membrane-bound vesicles secreted by producer cells.
[0087] In some embodiments, exosomes from producer cells have a size of about 20-290 nm, 20-280 nm, 20-270 nm, 20-260 nm, 20-250 nm, 20-240 nm, 20-230 nm, 20-220 nm, 20-210 nm, 20-200 nm, 20-190 nm, 20-180 nm, 20-170 nm, 20-160 nm, 20-150 nm, 20-140 nm, 20-130 nm, 20-120 nm, 20-110 nm, 20-100 nm, 20-90 nm, 20-80 nm, 20-70 nm, 20-60 nm, 20-50 nm, 20-60 nm, 20-70 nm, 20-80 nm, 20-90 nm, 20-100 nm, 20-120 nm, 20-130 nm, 20-140 nm, 20-150 nm, 20-160 nm, 20-170 nm, 20-180 nm, 20-190 nm, 20-200 nm, 20-220 nm, 20-240 nm, 20-250 nm, 20-260 nm, 20-270 nm, 20-280 nm, 20-290 nm, 20-300 nm, 20-320 nm, 20-340 nm, 20-360 nm, 20-380 nm, 20-390 nm, 20-400 nm, 20-420 nm, 20-440 nm, 20-460 nm, nm, 20~40nm, 20~30nm, 30~300nm, 30~290nm, 30~280nm, 30~270nm, 30~260n m, 30~250nm, 30~240nm, 30~230nm, 30~220nm, 30~210nm, 30~200nm, 30~190n m, 30~180nm, 30~170nm, 30~160nm, 30~150nm, 30~140nm, 30~130nm, 30~120 nm, 30~110nm, 30~100nm, 30~90nm, 30~80nm, 30~70nm, 30~60nm, 30~50nm, 30 ~40nm, 40~300nm, 40~290nm, 40~280nm, 40~270nm, 40~260nm, 40~250nm, 40 ~240nm, 40~230nm, 40~220nm, 40~210nm, 40~200nm, 40~190nm, 40~180nm, 40 ~170nm, 40~160nm, 40~150nm, 40~140nm, 40~130nm, 40~120nm, 40~110nm, 4 0~100nm, 40~90nm, 40~80nm, 40~70nm, 40~60nm, 40~50nm, 50~300nm, 50~290 nm, 50~280nm, 50~270nm, 50~260nm, 50~250nm, 50~240nm, 50~230nm, 50~22 0nm, 50~210nm, 50~200nm, 50~190nm, 50~180nm, 50~170nm, 50~160nm, 50~15 0nm, 50~140nm, 50~130nm, 50~120nm, 50~110nm, 50~100nm, 50~90nm, 50~80n m, 50~70nm, 50~60nm, 60~300nm, 60~290nm, 60~280nm, 60~270nm, 60~260nm,60~250nm, 60~240nm, 60~230nm, 60~220nm, 60~210nm, 60~200nm, 60~190nm, 60~180nm, 60~170nm, 60~160nm, 60~150nm, 60~140nm, 60 ~130nm, 60~120nm, 60~110nm, 60~100nm, 60~90nm, 60~80nm, 60~70nm, 70~300nm, 70~290nm, 70~280nm, 70~270nm, 70~260nm, 70~250nm , 70~240nm, 70~230nm, 70~220nm, 70~210nm, 70~200nm, 70~190nm, 70~180nm, 70~170nm, 70~160nm, 70~150nm, 70~140nm, 70~130nm, 7 0~120nm, 70~110nm, 70~100nm, 70~90nm, 70~80nm, 80~300nm, 80~290nm, 80~280nm, 80~270nm, 80~260nm, 80~250nm, 80~240nm, 80~230 nm, 80~220nm, 80~210nm, 80~200nm, 80~190nm, 80~180nm, 80~170nm, 80~160nm, 80~150nm, 80~140nm, 80~130nm, 80~120nm, 80~110nm , 80~100nm, 80~90nm, 90~300nm, 90~290nm, 90~280nm, 90~270nm, 90~260nm, 90~250nm, 90~240nm, 90~230nm, 90~220nm, 90~210nm, 90~ and having a longest dimension of about 20 to 300 nm, such as 200 nm, 90 to 190 nm, 90 to 180 nm, 90 to 170 nm, 90 to 160 nm, 90 to 150 nm, 90 to 140 nm, 90 to 130 nm, 90 to 120 nm, 90 to 110 nm, 90 to 100 nm, 100 to 300 nm, 110 to 290 nm, 120 to 280 nm, 130 to 270 nm, 140 to 260 nm, 150 to 250 nm, 160 to 240 nm, 170 to 230 nm, 180 to 220 nm, or 190 to 210 nm.
[0088] In a particularly preferred embodiment, the exosomes from the producer cells described herein have a longest dimension of about 30-100 nm. In another preferred embodiment, the exosomes from the producer cells have a longest dimension of about 20-300 nm. In another preferred embodiment, the exosomes from the producer cells have a longest dimension of about 40-200 nm. In another embodiment, the population of exosomes described herein comprises a population in which 90% of the exosomes have a longest dimension of 20-300 nm. In another embodiment, the population of exosomes described herein comprises a population in which 95% of the exosomes have a longest dimension of 20-300 nm. In another embodiment, the population of exosomes described herein comprises a population in which 99% of the exosomes have a longest dimension of 20-300 nm. In another embodiment, the population of exosomes described herein comprises a population in which 90% of the exosomes have a longest dimension of 40-200 nm. In another embodiment, the population of exosomes described herein comprises a population in which 95% of the exosomes have a longest dimension between 40 and 200 nm. In another embodiment, the population of exosomes described herein comprises a population in which 99% of the exosomes have a longest dimension between 40 and 200 nm. In other preferred embodiments, the size of the exosomes or population of exosomes described herein is measured according to the methods described below.
[0089] In some embodiments, the exosomes are produced by producer cells. In some embodiments, the exosome membrane comprises one or more molecules derived from the producer cells. In some embodiments, the exosomes are produced in a cell culture system and isolated (e.g., by separating the exosomes from the producer cells). Separation can be achieved by sedimentation. For example, exosomes can be produced at concentrations of 0.5-2.0, 0.6-1.0, 0.7-1.0, 0.8-1.0, 0.9-1.0, 1.0-1.1, 1.1-1.2, 1.2-1.3, 1.4-1.5, 1.0-1.5, 1.5-2.0, and 1.0-2.0 kg / m 3The specific gravity of the extracellular vesicles may be 0.01 to 0.01. Separation may also be achieved by affinity purification. For example, extracellular vesicles may be purified by binding a population containing extracellular vesicles to a resin, the resin comprising a plurality of ligands having specific affinity for one or more proteins on the surface of the extracellular vesicles. The one or more proteins on the surface of the extracellular vesicles may be tetraspanins (e.g., CD63, CD81 and / or CD9), EWI proteins / immunoglobulin superfamily members (e.g., PTGFRN, IGSF8 and / or IGSF3), integrins (e.g., ITGB1 and / or ITGA4), ATP transporter proteins (e.g., ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3 and / or ATP2B4), SLC3A2, BSG, or CD98hc. The protein can optionally have additional activity as an immune modulating component displayed on the surface of exosomes via fusion to a polypeptide moiety with desired pharmacological activity, such as, for example, an antibody, antibody fragment, scFv, etc. with checkpoint inhibitory activity. Such antibodies are known in the art, such as ipilimumab, which targets CTLA-4, nivolumab, cemiplimab, and pembrolizumab, which target PD-1, and atezolizumab, avelumab, durvalumab, each of which targets PD-L1 (see, for example, Pardoll DM (March 2012) "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12(4):252-64, which is incorporated herein by reference).
[0090] In some embodiments, the exosome membrane comprises an internal surface and an external surface. In certain embodiments, the internal surface faces the inner core of the exosome. In certain embodiments, the external surface may contact an endosome, multivesicular body, or membrane / cytoplasm of a producer or target cell.
[0091] In some embodiments, the exosome membrane comprises lipids and fatty acids. In some embodiments, the exosome membrane comprises phospholipids, glycolipids, fatty acids, sphingolipids, phosphoglycerides, sterols, cholesterol, and phosphatidylserine. In some embodiments, the lipids and fatty acids can be one or more of those listed in Table 1.
[0092] In certain embodiments, exosomes comprise a lipid bilayer composed of an inner leaflet and an outer leaflet. The composition of the inner and outer leaflets can be determined by transbilayer distribution assays known in the art, for example, see Kuypers et al. Biohim Biophys Acta 1985 819:170. In some embodiments, the composition of the outer leaflet is about 70-90% choline phospholipid, about 0-15% acid phospholipid, and about 5-30% phosphatidylethanolamine. In some embodiments, the composition of the inner leaflet is about 15-40% choline phospholipid, about 10-50% acid phospholipid, and about 30-60% phosphatidylethanolamine.
[0093] In some embodiments, the exosome membrane further comprises one or more polypeptides. In certain embodiments, the exosome membrane further comprises one or more polypeptides, such as spectrin, myosin-like polypeptide, band 3, SLC4A1, actin, actin-like polypeptide, glyceraldehyde 3-P dehydrogenase (G3PD), tetraspanins (e.g., CD63, CD81, and / or CD9), Alix and TSG101, integrins (e.g., ITGB1 and / or ITGA4), selectins, CR1, TNFRI, protease, glycosylphosphatidylinositol (GPI)-linked proteins, and the like. In some embodiments, the exosome comprises one or more polypeptides selected from the list below, including, but not limited to, proteins or histones, EWI proteins / immunoglobulin superfamily members (e.g., PTGFRN, IGSF8 and / or IGSF3), ATP transporter proteins (e.g., ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3 and / or ATP2B4), SLC3A2, BSG, or CD98hc. In some embodiments, the exosome comprises at least one polypeptide selected from Table 2.
[0094] In some embodiments, exosomes contain polypeptides on their surface. In some embodiments, exosomes are modified to contain one or more polypeptides. In some embodiments, producer cells are modified to contain one or more polypeptides. In some embodiments, producer cells naturally contain one or more polypeptides and exosomes derived therefrom also contain the polypeptides. The level of any desired surface marker can be modified directly on the exosomes (e.g., by contacting a complex with a recombinantly produced polypeptide to result in the complex being inserted or complexed into the membrane). Alternatively or additionally, the level of any desired surface marker can be modified directly on the producer cells (e.g., by contacting a complex with a recombinantly produced polypeptide to result in the complex being inserted or complexed into the membrane of the cell). Alternatively, the producer cells can be modified by transducing an exogenous nucleic acid into the producer cells to express the desired surface marker. The surface marker can already be naturally present on the producer cells, in which case the exogenous construct can result in overexpression of the marker and increased concentration of the marker in or on the producer cells. Alternatively, naturally expressed surface markers can be removed from the producer cells (e.g., by inducing gene silencing in the producer cells). The polypeptides can confer different functionalities to the exosomes (e.g., specific targeting capabilities, delivery functions (e.g., fusion molecules), enzymatic functions, increased or decreased half-life in vivo, etc.). In some embodiments, the polypeptides include, but are not limited to, CD47, CD55, CD49, CD40, CD133, CD59, glypican-1, CD9, CD63, CD81, integrins, selectins, lectins, and cadherins.
[0095] In certain embodiments, the exosome comprises one or more polypeptides on its surface, the polypeptides being selected from a group of proteins recently identified to be enriched on the surface of exosomes (described in detail in co-owned U.S. Patent Application Nos. 62 / 550,543 and PCT / US2018 / 048026, which are incorporated by reference in their entireties). This group of polypeptides includes prostaglandin F2 receptor negative regulator (PTGFRN), basigin (BSG), immunoglobulin superfamily member 3 (IGSF3), immunoglobulin superfamily member 8 (IGSF8), integrin beta-1 (ITGB1), integrin alpha-4 (ITGA4), 4F2 cell surface antigen heavy chain (SLC3A2), and the class of ATP transporter proteins (ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3, ATP2B4).
[0096] In various embodiments, one or more polypeptides on the exosome surface comprise an antibody or antigen-binding fragment. The antibody or antigen-binding fragment may be derived from a natural source or may be partially or wholly synthetically produced. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the monoclonal antibody is an IgG antibody. In certain embodiments, the monoclonal antibody is an IgG1, IgG2, IgG3, or IgG4. In some other embodiments, the antibody is a polyclonal antibody. In certain embodiments, the antigen-binding fragment is selected from Fab, Fab', and F(ab')2, F(ab1)2, Fv, dAb, and Fd fragments. In certain embodiments, the antigen-binding fragment is an scFv or (scFv)2 fragment. In certain other embodiments, the antibody or antigen-binding fragment is a Nanobody® (single domain antibody). In some embodiments, the antibody or antigen-binding fragment is a bispecific or multispecific antibody. In various embodiments, the antibody or antigen-binding fragment thereof binds to mesothelin.
[0097] In some embodiments, the exosome comprises on its surface a fusion protein comprising (1) PTGFRN, or a fragment thereof, and (2) an antibody, or antigen-binding fragment thereof, where the antibody, or antigen-binding fragment thereof, binds to PD-1, PD-1L, CSF1-R, or other immunomodulatory component.
[0098] In some embodiments, the exosome membrane further comprises one or more polysaccharides, such as glycans.
[0099] In some embodiments, exosomes deliver a payload (therapeutic agent) to a target. The payload is a therapeutic agent that acts on a target (e.g., a target cell) that comes into contact with the exosome. In certain embodiments, the payload is an immunomodulatory component, e.g., an inhibitory RNA. The contact can occur in vitro or in a subject. Payloads that can be introduced into exosomes and / or producer cells include therapeutic agents such as nucleotides (e.g., nucleotides that contain a detectable moiety or toxin or that disrupt transcription), nucleic acids (e.g., DNA or mRNA molecules that code for polypeptides such as enzymes, or RNA molecules with regulatory functions such as miRNA, dsDNA, lncRNA, siRNA), amino acids (e.g., amino acids that contain a detectable moiety or toxin that disrupts translation), polypeptides (e.g., enzymes), lipids, carbohydrates, small molecules (e.g., small molecule drugs and toxins), and combinations thereof. In certain embodiments, exosomes deliver two or more therapeutic agents. In certain embodiments, the therapeutic agent is one or more nucleic acids that inhibit one or more target genes. In certain embodiments, the therapeutic agent includes an antibody and a nucleic acid. In certain embodiments, therapeutic agents include nucleic acids and small molecules. In certain embodiments, therapeutic agents include CSF1R inhibitors such as clinical candidates pexidartinib, PLX7486, ARRY-382, JNJ-40346527, BLZ945, emactuzumab, AMG820, and IMC-CS4, including proteinaceous immunomodulatory components such as others described in Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Ruttinger D (2017) "Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy". Journal for Immunotherapy of Cancer. 5(1):53.See also Patel S, Player MR (2009) "Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease". Curr Top Med Chem. 9:599-610. A phase I / II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in early clinical trials for metastatic pancreatic cancer (TGCT, diffuse pigmented villonodular synovitis D-PVNS, A. (See Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread, and Novel Combination Shows Promising Responses in Pancreatic Cancer Nov 2017). In certain embodiments, the therapeutic agent comprises an immune checkpoint inhibitor. In certain embodiments, an immune checkpoint inhibitor, such as ipilimumab, which targets CTLA-4, nivolumab, cemiplimab, and pembrolizumab, which target PD-1, and antibodies such as atezolizumab, avelumab, and durvalumab, each of which targets PD-L1.
[0100] Exosomes can interact with target cells via membrane fusion and deliver the payload (e.g., therapeutic agent) in the exosome composition to the surface or cytoplasm of the target cell. In some embodiments, membrane fusion occurs between the exosome and the plasma membrane of the target cell. In other embodiments, membrane fusion occurs between the exosome and the endosomal membrane of the target cell.
[0101] In some embodiments, the exosome comprises a receiver polypeptide. The receiver polypeptide can be synthetic. In some embodiments, the receiver polypeptide is introduced into a producer cell (e.g., an exogenous nucleic acid encoding the receiver polypeptide is introduced into the producer cell), or a recombinant receiver polypeptide made outside of the producer cell (e.g., synthesized by a protein expression system). In some embodiments, the receiver polypeptide (e.g., a recombinantly produced polypeptide) is directly introduced into the exosome (e.g., after the exosome is isolated from the producer cell). In some embodiments, the receiver polypeptide can be on the surface of the exosome. In some embodiments, the receiver polypeptide can target the exosome to a specific target (e.g., a target such as a pathogen, a metabolite, a protein, a polypeptide complex, or a cell such as a non-functioning cell or a cancer cell) circulating in the circulatory system of a subject, such as blood, or a target resident in a tissue (such as a diseased tissue).
[0102] In some embodiments, the exosomes are synthetic. That is, after exosomes are recovered from producer cells, they are modified to add additional components. For example, exosomes can contain a payload, such as a therapeutic polypeptide, a nucleic acid (such as DNA or RNA) or other polynucleotide, a polysaccharide or glycan, a lipid or fatty acid, a large biological, a small molecule, or a toxin, that is not found in the exosomes when recovered from the producer cells. In some embodiments, the exosomes are modified (e.g., by introducing a payload or otherwise modifying the content of the complex, such as by changing the protein, lipid, or glycan content of the membrane). For example, exosomes are first isolated from producer cells and then modified as necessary, thereby generating synthetic exosomes. In some embodiments, the producer cells are modified. For example, exogenous nucleic acids, exogenous polypeptides, or small molecules, or toxins can be introduced into the producer cells. Alternatively or in addition, the producer cells can be modified in other ways (e.g., by modifying the cell or membrane content, such as by changing the lipid or glycan content of the cell membrane). The exosomes generated from the modified producer cells contain one or more of the modifications of the producer cells. This process produces synthetic exosomes. In some embodiments, both the producer cells and the exosomes isolated from the producer cells are modified as described herein.
[0103] Nanovesicles In various embodiments, the extracellular vesicles are nanovesicles. In certain embodiments, nanovesicles are small cell-derived vesicles that include a membrane that encloses an internal space and are generated from cells by direct or indirect manipulation such that nanovesicles are not produced by cells without manipulation. Suitable manipulation of cells includes, but is not limited to, continuous extrusion, treatment with alkaline solutions, sonication, or combinations thereof, which in some instances may result in the destruction of producer cells.
[0104] In various embodiments, the nanovesicles have a longest dimension of about 20-250 nm, such as about 20-100 nm, 20-150 nm, 20-200 nm, 30-100 nm, 30-150 nm, 30-200 nm, 30-250 nm, 40-100 nm, 40-150 nm, 40-200 nm, 40-250 nm, 50-100 nm, 50-150 nm, 50-200 nm, 50-250 nm, 100-200 nm, or 150-250 nm.
[0105] In various embodiments, the nanovesicles are derived from producer cells. In certain embodiments, the nanovesicles are generated from producer cells by direct or indirect manipulation. Suitable manipulations include, but are not limited to, continuous extrusion, treatment with alkaline solutions, sonication, or combinations thereof. In some of these embodiments, the manipulations may result in the destruction of producer cells. In some preferred embodiments, the population of nanovesicles is substantially free of vesicles derived from producer cells by direct budding from the plasma membrane or fusion with the plasma membrane of late endosomes.
[0106] In some embodiments, the nanovesicles are isolated from the producer cells based on their size, density, biochemical parameters, or a combination thereof. In certain embodiments, isolation can be achieved by sedimentation. For example, the nanovesicles can be isolated from the producer cells based on their size, density, biochemical parameters, or a combination thereof. For example, the nanovesicles can be isolated from the producer cells based on their size, density, biochemical parameters, or a combination thereof. In certain embodiments, isolation can be achieved by sedimentation. For example, the nanovesicles can be isolated from the producer cells based on their size, density, biochemical parameters, or a combination thereof. 3 It may have a specific gravity of
[0107] In various embodiments, the nanovesicles comprise a lipid or fatty acid and a polypeptide. In certain embodiments, the nanovesicles further comprise a sugar. In certain embodiments, the nanovesicles further comprise a polynucleotide. In some embodiments, the nanovesicles further comprise a receiver. In some embodiments, the nanovesicles further comprise a payload. In some of these embodiments, the payload comprises a nucleic acid, a protein, a carbohydrate, a lipid, a small molecule, and / or a combination thereof.
[0108] immunomodulatory component In one aspect, the extracellular vesicle, e.g., exosome, comprises at least one immunomodulatory component that increases macrophage polarization from M2 phenotype to M1 phenotype. In one aspect, the increase from M2 phenotype to M1 phenotype is evaluated with respect to a reference sample that comprises a population of M2 macrophages. In one aspect, the increase achieved by the extracellular vesicles of the present disclosure is greater than or equal to that achieved by an equimolar amount of the immunomodulatory component alone. In certain embodiments, the immunomodulatory component is a polynucleotide that increases macrophage polarization. In certain embodiments, the polynucleotide is a nucleic acid that inhibits at least one gene, such as proto-oncogenes and other types of genes whose inhibition promotes increased polarization from an M2 phenotype to an M1 phenotype, including, but not limited to, the following genes: KRAS, HRAS, NRAS, HIF1-alpha, HIF1-beta, Sp1, P300, LKB1, AMPK, STAT3, STAT6, n-MYC, c-MYC, HCAR1, A2AB, IDO, TDO, arginase, glutaminase, CEBP / β, Pi3Kγ, and PKM2.In certain embodiments, combinations of polynucleotides with proteinaceous immunomodulatory components are contemplated, such as antibodies or antibody fragments targeting PD-1, PD-L1, CTLA-4 (e.g., ipilimumab, which targets CTLA-4, nivolumab, cemiplimab, and pembrolizumab, which target PD-1, and atezolizumab, avelumab, and durvalumab, each of which targets PD-L1), CSF1R inhibitors (e.g., clinical candidates pexidartinib, PLX7486, ARRY-382, JNJ-40346527, BLZ945, emactuzumab, AMG820, and IMC-CS4, and other combinations of polynucleotides, such as, for example, Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Ruttinger D (2017) "Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy". Journal of for Immunotherapy of Cancer. 5(1):53, (Patel S, Player MR (2009) "Colony-stimulating factor-1 receptor inhibitors. for the treatment of cancer and inflammatory disease”. Curr Top Med Chem. 9:599-610. A phase I / II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R monoclonal antibody in early clinical trials for metastatic pancreatic cancer. See, e.g., antibodies, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS, A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread, and Novel Combination Shows Promising Responses in Pancreatic Cancer Nov 2017, as well as other immunomodulatory components useful in the treatment of cancer and inflammatory conditions.
[0109] In some of these embodiments, the nucleic acid includes, but is not limited to, mRNA, miRNA, siRNA, antisense RNA, shRNA, lncRNA, and dsDNA. In some of these embodiments, the nucleic acid is RNA (e.g., mRNA, miRNA, siRNA, antisense RNA, shRNA, or lncRNA). In some of these embodiments, when the polynucleotide is an mRNA, it can be translated into a desired polypeptide. In some of these embodiments, the polynucleotide is a microRNA (miRNA), pri-miRNA, or pre-miRNA molecule. In some of these embodiments, the miRNA is delivered to the cytoplasm of the target cell such that the miRNA molecule can silence the native mRNA in the target cell. In some of these embodiments, the polynucleotide is a small interfering RNA (siRNA) or a short hairpin RNA (shRNA) that can interfere with the expression of an oncogene or other dysregulated polypeptide. In some of these embodiments, the siRNA is delivered to the cytoplasm of the target cell such that the siRNA molecule can silence the native mRNA in the target cell. In some of these embodiments, the polynucleotide is an antisense RNA complementary to the mRNA. In some embodiments, the polynucleotide is a long non-coding RNA (lncRNA) that can control gene expression and regulate disease. In some embodiments, the polynucleotide is an antisense oligonucleotide (ASO). In various embodiments, the ASO is single-stranded or double-stranded DNA, RNA, or a DNA / RNA hybrid. See, for example, Antisense Oligodeoxynucleotides and Antisense RNA: Novel Pharmacological and Therapeutic Drugs, incorporated herein by reference for all purposes. See Agents, CRC Press, Boca Raton, FL, 1997.
[0110] In some embodiments, the polynucleotide is a DNA that can be transcribed into RNA. In some of these embodiments, the transcribed RNA can be translated into a desired polypeptide. In certain embodiments, the nucleic acid inhibits at least one gene consisting of KRAS, HRAS, NRAS, HIF1-alpha, HIF1-beta, Sp1, P300, LKB1, AMPK, STAT3, STAT6, n-MYC, c-MYC, HCAR1, A2AB, IDO, TDO, arginase, CEBP / β, Pi3Kγ, glutaminase, and PKM2. In certain embodiments, the nucleic acid inhibits at least one gene consisting of STAT3, STAT6, CEBP / β, Pi3Kγ, KRAS, and HIF1-alpha. In certain embodiments, the nucleic acid is an inhibitory RNA that inhibits at least one gene consisting of KRAS, HRAS, NRAS, HIF1-alpha, HIF1-beta, Sp1, P300, LKB1, AMPK, STAT3, STAT6, n-MYC, c-MYC, HCAR1, A2AB, IDO, TDO, arginase, CEBP / β, Pi3Kγ, glutaminase, and PKM2. In certain embodiments, the nucleic acid is an inhibitory RNA that inhibits at least one gene consisting of STAT3, STAT6, CEBP / β, Pi3Kγ, KRAS, and HIF1-alpha. In certain embodiments, the nucleic acid is an antisense oligonucleotide (ASO) that inhibits at least one gene consisting of KRAS, HRAS, NRAS, HIF1-alpha, HIF1-beta, Sp1, P300, LKB1, AMPK, STAT3, STAT6, n-MYC, c-MYC, HCAR1, A2AB, IDO, TDO, arginase, CEBP / β, Pi3Kγ, glutaminase, and PKM2. In certain embodiments, the nucleic acid is an antisense oligonucleotide (ASO) that inhibits at least one gene consisting of STAT3, STAT6, CEBP / β, Pi3Kγ, KRAS, and HIF1-alpha. In certain embodiments, the nucleic acid inhibits the human KRAS proto-oncogene. In certain embodiments, the nucleic acid is an inhibitory RNA that inhibits the human KRAS proto-oncogene. In certain embodiments, the nucleic acid inhibits STAT3.
[0111] In some embodiments of the invention, the nucleic acid is a known antisense oligonucleotide (ASO), examples of which are listed in Table 0. In certain embodiments, the ASO comprises a sequence at least 90%-99% identical to a known ASO, such as those listed in Table 0. In certain embodiments, the ASO inhibits STAT3. In various embodiments, the ASO comprises a sequence at least 90%-99% identical to TAAGCTGATAATTCAACTCA (SEQ ID NO: 1). In certain embodiments, the ASO comprises a sequence at least 90% identical to SEQ ID NO: 1. In certain embodiments, the ASO comprises a sequence at least 91% identical to SEQ ID NO: 1. In certain embodiments, the ASO comprises a sequence at least 92% identical to SEQ ID NO: 1. In certain embodiments, the ASO comprises a sequence at least 93% identical to SEQ ID NO: 1. In certain embodiments, the ASO comprises a sequence at least 94% identical to SEQ ID NO: 1. In certain embodiments, the ASO comprises a sequence at least 95% identical to SEQ ID NO: 1. In certain embodiments, the ASO comprises a sequence at least 96% identical to SEQ ID NO: 1. In certain embodiments, the ASO comprises a sequence at least 97% identical to SEQ ID NO: 1. In certain embodiments, the ASO comprises a sequence at least 98% identical to SEQ ID NO: 1. In certain embodiments, the ASO comprises a sequence at least 99% identical to SEQ ID NO: 1. In certain embodiments, the ASO comprises the sequence of SEQ ID NO: 1. In some embodiments, the ASO is modified by MOE, O-methyl, or LNA chemistry. In some embodiments, the ASO further comprises a cholesterol tag at the 5' or 3' end.
[0112] In some embodiments, the nucleic acid is an antisense oligonucleotide (ASO) that inhibits STAT6. In various embodiments, the ASO comprises a sequence at least 90%-99% identical to TGAGCGAATGGACAGGTCTT (SEQ ID NO:2). In certain embodiments, the ASO comprises a sequence at least 90% identical to SEQ ID NO:2. In certain embodiments, the ASO comprises a sequence at least 91% identical to SEQ ID NO:2. In certain embodiments, the ASO comprises a sequence at least 92% identical to SEQ ID NO:2. In certain embodiments, the ASO comprises a sequence at least 93% identical to SEQ ID NO:2. In certain embodiments, the ASO comprises a sequence at least 94% identical to SEQ ID NO:2. In certain embodiments, the ASO comprises a sequence at least 95% identical to SEQ ID NO:2. In certain embodiments, the ASO comprises a sequence at least 96% identical to SEQ ID NO:2. In certain embodiments, the ASO comprises a sequence at least 97% identical to SEQ ID NO:2. In certain embodiments, the ASO comprises a sequence at least 98% identical to SEQ ID NO:2. In certain embodiments, the ASO comprises a sequence at least 99% identical to SEQ ID NO:2. In certain embodiments, the ASO comprises the sequence of SEQ ID NO: 2. In some embodiments, the ASO is modified with MOE, O-methyl, or LNA chemistry. In some embodiments, the ASO further comprises a cholesterol tag at the 5' or 3' end.
[0113] In some embodiments, the nucleic acid is an antisense oligonucleotide (ASO) that inhibits CebpB. In various embodiments, the ASO comprises a sequence at least 90%-99% identical to TGGATTTAAAGGCAGGCGGC (SEQ ID NO:3). In certain embodiments, the ASO comprises a sequence at least 90% identical to SEQ ID NO:3. In certain embodiments, the ASO comprises a sequence at least 91% identical to SEQ ID NO:3. In certain embodiments, the ASO comprises a sequence at least 92% identical to SEQ ID NO:3. In certain embodiments, the ASO comprises a sequence at least 93% identical to SEQ ID NO:3. In certain embodiments, the ASO comprises a sequence at least 94% identical to SEQ ID NO:3. In certain embodiments, the ASO comprises a sequence at least 95% identical to SEQ ID NO:3. In certain embodiments, the ASO comprises a sequence at least 96% identical to SEQ ID NO:3. In certain embodiments, the ASO comprises a sequence at least 97% identical to SEQ ID NO:3. In certain embodiments, the ASO comprises a sequence at least 98% identical to SEQ ID NO:3. In certain embodiments, the ASO comprises a sequence at least 99% identical to SEQ ID NO:3. In certain embodiments, the ASO comprises the sequence of SEQ ID NO: 3. In some embodiments, the ASO is modified with MOE, O-methyl, or LNA chemistry. In some embodiments, the ASO further comprises a cholesterol tag at the 5' or 3' end.
[0114] In some embodiments, the nucleic acid is an antisense oligonucleotide (ASO) that inhibits Pi3Kγ. In various embodiments, the ASO comprises a sequence at least 90%-99% identical to TTGGGTAAAGTCGTGCAGCA (SEQ ID NO: 4). In certain embodiments, the ASO comprises a sequence at least 90% identical to SEQ ID NO: 4. In certain embodiments, the ASO comprises a sequence at least 91% identical to SEQ ID NO: 4. In certain embodiments, the ASO comprises a sequence at least 92% identical to SEQ ID NO: 4. In certain embodiments, the ASO comprises a sequence at least 93% identical to SEQ ID NO: 4. In certain embodiments, the ASO comprises a sequence at least 94% identical to SEQ ID NO: 4. In certain embodiments, the ASO comprises a sequence at least 95% identical to SEQ ID NO: 4. In certain embodiments, the ASO comprises a sequence at least 96% identical to SEQ ID NO: 4. In certain embodiments, the ASO comprises a sequence at least 97% identical to SEQ ID NO: 4. In certain embodiments, the ASO comprises a sequence at least 98% identical to SEQ ID NO: 4. In certain embodiments, the ASO comprises a sequence at least 99% identical to SEQ ID NO: 4. In certain embodiments, the ASO comprises the sequence of SEQ ID NO: 4. In some embodiments, the ASO is modified with MOE, O-methyl, or LNA chemistry. In some embodiments, the ASO further comprises a cholesterol tag at the 5' or 3' end.
[0115] In some embodiments, the nucleic acid is an antisense oligonucleotide (ASO) that inhibits HIF1α. In various embodiments, the ASO comprises a sequence at least 90%-99% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 90% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 91% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 92% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 93% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 94% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 95% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 96% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 97% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 98% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 99% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises the sequence of SEQ ID NO: 5. In some embodiments, the ASO is modified with MOE, O-methyl, or LNA chemistry. In some embodiments, the ASO further comprises a cholesterol tag at the 5' or 3' end.
[0116] In some embodiments, the nucleic acid is an antisense oligonucleotide (ASO) that inhibits HIF1α. In various embodiments, the ASO comprises a sequence at least 90%-99% identical to GTGCAGTATTGTAGCCAGGC (SEQ ID NO:5). In certain embodiments, the ASO comprises a sequence at least 90% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 91% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 92% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 93% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 94% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 95% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 96% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 97% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 98% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises a sequence at least 99% identical to SEQ ID NO:5. In certain embodiments, the ASO comprises the sequence of SEQ ID NO: 5. In some embodiments, the ASO is modified with MOE, O-methyl, or LNA chemistry. In some embodiments, the ASO further comprises a cholesterol tag at the 5' or 3' end.
[0117] In some embodiments, the nucleic acid is an antisense oligonucleotide (ASO) that inhibits Kras. In various embodiments, the ASO comprises a sequence at least 90%-99% identical to GTAGCATGTAAATATAGCCC (SEQ ID NO: 6). In certain embodiments, the ASO comprises a sequence at least 90% identical to SEQ ID NO: 6. In certain embodiments, the ASO comprises a sequence at least 91% identical to SEQ ID NO: 6. In certain embodiments, the ASO comprises a sequence at least 92% identical to SEQ ID NO: 6. In certain embodiments, the ASO comprises a sequence at least 93% identical to SEQ ID NO: 6. In certain embodiments, the ASO comprises a sequence at least 94% identical to SEQ ID NO: 6. In certain embodiments, the ASO comprises a sequence at least 95% identical to SEQ ID NO: 6. In certain embodiments, the ASO comprises a sequence at least 96% identical to SEQ ID NO: 6. In certain embodiments, the ASO comprises a sequence at least 97% identical to SEQ ID NO: 6. In certain embodiments, the ASO comprises a sequence at least 98% identical to SEQ ID NO: 6. In certain embodiments, the ASO comprises a sequence at least 99% identical to SEQ ID NO: 6. In certain embodiments, the ASO comprises the sequence of SEQ ID NO: 6. In some embodiments, the ASO is modified with MOE, O-methyl, or LNA chemistry. In some embodiments, the ASO further comprises a cholesterol tag at the 5' or 3' end.
[0118] In certain embodiments, the composition comprises an extracellular vesicle, e.g., an exosome, and further comprises an additional immunomodulatory component that is a small molecule, an antibody, or an antibody fragment known to promote macrophage polarization, hi certain embodiments, the additional immunomodulatory component is a colony stimulating factor 1 receptor (CSF1R) inhibitor.
[0119] In certain embodiments, the composition comprises an additional immunomodulatory component having anti-tumor activity. In some embodiments, the additional immunomodulatory component regulates the innate immune response. In some of these embodiments, the additional immunomodulatory component targets natural killer cells. In some other embodiments, the additional immunomodulatory component regulates the adaptive immune response. In some of these embodiments, the additional immunomodulatory component targets cytotoxic T cells.
[0120] In some embodiments, the additional immunomodulatory component is located on the surface of the extracellular vesicle. In some embodiments, the additional immunomodulatory component is located on the interior of the extracellular vesicle. In some embodiments, the additional immunomodulatory component is located both on the surface and in the interior of the extracellular vesicle.
[0121] In some embodiments, the additional immunomodulatory component is expressed in its full-length form in the producer cell. In other embodiments, the additional immunomodulatory component is expressed as a translational fusion protein to an exosome surface protein, resulting in higher levels of expression of the biologically active portion of the immunomodulatory compound on the surface of the exosome. In some embodiments, the additional immunomodulatory compound is a soluble protein that is expressed as a translational fusion protein to an exosome surface protein such that the soluble protein is retained on the surface of the exosome.
[0122] In some embodiments, the additional immunomodulatory component is an inhibitor against a negative checkpoint regulator, such as, for example, A2AR, B7-H3 (CD276), B7-H4 (VTCN1), BTLA, CTLA-4, IDO, KIR, LAG3, NOX2, PD-1, TIM-3, VISTA, SIGLEC7 (CD328) and SIGLEC9 (CD329). In some embodiments, the additional immunomodulatory component is an inhibitor against a binding partner of a negative checkpoint regulator, such as, for example, PD-L1 and PD-L2.
[0123] In certain embodiments, the additional immunomodulatory component is an inhibitor of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). In some of these embodiments, the CTLA-4 inhibitor is a monoclonal antibody to CTLA-4. In certain embodiments, the inhibitor is a fragment of a monoclonal antibody to CTLA-4. In certain embodiments, the antibody fragment is an scFv, (scFv)2, Fab, Fab', and F(ab')2, F(ab1)2, Fv, dAb, or Fd of a monoclonal antibody to CTLA-4. In certain embodiments, the inhibitor is a nanobody, bispecific antibody, or multispecific antibody against CTLA-4. In some specific embodiments, the monoclonal antibody is ipilimumab. In some specific embodiments, the monoclonal antibody is tremelimumab.
[0124] In certain embodiments, the additional immunomodulatory component is an inhibitor of programmed cell death protein 1 (PD-1). In certain embodiments, the additional immunomodulatory component is an inhibitor of programmed death-ligand 1 (PD-L1). In certain embodiments, the additional immunomodulatory component is an inhibitor of programmed death-ligand 2 (PD-L2). In some embodiments, the PD-1, PD-L1, or PD-L2 inhibitor is a PD-1, PD-L1, or PD-L2 monoclonal antibody. In certain embodiments, the inhibitor is a fragment of a PD-1, PD-L1, or PD-L2 monoclonal antibody. In certain embodiments, the antibody fragment is an scFv, (scFv)2, Fab, Fab', and F(ab')2, F(ab1)2, Fv, dAb, or Fd of a PD-1, PD-L1, or PD-L2 monoclonal antibody. In certain embodiments, the inhibitor is a nanobody, bispecific antibody, or multispecific antibody against PD-1, PD-L1, or PD-L2. In some specific embodiments, the monoclonal antibody is nivolumab. In some specific embodiments, the monoclonal antibody is pembrolizumab. In some specific embodiments, the monoclonal antibody is pidilizumab. In some specific embodiments, the monoclonal antibody is atezolizumab. In some specific embodiments, the monoclonal antibody is avelumab.
[0125] In certain embodiments, the additional immunomodulatory component is an inhibitor of lymphocyte-associated gene 3 (LAG3). In some of these embodiments, the LAG3 inhibitor is a monoclonal antibody to LAG3, such as, for example, BMS-986016 (see Clinical Trial No. NCT01968109 for "Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors" at ClinicalTrials.gov).
[0126] In certain embodiments, the additional immunomodulatory component is an inhibitor of T cell immunoglobulin mucin-containing protein 3 (TIM-3). In certain embodiments, the additional immunomodulatory component is an inhibitor of B and T lymphocyte attenuation factor (BTLA). In certain embodiments, the additional immunomodulatory component is an inhibitor of T cell immunoreceptor with Ig and ITIM domains (TIGIT). In certain embodiments, the additional immunomodulatory component is an inhibitor of V domain Ig suppressor of T cell activation (VISTA). In certain embodiments, the additional immunomodulatory component is an inhibitor of adenosine A2a receptor (A2aR). In certain embodiments, the additional immunomodulatory component is an inhibitor of killer cell immunoglobulin-like receptor (KIR). In certain embodiments, the additional immunomodulatory component is an inhibitor of indoleamine 2,3-dioxygenase (IDO). In certain embodiments, the additional immunomodulatory component is an inhibitor of CD20, CD39, or CD73.
[0127] In some embodiments, the additional immunomodulatory component is an activator for a positive costimulatory molecule. In some embodiments, the additional immunomodulatory component is an activator for a binding partner of a positive costimulatory molecule.
[0128] In some embodiments, the additional immunomodulatory component is an activator of a TNF receptor superfamily member, such as an agonist antibody or a natural ligand or a TNF receptor superfamily member. In certain embodiments, the TNF receptor superfamily member is selected from the group consisting of CD120a, CD120b, CD18, OX40, CD40, Fas receptor, M68, CD27, CD30, 4-1BB, TRAILR1, TRAILR2, TRAILR3, TRAILR4, RANK, OCIF, TWEAK receptor, TACI, BAFF receptor, ATAR, CD271, CD269, GITR, TROY, CD358, TRAMP, and XEDAR. In some embodiments, the additional immunomodulatory component is a TNF superfamily member. In certain embodiments, the TNF superfamily member is selected from the group consisting of TNFα, TNF-C, OX40L, CD40L, FasL, LIGHT, TL1A, CD27L, Siva, CD153, 4-1BB ligand, TRAIL, RANKL, TWEAK, APRIL, BAFF, CAMLG, NGF, BDNF, NT-3, NT-4, GITR ligand, and EDA-2.
[0129] In certain embodiments, the additional immunomodulatory component is an activator of TNF receptor superfamily member 4 (OX40). In some of these embodiments, the activator of OX40 is an agonist antibody of OX40. In some others of these embodiments, the activator of OX40 is OX40 ligand (OX40L).
[0130] In certain embodiments, the additional immunomodulatory component is an activator of CD27. In some of these embodiments, the activator of CD27 is a CD27 agonist antibody. In some others of these embodiments, the activator of CD27 is a CD27 ligand (CD27L).
[0131] In certain embodiments, the additional immunomodulatory component is an activator of CD40. In some of these embodiments, the activator of CD40 is a CD40 agonist antibody. In some others of these embodiments, the activator of CD40 is CD40 ligand (CD40L).
[0132] In certain embodiments, the additional immunomodulatory component is an activator of glucocorticoid-induced TNFR-related protein (GITR). In some of these embodiments, the activator of GITR is an agonist antibody of GITR. In some others of these embodiments, the activator of GITR is a natural ligand of GITR.
[0133] In certain embodiments, the additional immunomodulatory component is an activator of 4-1BB. In some of these embodiments, the activator of 4-1BB is an agonistic antibody of 4-1BB. In some others of these embodiments, the activator of 4-1BB is a natural ligand of 4-1BB.
[0134] In some embodiments, the additional immunomodulatory component is a Fas receptor (Fas). In some of these embodiments, the Fas receptor is displayed on the surface of the extracellular vesicle. In some other embodiments, the additional immunomodulatory component is a Fas ligand (FasL). In some of these embodiments, the Fas ligand is displayed on the surface of the extracellular vesicle. In certain embodiments, the additional immunomodulatory component is an antibody to the Fas receptor. In certain embodiments, the additional immunomodulatory component is an antibody to the Fas ligand.
[0135] In some embodiments, the additional immunomodulatory component is an activator of a CD28 superfamily costimulatory molecule. In certain embodiments, the CD28 superfamily costimulatory molecule is ICOS or CD28. In certain embodiments, the additional immunomodulatory component is ICOSL, CD80, or CD86.
[0136] In certain embodiments, the additional immunomodulatory component is an activator of inducible T cell costimulator (ICOS). In some of these embodiments, the activator of ICOS is an agonist antibody of ICOS. In some others of these embodiments, the activator of ICOS is ICOS ligand (ICOSL).
[0137] In certain embodiments, the additional immunomodulatory component is an activator of CD28. In some of these embodiments, the activator of CD28 is an agonistic antibody of CD28. In some others of these embodiments, the activator of CD28 is a natural ligand of CD28. In certain embodiments, the ligand of CD28 is CD80.
[0138] In certain embodiments, the additional immunomodulatory component is a cytokine. In some embodiments, the cytokine is a soluble cytokine that is translationally fused to an exosome surface protein or fragment thereof. In some embodiments, the cytokine is IL-2. In some embodiments, the cytokine is IL-7. In some embodiments, the cytokine is IL-12. In some embodiments, the cytokine is IL-15.
[0139] In some embodiments, the additional immunomodulatory component is a T cell receptor (TCR) or a derivative thereof. In certain embodiments, the additional immunomodulatory component is a TCR alpha chain or a derivative thereof. In certain embodiments, the additional immunomodulatory component is a TCR beta chain or a derivative thereof. In some embodiments, the additional immunomodulatory component is a co-receptor for a T cell or a derivative thereof.
[0140] In some embodiments, the additional immunomodulatory component is a tumor antigen. In certain embodiments, the tumor antigen is selected from the group consisting of alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), epithelial tumor antigen (ETA), mucin 1 (MUC1), Tn-MUC1, mucin 16 (MUC16), tyrosinase, melanoma-associated antigen (MAGE), tumor protein p53 (p53), CD4, CD8, CD45, CD80, CD86, programmed death-ligand 1 (PD-L1), programmed death-ligand 2 (PD-L2), NY-ESO-1, PSMA, TAG-72, HER2, GD2, cMET, EGFR, mesothelin, VEGFR, alpha folate receptor, CE7R, IL-3, cancer-testis antigen, MART-1 gp100, and TNF-related apoptosis-inducing ligand.
[0141] In certain embodiments, the tumor antigen is carcinoembryonic antigen (CEA). In certain embodiments, the tumor antigen is epithelial tumor antigen (ETA).
[0142] In certain embodiments, the tumor antigen is a mucin. In some of these embodiments, the mucin is a secreted mucin. In some others of these embodiments, the mucin is a transmembrane mucin. In certain embodiments, the tumor antigen is mucin 1 (MUC1). In certain embodiments, the tumor antigen is Tn-MUC1. In certain embodiments, the tumor antigen is mucin 16 (MUC16).
[0143] In certain embodiments, the tumor antigen is a melanoma-associated antigen (MAGE). In some of these embodiments, the MAGE is a type I MAGE. In some others of these embodiments, the MAGE is a type II MAGE. In certain embodiments, the type I MAGE is MAGE-A2. In certain embodiments, the type I MAGE is MAGE-A4.
[0144] In certain embodiments, the tumor antigen is alpha-fetoprotein (AFP). In certain embodiments, the tumor antigen is tumor protein p53 (p53). In certain embodiments, the tumor antigen is tyrosinase. In certain embodiments, the tumor antigen is tyrosinase-related protein (TRP). In some embodiments, the tumor antigen is programmed death-ligand 1 (PD-L1) or programmed death-ligand 2 (PD-L2). In various embodiments, the tumor antigen is selected from the group consisting of CD4, CD8, CD45, CD80, and CD86.
[0145] In some embodiments, the immunomodulatory component is a chimeric antigen receptor (CAR) or a derivative thereof. In some embodiments, the CAR binds to one or more of alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), epithelial tumor antigen (ETA), mucin 1 (MUC1), Tn-MUC1, mucin 16 (MUC16), tyrosinase, melanoma-associated antigen (MAGE), tumor protein p53 (p53), CD4, CD8, CD45, CD80, CD86, programmed death-ligand 1 (PD-L1), programmed death-ligand 2 (PD-L2), NY-ESO-1, PSMA, TAG-72, HER2, GD2, cMET, EGFR, mesothelin, VEGFR, alpha folate receptor, CE7R, IL-3, cancer-testis antigen, MART-1 gp100, and TNF-related apoptosis-inducing ligand.
[0146] In some embodiments, the additional immunomodulatory component is an activator of a T cell receptor or co-receptor. In certain embodiments, the additional immunomodulatory component is an activator of CD3. In certain embodiments, the activator is a fragment of a monoclonal antibody of CD3. In certain embodiments, the antibody fragment is an scFv, (scFv)2, Fab, Fab', and F(ab')2, F(ab1)2, Fv, dAb, or Fd of a monoclonal antibody of CD3. In certain embodiments, the activator is a nanobody, bispecific antibody, or multispecific antibody against CD3. In certain embodiments, the additional immunomodulatory component is an activator of CD28. In certain embodiments, the activator is a fragment of a monoclonal antibody of CD28. In certain embodiments, the antibody fragment is an scFv, (scFv)2, Fab, Fab', and F(ab')2, F(ab1)2, Fv, dAb, or Fd of a monoclonal antibody of CD28. In certain embodiments, the activating agent is a nanobody, bispecific antibody, or multispecific antibody against CD28.
[0147] In some embodiments, the additional immunomodulatory component is a major histocompatibility complex (MHC) or a derivative thereof. In some of these embodiments, the additional immunomodulatory component is an MHC class I or a derivative thereof. In some of these embodiments, the additional immunomodulatory component is an MHC class II or a derivative thereof. In some of these embodiments, the additional immunomodulatory component is an MHC class III or a derivative thereof.
[0148] In some embodiments, the additional immunomodulatory component is a human leukocyte antigen (HLA) or a derivative thereof. In some of these embodiments, the additional immunomodulatory component is HLA-A, HLA-B, HLA-C, or a derivative thereof. In some of these embodiments, the additional immunomodulatory component is HLA-E, HLA-F, HLA-G, or a derivative thereof. In some of these embodiments, the additional immunomodulatory component is HLA-DP, HLA-DQ, HLA-DR, or a derivative thereof.
[0149] In various embodiments, the immunomodulatory component can be a polypeptide, polynucleotide, polysaccharide, lipid, small molecule, or toxin.
[0150] In some embodiments, the immunomodulatory component may be a protein, peptide, glycolipid, or glycoprotein.
[0151] In certain embodiments, the immunomodulatory component is an agonist. In some of these embodiments, the agonist is an endogenous agonist, such as a hormone or neurotransmitter. In some others of these embodiments, the agonist is an exogenous agonist, such as a drug. In some embodiments, the agonist is a physical agonist that can generate an agonist response without binding to the receptor. In some embodiments, the agonist is a superagonist that can generate a maximal response that is greater than that of an endogenous agonist. In certain embodiments, the agonist is a full agonist that has full potency at the receptor. In certain other embodiments, the agonist is a partial agonist that has only partial potency at the receptor compared to a full agonist. In some embodiments, the agonist is an inverse agonist that can inhibit the constitutive activity of the receptor. In some embodiments, the agonist is a co-agonist that works with other co-agonists to generate an effect on the receptor. In certain embodiments, the agonist is an irreversible agonist that permanently binds to the receptor through the formation of a covalent bond, hi certain embodiments, the agonist is a selective agonist for a particular type of receptor.
[0152] In certain embodiments, the immunomodulatory component is an antagonist. In some of these embodiments, the antagonist is a competitive antagonist, which reversibly binds to the receptor at the same binding site as the endogenous ligand or agonist without activating the receptor. A competitive antagonist can affect the amount of agonist required to achieve a maximum response. In some other of these embodiments, the antagonist is a non-competitive antagonist, which binds to the active site of the receptor or to the allosteric site of the receptor. A non-competitive antagonist can reduce the magnitude of the maximum response that can be achieved by a given amount of agonist. In some other embodiments, the antagonist is an uncompetitive antagonist, which requires receptor activation by an agonist before its binding to a separate allosteric binding site.
[0153] In various embodiments, the immunomodulatory component comprises an antibody or antigen-binding fragment. The immunomodulatory component may be a full-length protein or a fragment thereof. The antibody or antigen-binding fragment may be derived from a natural source or may be partially or wholly synthetically produced. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the monoclonal antibody is an IgG antibody. In certain embodiments, the monoclonal antibody is an IgG1, IgG2, IgG3, or IgG4. In some other embodiments, the antibody is a polyclonal antibody. In certain embodiments, the antigen-binding fragment is selected from Fab, Fab', and F(ab')2, F(ab1)2, Fv, dAb, and Fd fragments. In certain embodiments, the antigen-binding fragment is an scFv or (scFv)2 fragment. In certain other embodiments, the antibody or antigen-binding fragment is a Nanobody® (single domain antibody). In some embodiments, the antibody or antigen-binding fragment is a bispecific or multispecific antibody.
[0154] In various embodiments, the antibody or antigen-binding fragment is fully human. In some embodiments, the antibody or antigen-binding fragment is humanized. In some embodiments, the antibody or antigen-binding fragment is chimeric. In some of these embodiments, the chimeric antibody has a non-human V region domain and a human C region domain. In some embodiments, the antibody or antigen-binding fragment is non-human, such as murine or veterinary.
[0155] In some embodiments, the immunomodulatory component is a protein, peptide, glycolipid, or glycoprotein.
[0156] In various embodiments, the composition comprises two or more of the above immunomodulatory components, including mixtures, fusions, combinations, and complexes of atoms, molecules, etc. In certain embodiments, the composition comprises a nucleic acid combined with a polypeptide. In certain embodiments, the composition comprises two or more polypeptides complexed to one another. In certain embodiments, the composition comprises a protein complexed to a biologically active molecule. In some of these embodiments, the biologically active molecule is a prodrug.
[0157] Pharmaceutical Compositions A pharmaceutical composition generally comprises a plurality of extracellular vesicles and a pharma- ceutically acceptable excipient or carrier in a form suitable for administration to a subject. Pharmaceutically acceptable excipients or carriers are determined, in part, by the particular compound to be administered, as well as by the particular method used to administer the composition. Thus, there are a wide variety of suitable formulations of pharmaceutical compositions comprising a plurality of extracellular vesicles. (See, for example, Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 21st ed. (2005)). Pharmaceutical compositions are generally formulated in a sterile manner and in full compliance with all Good Manufacturing Practice (GMP) regulations of the U.S. Food and Drug Administration.
[0158] In some embodiments, the pharmaceutical composition comprises one or more therapeutic agents described herein and extracellular vesicles. In some embodiments, the extracellular vesicles are co-administered with one or more separate therapeutic agents, where co-administration includes administration of the separate therapeutic agent before, after, or simultaneously with administration of the extracellular vesicles.
[0159] Pharmaceutically acceptable excipients include excipients that are generally safe, non-toxic and desirable, including excipients acceptable for veterinary use as well as for human pharmaceutical use.
[0160] Examples of carriers or diluents include, but are not limited to, water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. The use of such media and compounds for pharma- ceutical active substances is known in the art. To the extent that any conventional media or compounds are incompatible with the extracellular vesicles described herein, their use in the compositions is contemplated. Supplementary therapeutic agents may also be incorporated into the compositions. Typically, pharmaceutical compositions are formulated to be compatible with their intended route of administration. Extracellular vesicles may be administered parenterally, topically, intravenously, orally, subcutaneously, intraarterially, intradermally, transdermally, rectally, intracranially, intraperitoneally, intranasally, intramuscularly, or by inhalation. In certain embodiments, pharmaceutical compositions comprising extracellular vesicles are administered intravenously, for example, by injection. Extracellular vesicles may be administered, optionally, in combination with other therapeutic agents that are at least partially effective in treating the disease, disorder, or condition for which the extracellular vesicles are intended.
[0161] The solution or suspension may contain the following components: water, saline, sterile diluents such as fixed oils, polyethylene glycol, glycerin, propylene glycol or other synthetic solvents, antimicrobial compounds such as benzyl alcohol or methylparaben, antioxidants such as ascorbic acid or sodium bisulfite, chelating agents such as ethylenediaminetetraacetic acid (EDTA), buffers such as acetates, citrates, or phosphates, and compounds for adjusting osmotic pressure such as sodium chloride or dextrose. The pH may be adjusted with acids or bases such as hydrochloric acid or sodium hydroxide. The preparation may be enclosed in ampoules, disposable syringes, or multiple dose vials made of glass or plastic.
[0162] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (if water soluble) or dispersions and sterile powders. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). The composition is generally sterile and fluid to the extent that easy syringeability exists. The carrier can be a solvent or dispersion containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal compounds, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. If desired, isotonic compounds, for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride, can be added to the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition a compound which delays absorption, for example, aluminum monostearate and gelatin.
[0163] Sterile injectable solutions can be prepared by incorporating extracellular vesicles into a suitable solvent with one or a combination of the components listed herein, as desired, in effective amounts.Generally, dispersions are prepared by incorporating extracellular vesicles into a sterile vehicle that contains a basic dispersion medium and any other desired components.In the case of sterile powders for preparing sterile injectable solutions, the preparation method is vacuum drying and lyophilization, which results in a powder of active ingredient and any additional desired ingredients from the solution that has been previously sterile filtered.Extracellular vesicles can be administered in the form of depot injection or implant preparations, which can be formulated in such a way that they allow sustained or pulsatile release of extracellular vesicles.
[0164] Systemic administration of the composition comprising extracellular vesicles can also be via transmucosal means. For transmucosal administration, a penetrant suitable for the barrier to be permeated is used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be achieved, for example, through the use of nasal drops.
[0165] In certain embodiments, the pharmaceutical composition comprising extracellular vesicles is administered intravenously to a subject who will benefit from the pharmaceutical composition.In certain other embodiments, the composition is administered to the lymphatic system, for example, by intralymphatic injection or intranodal injection (see, for example, Senti et al., PNAS 105(46):17908(2008)), or by intramuscular injection, by subcutaneous injection, by direct injection into the thymus or liver.
[0166] In certain embodiments, the pharmaceutical composition comprising extracellular vesicles is administered as a liquid suspension.In certain embodiments, the pharmaceutical composition is administered as a formulation that can form a depot following administration.In certain preferred embodiments, the depot slowly releases extracellular vesicles into circulation or remains in depot form.
[0167] Typically, a pharma- ceutically acceptable composition is highly purified to be free of contaminants, biocompatible, non-toxic, and suitable for administration to a subject. When water is a component of the carrier, the water is highly purified and processed to be free of contaminants, such as endotoxins.
[0168] The pharma- ceutically acceptable carrier may be, but is not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and / or mineral oil.The pharmaceutical composition may further comprise a lubricant, a wetting agent, a sweetener, a flavor enhancer, an emulsifier, a suspending agent, and / or a preservative.
[0169] The pharmaceutical compositions described herein comprise the extracellular vesicles described herein and, optionally, a pharma- ceutical active agent or therapeutic agent. The therapeutic agent may be a biological agent, a small molecule agent, or a nucleic acid agent.
[0170] Dosage forms are provided that include pharmaceutical compositions that include the extracellular vesicles described herein. In some embodiments, the dosage forms are formulated as liquid suspensions for intravenous injection.
[0171] In certain embodiments, the preparation of extracellular vesicles is exposed to radiation, e.g., X-rays, gamma rays, beta particles, alpha particles, neutrons, protons, elemental nuclei, ultraviolet light, to damage residual replication-competent nucleic acid.
[0172] In certain embodiments, the preparation of extracellular vesicles is exposed to gamma irradiation using a radiation dose of greater than 1, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, or greater than 100 kGy.
[0173] In certain embodiments, the preparation of extracellular vesicles is exposed to X-ray irradiation using a radiation dose of greater than 0.1, 0.5, 1, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, or greater than 10000 mSv.
[0174] method Aspects of the present disclosure also include methods of producing compositions comprising extracellular vesicles and an immunomodulatory component. In some embodiments, the method comprises obtaining extracellular vesicles from producer cells, where the producer cells naturally contain an immunomodulatory component, and optionally isolating the obtained extracellular vesicles. In some embodiments, the method comprises modifying producer cells with an immunomodulatory component, obtaining extracellular vesicles from the modified producer cells, and optionally isolating the obtained extracellular vesicles. In some other embodiments, the method comprises obtaining extracellular vesicles from producer cells, isolating the obtained extracellular vesicles, and modifying the isolated extracellular vesicles with an immunomodulatory component. In certain embodiments, the method further comprises formulating the isolated extracellular vesicles into a pharmaceutical composition.
[0175] Methods for Producing Extracellular Vesicles Methods for modifying producer cells with immunomodulatory moieties In various embodiments, the methods involve modifying producer cells with an immunomodulatory moiety.
[0176] The producer cell may be a mammalian cell line, a plant cell line, an insect cell line, a fungal cell line, or a prokaryotic cell line. In certain embodiments, the producer cell is a mammalian cell line. Mammalian cell lines include, but are not limited to, human embryonic kidney (HEK) cell lines, Chinese hamster ovary (CHO) cell lines, HT-1080 cell lines, HeLa cell lines, PERC-6 cell lines, CEVEC cell lines, fibroblast cell lines, amniotic cell lines, epithelial cell lines, and mesenchymal stem cell (MSC) cell lines. In some preferred embodiments, the mammalian cell line may be HEK-293 cells, BJ human foreskin fibroblast cells, fHDF fibroblast cells, AGE.HN® neural progenitor cells, CAP® amniotic cells, adipose mesenchymal stem cells, or RPTEC / TERT1 cells. The producer cell may also be a primary cell. In various embodiments, the primary cell can be a primary mammalian cell, a primary plant cell, a primary insect cell, a primary fungal cell, or a primary prokaryotic cell.
[0177] In certain embodiments, the producer cell is an immune cell such as a dendritic cell, a T cell, a B cell, a natural killer cell (NK cell), an antigen presenting cell, a macrophage, a T helper cell, or a regulatory T cell (Treg cell).
[0178] In various embodiments, the immunomodulatory components may be expressed in the producer cells from a transgene or mRNA introduced into the producer cells, which may be achieved by transfection (see, e.g., Bacchetti S, Graham FL (April 1977) "Transfer of the gene for thymidine kinase to thymidine kinase-deficient human cells by purified herpes simplex viral DNA”.Proceedings of the National Academy of Sciences of the United States of America.74(4):1590-4、Kriegler M(1991)Transfer and Expression:A Laboratory Manual.W.H.Freeman.pp.96-97、Felgner PL,Gadek TR,Holm M,Roman R,Chan HW,Wenz M,Northrop JP,Ringold GM,Danielsen M(November 1987)”Lipofection:a highly efficient,lipid-mediated DNA-transfection procedure”.Proceedings of the National Academy of Sciences of the United States of America.84(21):7413-7、Felgner JH,Kumar R,Sridhar CN,Wheeler CJ,Tsai YJ,Border R,Ramsey P,Martin M, Felgner PL (January 1994) "Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations". The Journal of Biological Chemistry. 269(4):2550-61), viral transduction (see, e.g., Griffiths AJ, Miller JH, Suzuki DT, Lewontin RC, Gelbart WM (2000) "Transduction". An Introduction to Genetic Analysis (7th ed.)), electroporation (see, e.g., Neumann, E; Schaefer-Ridder, M; Wang, Y; Hofschneider, PH (1982) "Gene transfer into mouse lyoma cells by electroporation in high electric fields". The EMBO Journal. 1(7):841-5)), extrusion (see, e.g., Sharei A, Zoldan J, Adamo A, Sim WY, Cho N, Jackson E, Mao S, Schneider S, Han MJ, Lytton-Jean A, Basto PA, Jhunjhunwala S, Lee J, Heller DA, Kang JW, Hartoularos GC, Kim KS, Anderson DG, Langer R, Jensen KF (February 2013) “A vector-free microfluidic platform for intracellular delivery”. Proceedings of the National Academy of Sciences of the United States of America. 110(6):2082-7, sonication (see, e.g., Yizhi Song (2007) "Ultrasound-mediated DNA transfer for bacteria". Nucleic Acids Res. 35(19):e129.), cell fusion (see, e.g., Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M (November 1987) "Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure". Proceedings of the National Academy of Sciences of the United States of America. 84(21):7413-), or other methods known to those of skill in the art.
[0179] In certain embodiments, the immunomodulatory component is introduced into the producer cell by transfection. In some embodiments, the immunomodulatory component may be introduced into a suitable producer cell using synthetic macromolecules such as cationic lipids and polymers (Papapetrou et al., Gene Therapy 12:S118-S130 (2005)). In some embodiments, the cationic lipid forms a complex with the immunomodulatory component through charge interactions. In some of these embodiments, the positively charged complex binds to the negatively charged cell surface and is taken up by the cell by endocytosis. In some other embodiments, a cationic polymer may be used to transfect the producer cell. In some of these embodiments, the cationic polymer is polyethyleneimine (PEI). In certain embodiments, chemicals such as calcium phosphate, cyclodextrin, or polybrene may be used to introduce the immunomodulatory component into the producer cell. Immunomodulatory components can also be introduced into producer cells using physical methods such as particle-mediated transfection, "gene gun", biolistic, or particle bombardment techniques (Papapetrou et al., Gene Therapy 12:S118-S130 (2005)). For example, reporter genes such as beta-galactosidase, chloramphenicol acetyltransferase, luciferase, or green fluorescent protein can be used to assess the transfection efficiency of producer cells.
[0180] In certain embodiments, the immunomodulatory components are introduced into the producer cells by viral transduction. Many viruses can be used as gene transfer vehicles, including Moloney murine leukemia virus (MMLV), adenovirus, adeno-associated virus (AAV), herpes simplex virus (HSV), lentivirus, and spumavirus. Viral-mediated gene transfer vehicles include vectors based on DNA viruses such as adenovirus, adeno-associated virus, and herpes virus, as well as retroviruses.
[0181] In certain embodiments, immunomodulatory components are introduced into producer cells by electroporation. Electroporation creates temporary pores in the cell membrane, allowing the introduction of various molecules into the cells. In some embodiments, DNA and RNA, as well as polypeptide and non-polypeptide therapeutic agents, can be introduced into producer cells by electroporation.
[0182] In certain embodiments, the immunomodulatory components are introduced into the producer cells by microinjection, hi some embodiments, a glass micropipette may be used to inject the immunomodulatory components into the producer cells at the microscopic level.
[0183] In certain embodiments, the immunomodulatory components are introduced into the producer cells by extrusion.
[0184] In certain embodiments, the immunomodulatory component is introduced into the producer cells by sonication, hi some embodiments, the producer cells are exposed to high intensity sound waves, causing temporary disruption of the cell membrane to allow loading of the immunomodulatory component.
[0185] In certain embodiments, the immunomodulatory moieties are introduced into the producer cells by cell fusion. In some embodiments, the immunomodulatory moieties are introduced into the producer cells by electrical cell fusion. In some other embodiments, polyethylene glycol (PEG) is used to fuse the producer cells. In some other embodiments, Sendai virus is used to fuse the producer cells.
[0186] In some embodiments, the immunomodulatory components are introduced into the producer cells by hypotonic lysis. In some of these embodiments, the producer cells are exposed to a low ionic strength buffer to rupture them and allow loading of the immunomodulatory components. In some alternative embodiments, controlled dialysis against a hypotonic solution is used to swell the producer cells and create pores in the producer cell membrane. The producer cells are then exposed to conditions that allow resealing of the membrane.
[0187] In some embodiments, the immunomodulatory components are introduced into the producer cells by detergent treatment. In certain embodiments, the producer cells are treated with a mild detergent that temporarily compromises the producer cell membrane by creating pores that allow loading of the immunomodulatory components. After the producer cells are loaded, the detergent is washed away, thereby resealing the membrane.
[0188] In some embodiments, the immunomodulatory component is introduced into the producer cell by receptor-mediated endocytosis, hi certain embodiments, the producer cell has a surface receptor that upon binding of the immunomodulatory component induces internalization of the receptor and the associated immunomodulatory component.
[0189] In some embodiments, the immunomodulatory component is introduced into the producer cells by filtration, hi certain embodiments, the producer cells and immunomodulatory component are forced through a filter with a smaller pore size than the producer cells, causing a temporary disruption of the producer cell membrane, allowing the immunomodulatory component to enter the producer cells.
[0190] In some embodiments, the producer cells are subjected to several freeze-thaw cycles, resulting in cell membrane disruption and allowing loading of the immunomodulatory component.
[0191] Methods for modifying extracellular vesicles with immunomodulatory moieties In various alternative embodiments, the immunomodulatory moiety is introduced directly into the extracellular vesicles following isolation of the extracellular vesicles.
[0192] In certain embodiments, immunomodulatory components are introduced into the extracellular vesicles by transfection. In some embodiments, immunomodulatory components can be introduced into the extracellular vesicles using synthetic macromolecules such as cationic lipids and polymers (Papapetrou et al., Gene Therapy 12:S118-S130(2005)). In certain embodiments, chemicals such as calcium phosphate, cyclodextrin, or polybrene can be used to introduce the immunomodulatory components into the extracellular vesicles.
[0193] In certain embodiments, the immunomodulatory components are introduced into the extracellular vesicles by electroporation, hi some embodiments, the extracellular vesicles are exposed to an electric field that creates temporary pores in the extracellular vesicle membrane, allowing loading of the immunomodulatory components.
[0194] In certain embodiments, the immunomodulatory components are introduced into the extracellular vesicles by microinjection. In some embodiments, a glass micropipette can be used to inject the immunomodulatory components directly into the extracellular vesicles at the microscopic level.
[0195] In certain embodiments, the immunomodulatory components are introduced into the extracellular vesicles by extrusion.
[0196] In certain embodiments, the immunomodulatory components are introduced into the extracellular vesicles by sonication, hi some embodiments, the extracellular vesicles are exposed to high intensity sound waves, causing temporary disruption of the extracellular vesicle membrane to allow loading of the immunomodulatory components.
[0197] In some embodiments, the immunomodulatory component may be conjugated to the surface of the extracellular vesicle. Conjugation may be accomplished chemically or enzymatically by methods known in the art.
[0198] In some embodiments, the extracellular vesicles comprise a chemically conjugated immunomodulatory component. Chemical conjugation can be achieved by covalently linking the immunomodulatory component to another molecule, with or without a linker. The formation of such conjugates is within the skill of the art, and a variety of techniques are known for achieving conjugation, with the selection of a particular technique being guided by the material to be conjugated. In certain embodiments, polypeptides are conjugated to the extracellular vesicles. In certain other embodiments, non-polypeptides, such as lipids, carbohydrates, nucleic acids, and small molecules, are conjugated to the extracellular vesicles.
[0199] In some embodiments, the immunomodulatory components are introduced into the extracellular vesicles by hypotonic lysis. In some of these embodiments, the extracellular vesicles are exposed to a low ionic strength buffer to rupture them and allow loading of the immunomodulatory components. In some alternative embodiments, controlled dialysis against a hypotonic solution is used to swell the extracellular vesicles and create holes in the extracellular vesicle membrane. The extracellular vesicles are then exposed to conditions that allow resealing of the membrane.
[0200] In some embodiments, the immunomodulatory component is introduced into the extracellular vesicles by detergent treatment. In certain embodiments, the extracellular vesicles are treated with a mild detergent that temporarily damages the extracellular vesicle membrane by creating holes that allow loading of the immunomodulatory component. After the extracellular vesicles are loaded, the detergent is washed away, thereby resealing the membrane.
[0201] In some embodiments, the immunomodulatory component is introduced into the extracellular vesicle by receptor-mediated endocytosis, in certain embodiments, the extracellular vesicle has a surface receptor that upon binding of the immunomodulatory component induces internalization of the receptor and associated immunomodulatory component.
[0202] In some embodiments, the immunomodulatory component is introduced into the extracellular vesicles by mechanical firing. In certain embodiments, the extracellular vesicles can be bombarded with immunomodulatory components attached to heavy or charged particles, such as gold microcarriers. In some of these embodiments, the particles can be mechanically or electrically accelerated so that they cross the extracellular vesicle membrane.
[0203] In some embodiments, the immunomodulatory component is introduced into the extracellular vesicle by filtration, hi certain embodiments, the extracellular vesicle and the immunomodulatory component are forced through a filter with a smaller pore size than the extracellular vesicle, causing a temporary disruption of the extracellular vesicle membrane and allowing the immunomodulatory component to enter the extracellular vesicle.
[0204] In some embodiments, the extracellular vesicles are exposed to several freeze-thaw cycles, resulting in extracellular vesicle membrane disruption and allowing loading of the immunomodulatory component.
[0205] Methods for isolating extracellular vesicles Extracellular vesicles can be isolated from producer cells. In certain embodiments, extracellular vesicles are released into cell culture medium by producer cells. It is contemplated that all known modes of isolation of extracellular vesicles are suitable for use herein. For example, physical properties of extracellular vesicles can be employed to separate them from medium or other source materials, including separation based on charge (e.g., electrophoretic separation), size (e.g., filtration, molecular sieving, etc.), density (e.g., normal centrifugation or gradient centrifugation), Svedberg constant (e.g., sedimentation with or without external force, etc.). Alternatively or additionally, isolation can be based on one or more biological properties, including methods that can employ surface markers (e.g., precipitation, reversible binding to solid phase, FACS separation, specific ligand binding, non-specific ligand binding, affinity purification, etc.).
[0206] Isolation and enrichment can be performed in a general and non-selective manner, typically involving continuous centrifugation. Alternatively, isolation and enrichment can be performed in a more specific and selective manner, such as using extracellular vesicles or producer cell-specific surface markers. For example, specific surface markers can be used in immunoprecipitation, FACS sorting, affinity purification, and magnetic separation using bead-bound ligands.
[0207] In some embodiments, size exclusion chromatography may be used to isolate extracellular vesicles. Size exclusion chromatography techniques are known in the art. Exemplary, non-limiting techniques are provided herein. In some embodiments, the void volume fraction is isolated and contains the extracellular vesicles of interest. Furthermore, in some embodiments, the extracellular vesicles may be further isolated after chromatographic separation by centrifugation techniques (of one or more chromatographic fractions), as generally known in the art. In some embodiments, for example, density gradient centrifugation may be utilized to further isolate the extracellular vesicles. In certain embodiments, it may be desirable to further separate the producer cell-derived extracellular vesicles from extracellular vesicles of other origins. For example, the producer cell-derived extracellular vesicles may be separated from the non-producer cell-derived extracellular vesicles by immunosorbent capture using antigen-antibodies specific to the producer cells.
[0208] In some embodiments, isolation of extracellular vesicles can involve a combination of methods including, but not limited to, differential centrifugation, size-based membrane filtration, immunoprecipitation, FACS sorting, and magnetic separation.
[0209] How to measure the size of extracellular vesicles In some embodiments, the methods described herein include measuring the size of extracellular vesicles and / or populations of extracellular vesicles. Generally, the size of an extracellular vesicle is measured as its longest measurable dimension. Generally, the longest measurable dimension of an extracellular vesicle is also referred to as its diameter.
[0210] Extracellular vesicle size can be measured using dynamic light scattering (DLS) and / or multi-angle light scattering (MALS). Methods of using DLS and / or MALS to measure the size of extracellular vesicles are known to those of skill in the art and include nanoparticle tracking assays (NTA, e.g., using a Malvern NanoSight NS300 nanoparticle tracking device). In certain embodiments, extracellular vesicle size is determined using a Malvern NanoSight NS300. In some embodiments, the extracellular vesicles described herein have a longest dimension of about 20-300 nm when measured by NTA (e.g., using a Malvern NanoSight NS300). In other embodiments, the extracellular vesicles described herein have a longest dimension of about 40-200 nm when measured by NTA (e.g., using a Malvern NanoSight NS300). In other embodiments, the extracellular vesicle populations described herein include populations where 90% of the extracellular vesicles have a longest dimension of about 20-300 nm as measured by NTA (e.g., using a Malvern NanoSight NS300). In other embodiments, the extracellular vesicle populations described herein include populations where 95% of the extracellular vesicles have a longest dimension of about 20-300 nm as measured by NTA (e.g., using a Malvern NanoSight NS300). In other embodiments, the extracellular vesicle populations described herein include populations where 99% of the extracellular vesicles have a longest dimension of about 20-300 nm as measured by NTA (e.g., using a Malvern NanoSight NS300). In other embodiments, the extracellular vesicle populations described herein include populations where 90% of the extracellular vesicles have a longest dimension of about 40-200 nm as measured by NTA (e.g., using a Malvern NanoSight NS300). In other embodiments, the extracellular vesicle populations described herein include populations where 95% of the extracellular vesicles have a longest dimension of about 40-200 nm as measured by NTA (e.g., using a Malvern NanoSight NS300).In other embodiments, the extracellular vesicle populations described herein include populations, in which 99% of the extracellular vesicles have a longest dimension of about 40-200 nm as measured by NTA (e.g., using a Malvern NanoSight NS300).
[0211] Extracellular vesicle size may be measured using tunable resistive pulse sensing (TRPS). In certain embodiments, the extracellular vesicle size measured by TRPS is determined using iZON qNANO Gold. In some embodiments, the extracellular vesicles described herein have a longest dimension of about 20-300 nm when measured by TRPS (e.g., using iZON qNano Gold). In other embodiments, the extracellular vesicles described herein have a longest dimension of about 40-200 nm when measured by TRPS (e.g., using iZON qNano Gold). In other embodiments, the extracellular vesicle population described herein includes a population, 90% of the extracellular vesicles have a longest dimension of about 20-300 nm when measured by TRPS (e.g., using iZON qNano Gold). In other embodiments, the extracellular vesicle populations described herein include populations, where 95% of the extracellular vesicles have a longest dimension of about 20-300 nm when measured by TRPS (e.g., using iZON qNano Gold). In other embodiments, the extracellular vesicle populations described herein include populations, where 99% of the extracellular vesicles have a longest dimension of about 20-300 nm when measured by TRPS (e.g., using iZON qNano Gold). In other embodiments, the extracellular vesicle populations described herein include populations, where 90% of the extracellular vesicles have a longest dimension of about 40-200 nm when measured by TRPS (e.g., using iZON qNano Gold). In other embodiments, the extracellular vesicle populations described herein include populations, where 95% of the extracellular vesicles have a longest dimension of about 40-200 nm when measured by TRPS (e.g., using iZON qNano Gold). In other embodiments, the extracellular vesicle populations described herein include populations, where 99% of the extracellular vesicles are soluble in water as measured by TRPS (e.g., iZON qNano Gold), with a longest dimension of about 40-200 nm.
[0212] Extracellular vesicle size can be measured using electron microscopy. In some embodiments, the electron microscopy used to measure extracellular vesicle size is transmission electron microscopy. In certain embodiments, the transmission electron microscope used to measure extracellular vesicle size is Tecnai™ G 2 The method of measuring extracellular vesicle size using electron microscopy is well known to those skilled in the art, and any such method may be suitable for measuring extracellular vesicle size. In some embodiments, the extracellular vesicles described herein are measured using a scanning electron microscope (e.g., Tecnai™ G 2 In other embodiments, the extracellular vesicles described herein have a longest dimension of about 20-300 nm as measured by scanning electron microscope (e.g., Tecnai™ G). 2 In other embodiments, the extracellular vesicle populations described herein comprise a population, and 90% of the extracellular vesicles are 40-200 nm in length, as measured by scanning electron microscopy (e.g., Tecnai™ G). 2 In other embodiments, the extracellular vesicle populations described herein comprise a population, and 95% of the extracellular vesicles are chromatographically resolved, as measured by scanning electron microscopy (e.g., Tecnai™ G). 2 In other embodiments, the extracellular vesicle populations described herein comprise a population, and 99% of the extracellular vesicles are chromatographically resolved, as measured by scanning electron microscopy (e.g., Tecnai™ G). 2 In other embodiments, the extracellular vesicle populations described herein comprise a population, and 90% of the extracellular vesicles are cytoplasmic, as measured by scanning electron microscopy (e.g., Tecnai™ G). 2In other embodiments, the extracellular vesicle populations described herein comprise a population, and 95% of the extracellular vesicles are 40-200 nm in length, as measured by scanning electron microscopy (e.g., Tecnai™ G). 2 In other embodiments, the extracellular vesicle populations described herein comprise a population, and 99% of the extracellular vesicles are 50-60 nm in length, as measured by scanning electron microscopy (e.g., Tecnai™ G). 2 It has a longest dimension of about 40-200 nm as measured by a Spirit BioTWIN scanning electron microscope.
[0213] Methods for determining macrophage polarization Disclosed herein are methods and compositions for increasing macrophage polarization from M2 to M1 phenotype using extracellular vesicles containing one or more immunomodulatory component(s) that inhibit expression of macrophage target genes. The compositions are preferentially taken up by macrophages (compared to other cell types such as T cells, B cells, macrophages, or dendritic cells) and are as or more effective at increasing macrophage polarization than equimolar amounts of the immunomodulatory component alone. Methods for determining macrophage polarization, including detection of macrophage M2 and M1 phenotypes, can be performed by any method known in the art for determining M2 and M1 phenotypes. Tissue sections (e.g., from tumor biopsies), blood samples, etc., may be subjected to analysis of M2 cell surface markers (e.g., YM1, FIZZ1, Dectin-1, MGL), M2-associated cytokines (e.g., IL-10, TGFβ, PGE2, CCL2, CCL17, CCL18, CCL22, and CCL24), M1-associated cytokines (e.g., INFγ, IL-12, IL-23, TNFα, IL-6, IL-1, CCL5, CSCL9, CXCL10, and CXCL11), growth factors (e.g., VEGF-A, VEGF-C, EGF, and TGF-β), enzymes (e.g., matrix metalloproteinases MMP2, MMP9, cysteine cathepsin proteases), M2-associated miRNAs (e.g., miRNA146a, miRNA lett, miRNA 2010, miRNA 211, miRNA 222, miRNA 231, miRNA 232, miRNA 233, miRNA 234, miRNA 235, miRNA 236, miRNA 237, miRNA 238, miRNA 239 ... The cells may be assayed (e.g., stained) for markers of pan-macrophage, as well as M2 and M1 macrophages, including, but not limited to, M1-associated miRNAs (e.g., miRNA155, miR-33), and / or M2-associated miRNAs (e.g., miR-7b, and miR-223).See, for example, Mosser, DM, & Edwards, JP (2008). Exploring the full spectrum of macrophage activation. Nature Reviews Immunology, 8(12), 958-969; Murray, PJ, Allen, JE, Biswas, SK, Fisher, EA, Gilroy, DW, Goerdt, S., Wynn, TA (2014). Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity, 41(1), 14-20. Macrophages and / or macrophage components, secretions or macrophage activity within a sample (see, e.g., Gautier, E. L., Shay, T., Miller, J., Greter, M., Jakubzick, C., Ivanov, S., Randolph, G. J. (2007). Gene expression profiles and transcriptional regulatory pathways underlying mouse tissue macrophage identity and diversity, Nature Immunology 13(11), 1118-1128) may be detected by flow cytometry, immunohistochemistry, immunoblotting, quantitative PCR, or any other method known in the art for detecting cells or cell products in a biological sample.
[0214] How to Treat Cancer Also provided herein are methods of treating cancer in a subject.
[0215] In various embodiments, a composition of extracellular vesicles, e.g., exosomes, comprising one or more immunomodulatory components that inhibit at least one gene, thereby increasing macrophage polarization from the M2 phenotype to the M1 phenotype, is administered to a subject with cancer. In some of these embodiments, the composition can upregulate the immune response and enhance tumor targeting of the subject's immune system. In some aspects, the increase in macrophage polarization from the M2 phenotype to the M1 phenotype itself upregulates the subject's immune response and enhances tumor targeting of the subject's immune system. Some authors refer to the activation of the M2d subtype in response to IL-6 and adenosine, and these macrophages are also referred to as tumor-associated macrophages (TAMs). See, e.g., Roszer, T. (2015). Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms.Mediators of Inflammation,2015,1-16, Funes, SC, Rios, M., Escobar-Vera, J., & Kalergis, AM (2018). Implications of macrophage polarization in autoimmunity. Immunology, 154(2), 186-195, and Q. Wang, H. Ni, L. Lan, X. Wei, R. Xiang, and Y. Wang, “Fra-1 protooncogene regulates IL6 expression in macrophages and promotes the generation of M2d macrophages,” Cell Please refer to Research, vol. 20, no. 6, pp. 701-712, 2010. Tumor-associated macrophages (TAMs) are typically typified for their protumoral functions, such as promoting cancer cell motility, metastasis formation and angiogenesis, and their formation depends on microenvironmental factors present in the developing tumor. TAMs produce immunosuppressive cytokines such as IL-10, TGFβ, PGE2, very small amounts of NO or ROI, and low levels of inflammatory cytokines (IL-12, IL-1β, TNFα, IL-6). The ability of TAMs to present tumor-associated antigens is reduced, as is the stimulation of antitumor functions of T and NK cells. Also, TAMs are unable to lyse tumor cells. https: / / en.wikipedia.org / wiki / Macrophage_polarization-cite_note-Sica2008-31 Targeting TAMs is a novel therapeutic strategy for cancer, as demonstrated through the delivery of agents that either alter TAM recruitment and distribution, deplete existing TAMs, or induce reeducation of TAMs from an M2 to an M1 phenotype. For example, Lewis, Claire E., and Jeffrey W. Pollard. “Distinct role of macrophages in different tumor microenvironments.” Cancer research 66.2(2006):605-612, Sica, Antonio, et al. “Macrophage polarization in tumor progression.” Seminars in Cancer Biology. Vol. 18. No. 5. Academic Press, 2008, Sica, Antonio, et al. al.Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages.J Immunol.2000 Jan 15;164(2):762-7, Cuccarese,Michael F.;Dubach,J.Matthew;Pfirschke,Christina;Engblom,Camilla;Garris,Christopher;Miller,Miles A.; Pittet, Mikael J.;Weissleder,Ralph(2017-02-08)”Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging”.Nature Communications.8:14293、Zeisberger,SM;Odermatt,B;Marty,C;Zehnder-Fjallman,AHM;Ballmer-Hofer,K;Schwendener,RA(2006-07-11)”Clodronate-liposome-mediated depletion of tumor-associated macrophages:a new and highly effective antiangiogenic therapy approach”.British Journal of Cancer.95(3):272-281 S.;Kohler,Rainer H.;Pittet,Mikael J.;Weissleder,Ralph(2018-05-21)”TLR7 / 8-agonist-loaded nanoparticles promote the polarization of tumor-associated macrophages to enhance cancer immunotherapy”.Nature Biomedical Engineering、Guerriero,Jennifer L.;Sotayo,Alaba;Ponichtera,Holly E.;Castrillon,Jessica A.;Pourzia,Alexandra L.;Schad,Sara;Johnson,Shawn F.;Carrasco,Ruben D.;Lazo,Suzan (March 2017).” Class IIa HDAC inhibition reduces breast tumors and metastases through anti-tumor macrophages”.Nature.543(7645):428-432.
[0216] In some embodiments, the cancer being treated is characterized by infiltration of leukocytes (T cells, B cells, macrophages, dendritic cells, monocytes) into the tumor microenvironment, or by the so-called "hot tumor" In some embodiments, the cancer being treated is characterized by low or undetectable levels of leukocyte infiltration into the tumor microenvironment, or a so-called "cold tumor" or "non-inflammatory tumor." In some embodiments, the composition is administered in an amount and for a time sufficient to convert a "cold tumor" to a "hot tumor," i.e., the administration results in the infiltration of leukocytes (such as T cells) into the tumor microenvironment.
[0217] In some embodiments, the compositions include extracellular vesicles and a combination of two or more immunomodulatory components, including a component that promotes macrophage polarization from an M2 phenotype to an M1 phenotype, and a component that additionally enhances the immune response, such as checkpoint blockade inhibitors, e.g., ipilimumab, which targets CTLA-4, nivolumab, cemiplimab, and pembrolizumab, which target PD-1, atezolizumab, avelumab, durvalumab, and pexidartinib, each of which targets PD-L1, inhibitors of CSFR-1, such as PLX7486, ARRY-382, JNJ-40346527, BLZ945, emactuzumab, AMG820, IMC-CS4, and cabilalizumab. Administration of these compositions as a treatment for a subject with cancer can further upregulate the immune response and enhance tumor targeting of the subject's immune system through the combined action of the immunomodulatory components.
[0218] In some embodiments, the additional immunomodulatory component is an antibody or active fragment that targets CTLA-4, PD-1, PD-L1, or CSF1-R. In embodiments, the antibody or active fragment comprises a CDR that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the CDRs of ipilimumab. In embodiments, the antibody or active fragment comprises a CDR that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the CDRs of nivolumab. In embodiments, the antibody or active fragment thereof comprises a CDR that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the CDR of cemiplimab. In embodiments, the antibody or active fragment thereof comprises a CDR that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the CDR of pembrolizumab. In embodiments, the antibody or active fragment thereof comprises a CDR that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the CDR of atezolizumab. In embodiments, the antibody or active fragment thereof comprises a CDR that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the CDRs of avelumab. In embodiments, the antibody or active fragment thereof comprises a CDR that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the CDRs of durvalumab. In embodiments, the antibody or active fragment thereof comprises a CDR that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the CDRs of pexidartinib. In embodiments, the antibody or active fragment thereof comprises CDRs that are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the CDRs of PLX7486.In embodiments, the antibody or active fragment thereof comprises a CDR that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the CDR of ARRY-382. In embodiments, the antibody or active fragment thereof comprises a CDR that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the CDR of JNJ-40346527. In embodiments, the antibody or active fragment thereof comprises a CDR that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the CDR of BLZ945. In embodiments, the antibody or active fragment thereof comprises a CDR that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the CDRs of emactuzumab. In embodiments, the antibody or active fragment thereof comprises a CDR that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the CDRs of AMG820. In embodiments, the antibody or active fragment thereof comprises a CDR that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the CDRs of IMC-CS4. In embodiments, the antibody or active fragment thereof comprises CDRs that are at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the CDRs of cabilalizumab.
[0219] In some embodiments, the composition comprising the extracellular vesicles and the immunomodulatory component is administered to the subject as a cancer vaccine. In some of these embodiments, the composition is administered to the subject as a personalized cancer vaccine. In some embodiments, the immunomodulatory component is a tumor antigen or a peptide derived from a tumor antigen. Examples of suitable tumor antigens include alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), epithelial tumor antigen (ETA), mucin 1 (MUC1), Tn-MUC1, mucin 16 (MUC16), tyrosinase, melanoma-associated antigen (MAGE), tumor protein p53 (p53), CD4, CD8, CD45, CD80, CD86, programmed death-ligand 1 (PD-L1), programmed death-ligand 2 (PD-L2), NY-ESO-1, PSMA, TAG-72, HER2, GD2, cMET, EGFR, mesothelin, VEGFR, alpha folate receptor, CE7R, IL-3, cancer testis antigen, MART-1 gp100, and TNF-related apoptosis-inducing ligand. In certain embodiments, the tumor antigen is derived from a reference genome sequence. In certain embodiments, the tumor antigen is derived from a genome sequence of the subject receiving the composition.
[0220] Cancers that may be treated with the compositions include, but are not limited to, those listed in Table 5.
[0221] Methods for regulating gene expression, transcriptional networks and polarization in macrophages Some embodiments provide a method of modulating gene expression in macrophages, comprising administering to a subject extracellular vesicles comprising one or more immunomodulatory components, wherein the immunomodulatory components are targeted to a gene, and the modulation is greater than or equal to the modulation produced by administration of an equimolar amount of free immunomodulatory components targeted to the gene. Also provided is a method of inhibiting gene expression in macrophages, comprising administering to a subject extracellular vesicles comprising one or more immunomodulatory components, wherein the immunomodulatory components are targeted to a gene, and the inhibition is greater than or equal to the inhibition produced by administration of an equimolar amount of free immunomodulatory components targeted to the gene. Some embodiments provide a method of suppressing downstream targets of a gene in macrophages, comprising administering to a subject extracellular vesicles comprising one or more immunomodulatory components, wherein the immunomodulatory components are targeted to a gene, and the inhibition is greater than or equal to the inhibition produced by administration of an equimolar amount of free immunomodulatory components targeted to the gene. Some embodiments provide a method of altering the polarization of a population of macrophages comprising administering to a subject extracellular vesicles comprising one or more immunomodulatory component(s), wherein the immunomodulatory component(s) are genetically targeted, and the alteration in polarization is greater than or equal to the alteration in polarization produced by administration of an equimolar amount of free genetically targeted immunomodulatory component. In some embodiments, the extracellular vesicles are exosomes. In some embodiments, the immunomodulatory component is an ASO. In some embodiments, the alteration in polarization is a change from an M2 phenotype to an M1 phenotype.
[0222] Methods of Treating Fibrotic Conditions Also provided herein is a method of treating a fibrotic condition in a subject in need thereof, comprising administering to a subject in need thereof an effective amount of a composition comprising an exosome comprising an immunomodulatory component that repolarizes macrophages from an M2 phenotype to an M1 phenotype. In some embodiments, the fibrotic condition is pulmonary fibrosis, liver fibrosis, or pancreatic fibrosis. In certain embodiments, the liver fibrosis is nonalcoholic steatohepatitis, or NASH. See, e.g., Mayo Clinic Staff. "Definition [of pulmonary fibrosis]." Mayo Foundation for Medical Education and Research. Archived from the original on 15 July 2014. Retrieved 26 July 2014. 2014, available from the world wide at webmayoclinic.org / diseases-conditions / pulmonary-fibrosis / symptoms-causes / syc-20353690, Ferri FF. Idiopathic pulmonary fibrosis. In: Ferri's Clinical Advisor 2016. Philadelphia, Pa.: Mosby Elsevier; 2016, Gross TJ, Hunninghake GW(2001)”Idiopathic pulmonary fibrosis”.N Engl J Med.345(7):517-525, Friedman LS(2014)Current medical diagnosis and treatment 2014.[Sl]:Mcgraw-Hill.pp.Chapter 16.Liver, Biliary Tract,& Pancreas Disorders, Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ (January 2018).”The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases”.Hepatology.67(1):328-357, Xue J, Sharma V, Hsieh MH, Chawla A, Murali R, Pandol. See SJ, Habtezion A. Nat Commun.2015 May 18;6:7158.
[0223] Mechanism of Administration In some embodiments, the composition is administered intravenously into the subject's circulatory system, hi some embodiments, the composition is injected into a suitable fluid and administered into the subject's vein.
[0224] In some embodiments, the composition is administered intra-arterially to the subject's circulatory system, hi some embodiments, the composition is injected into a suitable fluid and administered into the subject's artery.
[0225] In some embodiments, the composition is administered to the subject by intrathecal administration. In some embodiments, the composition is administered via injection into the spinal canal or subarachnoid space so that the composition reaches the cerebrospinal fluid (CSF).
[0226] In some embodiments, the composition is administered to the subject by intranasal administration. In some embodiments, the composition can be inhaled through the nose, either in the form of local administration or systemic administration. In certain embodiments, the composition is administered as a nasal spray.
[0227] In some embodiments, the composition is administered to the subject by intraperitoneal administration. In some embodiments, the composition is injected into a suitable liquid and administered into the subject's peritoneum. In some embodiments, the intraperitoneal administration results in distribution of the composition (e.g., extracellular vesicles in the composition) to lymphatic vessels. In some embodiments, the intraperitoneal administration results in distribution of the composition (e.g., extracellular vesicles in the composition) to the thymus, spleen, and / or bone marrow. In some embodiments, the intraperitoneal administration results in distribution of the composition (e.g., extracellular vesicles in the composition) to one or more lymph nodes. In some embodiments, the intraperitoneal administration results in distribution of the composition (e.g., extracellular vesicles in the composition) to one or more of the following: cervical lymph nodes, inguinal lymph nodes, mediastinal lymph nodes, sternal lymph nodes. In some embodiments, the intraperitoneal administration results in distribution of the composition (e.g., extracellular vesicles in the composition) to the pancreas.
[0228] In some embodiments, the composition is administered to the subject by peribulbar administration. In some embodiments, the composition is injected into the peribulbar tissue. Peribulbar drug administration includes subconjunctival, anterior sub-Tenon, posterior sub-Tenon, and retrobulbar routes of administration.
[0229] In some embodiments, the composition is administered to the same subject by multiple routes of administration. In some embodiments, the multiple routes of administration include intravenous administration, intraarterial administration, intrathecal administration, intranasal administration, intraperitoneal administration, and / or periocular administration. In a preferred embodiment, the multiple routes of administration include intravenous administration and intraperitoneal administration.
[0230] In certain embodiments, the dosage of extracellular vesicles is between 1 ng and 10 ng, 10 ng and 100 ng, 100 ng and 1 μg, 1 μg and 5 μg, 5 μg and 10 μg, 10 μg and 50 μg, 50 μg and 75 μg, 75 μg and 100 μg, 100 μg and 150 μg, 150 μg and 200 μg, 200 μg and 300 μg, 300 μg and 500 μg, 500 μg and 1 mg, or 1 mg and 10 mg.
[0231] The composition may be administered once to the subject. Alternatively, multiple administrations may be performed over a period of time. For example, 2, 3, 4, 5, or more administrations may be given to the subject. In some embodiments, administration may be given as needed, for example, for symptoms related to a disease, disorder, or condition. In some embodiments, repeated administration may be indicated throughout the life of the subject. The duration of treatment may vary, for example, within 1 year, 6 months, 3 months, 2 months, 1 month, 2 weeks, 1 week, 3 days, 2 days, or within 1 day.
[0232] In certain embodiments, doses of extracellular vesicles are administered at intervals such as once daily, every other day, once weekly, twice weekly, once monthly, or twice monthly.
[0233] In some embodiments, the pharmaceutical compositions are administered frequently enough to effectively increase the concentration of the immunomodulatory component in the target cell or tissue above levels associated with the symptoms of a disease, disorder, or condition.
[0234] In some embodiments, the composition is administered at least twice over a treatment period such that the disease, disorder, or condition is treated or its symptoms are improved. In some embodiments, the composition is administered at least twice over a treatment period such that the disease, disorder, or condition is treated or its symptoms are prevented. In some embodiments, the pharmaceutical composition is administered a sufficient number of times over a treatment period such that a sufficient amount of the immunomodulatory component is delivered to a target cell or tissue during the treatment period. In some embodiments, the pharmaceutical composition is administered a sufficient number of times over a treatment period such that a sufficient amount of the immunomodulatory component is delivered to a target cell or tissue during the treatment period such that one or more symptoms of the disease, disorder, or condition are prevented, reduced, ameliorated, or delayed. In some embodiments, increasing the concentration of the immunomodulatory component in a target cell or tissue includes increasing the peak concentration, while in other embodiments, it includes increasing the average concentration. In some embodiments, a substantial increase during a treatment period can be determined by comparing pre-treatment or post-treatment periods in a subject, or by comparing measurements made in a treated population to a corresponding untreated control population.
[0235] In some embodiments, the pharmaceutical composition is administered a sufficient number of times per treatment period such that the concentration of the immunomodulatory component in the target cell or tissue is increased for at least about 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, or 6 months or more. In some embodiments, the pharmaceutical composition is administered a sufficient number of times per treatment period such that the concentration of the immunomodulatory component in the target cell or tissue is increased for at least the treatment period.
[0236] In some embodiments, the time interval between repeated administrations within a treatment period is equal to or less than the period during which the number of extracellular vesicles in circulation falls to less than about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the number of extracellular vesicles present in the administered pharmaceutical composition.
[0237] In some embodiments, the method of treatment further comprises one or more doses of non-therapeutic extracellular vesicles prior to injection of a suitable therapeutic dose of extracellular vesicles carrying a therapeutic agent. In certain embodiments, the non-therapeutic extracellular vesicles are administered separately from the therapeutic extracellular vesicles at different dosages. In certain embodiments, the dosage of the non-therapeutic extracellular vesicles is greater than the dosage of the therapeutic extracellular vesicles. In certain other embodiments, the dosage of the non-therapeutic extracellular vesicles is less than the dosage of the therapeutic extracellular vesicles. In certain embodiments, the dosage of the non-therapeutic extracellular vesicles is the same as the therapeutic extracellular vesicles. In various embodiments, the method of non-therapeutic extracellular vesicles prior to injection of a suitable dose of therapeutic extracellular vesicles reduces renewal of the therapeutic extracellular vesicles in the liver, lungs, and / or spleen. See commonly owned PCT application PCT / US2017 / 047794, which is incorporated herein by reference for all purposes.
[0238] An effective amount of the composition is provided based, at least in part, on the target tissue, the target cell type, the means of administration, the physical characteristics of the extracellular vesicles (e.g., size and, in some cases, the extent of the molecules being delivered), and other determinants. In general, an effective amount of the composition provides an efficient cellular response of the target cells. Increased efficiency can be demonstrated by increased cell transfection (i.e., the percentage of cells transfected with the extracellular vesicle components), increased cellular response, or reduced innate immune response of the host subject.
[0239] The dose and frequency of administration of the extracellular vesicles and pharmaceutical compositions thereof can be determined by the attending physician based on various factors, such as the severity of the disease, the age, sex and diet of the patient, the severity of any inflammation, the administration time and other clinical factors.In an example, intravenous administration is initiated at a dose that is minimally effective, and the dose is increased over a preselected time course until a positive effect is observed.Then, the dose escalation is limited to a level that produces a corresponding increase in effect, while taking into account any adverse effects that may appear.
[0240] Additional Embodiments Other aspects and embodiments are provided in the numbered items below. 1. Extracellular vesicles comprising one or more nucleic acid molecules that inhibit at least one gene, thereby increasing macrophage polarization from an M2 to an M1 phenotype. 2. The extracellular vesicle of embodiment 1, wherein the extracellular vesicle is an exosome. 3. The extracellular vesicle of embodiment 1 or 2, wherein the nucleic acid is an inhibitory RNA. 4. An extracellular vesicle described in any one of embodiments 1 to 3, wherein the inhibitory RNA is an antisense RNA, an siRNA, an ShRNA, an miRNA, an lncRNA or a pre-miRNA. 5. The extracellular vesicles of any one of embodiments 1 to 4, wherein at least one gene is selected from the group consisting of: KRAS, HRAS, NRAS, HIF1-alpha, HIF1-beta, Sp1, P300, LKB1, AMPK, STAT3, STAT6, n-MYC, and c-MYC, HCAR1, A2AB, IDO, TDO, arginase, glutaminase, and PKM2. 6. The extracellular vesicle of embodiment 5, wherein the gene is KRAS. 7. The extracellular vesicle of embodiment 6, wherein the nucleic acid is an inhibitory RNA targeting wild-type human KRAS. 8. Inhibitory RNA inhibits mouse Kras G12D The extracellular vesicle of embodiment 7, which also targets 9. An extracellular vesicle described in any one of embodiments 1 to 8, wherein the macrophage is a tumor-resident macrophage. 10. The extracellular vesicle described in embodiment 9, wherein the tumor is a pancreatic tumor. 11. An extracellular vesicle described in any one of embodiments 1 to 10, further comprising an additional immunomodulatory component. 12. The extracellular vesicle of embodiment 11, wherein the additional immunomodulatory component is a small molecule drug, an antibody or a therapeutic protein. 13. The extracellular vesicle according to embodiment 12, wherein the antibody is an immune checkpoint inhibitor. 14. A pharmaceutical composition comprising the extracellular vesicle according to any one of embodiments 1 to 13. 15. A method for treating a disease in a patient in need thereof, comprising administering to the patient an extracellular vesicle described in any one of embodiments 1 to 13 or a pharmaceutical composition described in embodiment 14, thereby treating the disease in the patient. 16. The method of embodiment 15, wherein the disease is cancer. 17. The method of embodiment 15 or 16, wherein the patient is a human. 18. The method of any one of embodiments 1 to 17, wherein the nucleic acid is an inhibitory RNA targeting a proto-oncogene. 19. The method of embodiment 18, wherein the proto-oncogene is human KRAS. 20. The method of embodiment 19, wherein the cancer is pancreatic cancer. 21. The method of any one of embodiments 15 to 20, further comprising administering at least a second therapy. 22. The method of embodiment 21, wherein the second therapy comprises surgical therapy, chemotherapy, radiation therapy, cryotherapy, hormone therapy, or immunotherapy. 23. Extracellular vesicles according to any one of the above embodiments, wherein the M2 macrophage is a tumor-associated macrophage selected from the group consisting of M2a, M2b, and M2c macrophages. 24. Extracellular vesicles according to any one of the preceding embodiments, wherein M1 macrophages exhibit increased secretion of inflammatory cytokines and chemokines selected from the group consisting of INFγ, IL-12, IL-23, TNFα, IL-6, IL-1, CSCL9, CXCL10 and CXCL11 compared to pre-polarized M2 macrophages. 25. Extracellular vesicles according to any one of the preceding embodiments, wherein M1 macrophages exhibit reduced secretion of immunosuppressive cytokines and chemokines selected from the group consisting of IL-10, TGFβ, PGE2, CCL2, CCL17, CCL18, CCL22 and CCL24 compared to pre-polarized M2 macrophages. 26. Extracellular vesicles according to any one of the above embodiments, wherein M1 macrophages express increased tumor-associated antigens compared to M2 macrophages prior to polarization. 27. M1 macrophages express more CD8 than M2 macrophages before polarization. + The extracellular vesicle according to any one of the above embodiments, which increases stimulation of T cells and / or natural killer cells. 28. A method of treating pancreatic cancer in a subject, comprising administering to the subject extracellular vesicles comprising inhibitory RNA targeting human wild-type KRAS, wherein the treatment increases the rate of polarization of tumor-resident macrophages from an M2 phenotype to an M1 phenotype by increasing the percentage of tumor-resident macrophages that are polarized to an M1 phenotype by increasing the percentage of tumor-resident macrophages that are polarized to an M1 phenotype by increasing the percentage of tumor-resident macrophages that are polarized to an M2 phenotype by increasing the percentage of tumor-resident macrophages that are polarized to an M1 ...2 phen G12D to levels higher than those observed in patients treated with an inhibitory RNA targeting the gene. EXAMPLES
[0241] Working Example The following examples are presented to provide those skilled in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention, nor are they intended to represent the following experiments as all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.), but some experimental error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric pressure. Standard abbreviations may be used, such as bp, base pair(s); kb, kilobase(s); pl, picoliter(s); s or sec, second(s); min, minute(s); h or hr, hour(s); aa, amino acid(s); nt, nucleotide, etc.
[0242] The practice of the present invention employs, unless otherwise indicated, conventional methods of protein chemistry, biochemistry, recombinant DNA technology, and pharmacology within the skill of the art. Such techniques are fully explained in the literature. See, for example, TECreighton, Proteins: Structures and Molecular Properties (WH Freeman and Company, 1993); ALLehninger, Biochemistry (Worth Publishers, Inc., current addition); Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); Remington's Pharmaceutical Sciences, 21st Edition (Easton, Pennsylvania: Mack Publishing Company, 2005); Carey and Sundberg Advanced Organic Chemistry 3rd Ed. (Plenum Press) Vols A and B (1992).
[0243] Example 1: Knockdown of transcription factors in M2 macrophages method: Monocyte isolation from PBMCs: Obtained 50ml of Buffy Coat 15ml of Ficoll was pipetted into a 50ml STEMCELL SepMate tube The buffy coat was diluted in PBS 2mM EDTA to a final volume of approximately 250 mL. The diluted buffy coat sample was poured into a Sepmate tube until the final volume of the tube was approximately 45-50 ml. The tubes were centrifuged at 1000g for 15 minutes with brake set to 1. Plasma was aspirated from the spun tube and the buffy coat layer was collected using a pipetaid into a 50ml conical tube. The tube was filled with PBS / EDTA and centrifuged at 500g for 3 minutes to pellet the cells. If red blood cells were predominantly present, the cells were resuspended in 10 ml of ACK lysis buffer (ThermoFisher, Cat. No. A1049201) and incubated at room temperature for 3 min (manufacturer's protocol). The tube was filled with PBS / EDTA and centrifuged at 500 g for 3 min. The tube was spun down at 400xg for 5 minutes and the pellet was washed once more with PBS EDTA and repelleted. The pellet was resuspended in RoboSep buffer (STEMCELL, Cat. No. 20104) and cells were counted using a 1:1 dilution with Trypan Blue (Thermofisher) (approximately 500 million PBMCs were obtained from one buffy coat) CD14+ monocytes were isolated using the EasySep Human Monocyte Enrichment Kit (STEMCELL, Cat. No. 19059RF) according to the manufacturer's protocol (approximately 10% of total cells were isolated as monocytes). Five million monocytes were seeded onto one plate in RPMI 10% FBS 1% anti-antibody + 40ng / ml M-CSF Macrophage Differentiation and Polarization: (Adapted from https: / / www.atsjournals.org / doi / full / 10.1165 / rcmb.2015-0012OC) Seeded cells were cultured in RPMI-1640 10% FBS 1% anti-antibody 1% PenStrep + 40ng / ml M-CSF (Biolegend) for 5-6 days at 37°C with 5% CO2. 5ml of the same fresh medium was added on days 1 and 3 after seeding. On day 5, polarizing cytokines were added as follows (40ng / ml M-CSF, all cytokines added at 20ng / ml): M0: No cytokines M2a:IL-4 M2c:IL-10 M2++: Il4, Il10, TGFb M1: IFN-g + LPS (100ng / ml) · TAM:75%Panc-1 supernatant Cells were incubated with cytokines for 24 hours. On day 6, aspirate the medium and wash the cells with PBS, then resuspend the cells in 10 ml of PBS 5 mM EDTA (ice cold) was added per plate and incubated at 4° C. for 30 minutes. · Cells were gently scraped off the plates and counted. · 50,000 cells per well were then seeded into 96-well plates in RPMI-1640 10% FBS 1% anti-1% PenStrep + 40ng / ml M-CSF (Biolegend) with the respective cytokines for the different macrophage populations (see above) for 24 hours, after which treatment was initiated.
[0244] Exosome purification: Exosomes were harvested from the supernatant of high-density suspension cultures of HEK293 SF cells after 9 days. The supernatant was filtered, fractionated by anion exchange chromatography, and eluted with a step gradient of sodium chloride. The peak fraction with the highest protein concentration contained exosomes and contaminating cellular components. The peak fraction was isolated and further fractionated on an Optiprep™ (60% iodixanol w / v) density gradient by ultracentrifugation.
[0245] The exosome fraction was concentrated by ultracentrifugation in a 38.5 mL Ultra-Clear (344058) tube for a SW 32 Ti rotor at 133,900xg for 3 hours at 4°C. The pelleted material was resuspended in 1 mL PBS and 3 mL Optiprep™ to a final iodixanol concentration of 45%. For the Optiprep™ gradient, a 4-layer sterile gradient was prepared in a 12 mL Ultra-Clear (344059) tube for a SW 41 Ti rotor with 4 mL of 45% iodixanol, 3 mL of 30% iodixanol, 2 mL of 22.5% iodixanol, 2 mL of 17.5% iodixanol, and 1 mL of PBS containing the resuspended material. The Optiprep™ was ultracentrifuged at 150,000xg for 16 hours at 4°C to separate the exosome fraction. Ultracentrifugation yielded a top fraction known to contain exosomes, a middle fraction containing medium density cellular debris, and a bottom fraction containing high density aggregates and cellular debris. The exosome layer was then gently collected from the top approximately 3mL of the tube.
[0246] The exosome fraction was diluted into approximately 32 mL of PBS in a 38.5 mL Ultra-Clear (344058) tube and ultracentrifuged at 133,900×g for 3 hours at 4° C. to pellet the purified exosomes. The pelleted exosomes were then resuspended in a minimal amount of PBS (approximately 200 μL) and stored at 4° C.
[0247] Many solid tumors are characterized by myeloid-rich cellular infiltrates that often contain tumor-associated macrophages that are characterized as having an alternatively activated, or M2, phenotype. M2 macrophages express high levels of phosphorylated STAT3 and STAT6, which promote the expression of the metabolic enzyme arginase (Arg1). To demonstrate that knockdown of key M2 genes alters the M2 phenotype of in vitro differentiated macrophages, murine RAW264.7 macrophages were polarized to an M2 state as described above. Cultured polarized macrophages were transfected with increasing amounts of siRNA targeting STAT3, STAT6, CEBPβ-1, CEBPβ-2, Pi3Kγ, or KRAS (12.5 nM, 25 nM, 50 nM, and 100 nM). Each of the genes was repressed in a dose-dependent manner (Fig. 1 ), and knockdown of each M2 gene led to a concomitant reduction in Arg1 (Fig. 2 ), demonstrating that the M2 phenotype can be altered by reducing expression of upstream regulators.
[0248] Example 2: Differential exosome uptake by macrophage subtypes Macrophage subtypes are characterized by altered metabolism and other phenotypic activities. To understand whether certain macrophage subtypes preferentially take up exosomes, six macrophage subpopulations (M0, M1, M2a, M2c, M2++, and TAM) were incubated with increasing levels of exosomes from HEK293SF engineered to express lumenal GFP. Exosome uptake was determined by measuring total cell GFP intensity over 36 hours in an IncuCyte® live cell analysis system (Essen Bioscience). As shown in Figure 3, all macrophage subtypes showed exosome uptake, but M0 macrophages were the least efficient at taking up exosomes, while M2++ macrophages were substantially more efficient at taking up exosomes compared to other macrophage subtypes.
[0249] Since M2 macrophages are efficient at taking up exosomes, we investigated whether ASO-loaded exosomes would be more efficient at targeting intracellular macrophage targets than ASOs alone (e.g., more efficient at knocking down the expression of target genes and downstream effector molecules in the gene's signaling pathway). 2'-Methoxyethyl (MOE) single-stranded DNA / RNA ASOs targeting STAT3 and carrying a Cy5 fluorescent tracer and a 5' cholesterol linker were generated. HEK293SF exosomes were mixed with cholesterol-tagged fluorescent ASOs, and free ASOs were removed by ultracentrifugation and removal of the supernatant containing the ASOs. M2 and M0 macrophages were seeded at equivalent densities and incubated with matched concentrations of free ASOs or ASO-loaded exosomes (Exo-ASOs), measured by total fluorescence intensity. Total cell fluorescence was measured over 48 hours and quantified using an IncuCyte® Live Cell Analysis System. As shown in Figure 4, M2 macrophages took up both free ASOs and Exo-ASOs more readily compared to M0 macrophages. Interestingly, Exo-ASOs were taken up more efficiently by both M0 and M2 macrophages, suggesting that delivery of ASOs to M2 macrophages may be enhanced by exosomal loading.
[0250] To determine whether exosomes or Exo-ASOs are differentially taken up by macrophages compared to other cell types in vivo, naïve mice were injected with 1x10 11 or 1x10 12GFP-containing exosomes were administered intraperitoneally. One hour after injection, total peritoneal cells were isolated and GFP positivity among different immune cell subsets, i.e., B cells, dendritic cells, neutrophils, natural killer (NK) cells, T cells, and macrophages, was characterized by flow cytometry. As shown in Figure 5A, at both doses, macrophages were the predominant cell type taking up fluorescent exosomes. To determine whether this difference occurred in a disease setting, B16F10 tumor-bearing mice were injected with a single dose of Cy5-labeled Exo-ASO or native unlabeled exosomes. Injected tumors were isolated, dissociated, and measured by flow cytometry. As shown in Figure 5B, macrophages took up Exo-ASO much more readily than tumor cells (approximately 100-fold greater than the overall Cy5 signal), suggesting that Exo-ASO delivery can reach macrophage populations in some complex cell mixtures. Furthermore, the preferential uptake of Exo-ASOs by macrophages, compared to other tested cell types (B cells, dendritic cells, neutrophils, natural killer (NK) cells, and T cells), allows for a method of targeted ASO delivery to macrophage cells, comprising administering an Exo-ASO composition to a subject, such that the administered composition is preferentially taken up by macrophages present in the subject (compared to uptake by other immune cell subsets, e.g., B cells, dendritic cells, neutrophils, natural killer (NK) cells, and T cells). This enhanced macrophage specificity of Exo-ASO compositions improves the safety of the administered composition by reducing effects on off-target cells.
[0251] Example 3: Exosome-mediated delivery of antisense oligos potently dysregulates macrophage transcriptional networks and alters polarization Previous experiments suggest that exosome-mediated delivery of ASOs may be an effective way to alter macrophage gene expression patterns. HEK293SF-derived exosomes purified according to the methods described above were loaded with five different cholesterol-tagged ASOs targeting STAT3 (4.1, double-stranded MOE chemistry; 5.1 and 5.2, single-stranded O-methyl chemistry; 5.3 and 5.4, single-stranded MOE chemistry). ASO sequences are shown in Table 0. M2-polarized mouse RAW264.7 cells were cultured with 5 μM free cholesterol-tagged ASO, or 1 × 10 ASOs loaded with cholesterol-tagged ASO. 5 Or 1×10 6 The cells were incubated with either exosomes or free ASOs. STAT3 transcript levels were measured 24 hours after treatment, revealing comparable or superior knockdown of STAT3 by Exo-ASO treatment compared to free ASO. Unmodified exosomes incubated with polarized macrophages did not affect STAT3 expression (Figure 6). To examine downstream targets of STAT3, ARG1 transcript levels were measured 48 hours after treatment. As shown in Figure 7, STAT3 knockdown using free or Exo-ASOs resulted in robust suppression of Arg1, in some cases more than 90% (Figure 7). M2-polarized RAW264.7 cells were incubated with high (4 μM) and low (0.4 μM) ASOs or Exo-ASOs against STAT3, KRAS, and C / EBPβ. As shown in Figures 8A-C, the Exo-ASO samples were equally (STAT3) or more potent (KRAS, C / EBPβ) at all doses tested (Figures 8A-C). The ASO sequences are shown in Table 0.
[0252] This result demonstrates that Exo-ASO is a strong regulator of macrophage expression network and can provide a superior differentiation modality compared to administration of free ASO for various therapeutic applications.One such method of regulating gene expression in macrophages comprises administering Exo-ASO to a subject, the ASO is targeted to a gene, and the regulation is equal to or greater than the regulation produced by administration of an equimolar amount of free ASO targeted to the gene.Another embodiment comprises a method of inhibiting gene expression in macrophages, the ASO is targeted to a gene, and the inhibition is equal to or greater than the inhibition produced by administration of an equimolar amount of free ASO targeted to the gene.Another embodiment comprises a method of suppressing downstream targets of a gene in macrophages, the ASO is targeted to a subject, and the inhibition is equal to or greater than the inhibition produced by administration of an equimolar amount of free ASO targeted to the gene. Yet another embodiment includes a method of altering the polarization of a population of macrophages comprising administering to a subject an Exo-ASO, wherein the ASO is targeted to gene expression in the macrophages, and the alteration in polarization is equal to or greater than the alteration in polarization produced by administration of an equimolar amount of free gene-targeted ASO. In such an embodiment, the alteration in polarization can be a change from an M2 phenotype to an M1 phenotype.
[0253] To test the role of Exo-ASO in human cells, primary human macrophages were polarized to the M2 phenotype and treated with different doses of free STAT3 ASO or STAT3 Exo-ASO. Using macrophages from three separate human donors, Exo-ASO was consistently more potent in suppressing STAT3 transcript levels 24 hours after treatment (Figure 9A). CD163, a downstream human marker of M2 polarization, was also dramatically more regulated by Exo-ASO compared to free ASO (Figure 9B). Human M2 macrophages were also treated with 4 μM free ASO or Exo-ASO against HIF1α, Pi3Kγ, CEBP / β, STAT6, and STAT3. As shown in Figure 10, all treatment groups resulted in suppression of target genes, but in all cases Exo-ASO was more potent than free ASO treatment. Importantly, Exo-ASO knockdown of both macrophage targets resulted in a robust reduction in CD163 expression (Figure 11), demonstrating that exosome-mediated delivery of ASOs potently and reproducibly disrupts key macrophage signaling networks.
[0254] The functional outcome of M2 macrophage polarization is a reduction in proinflammatory cytokines that contribute to a protumorigenic microenvironment. Thus, conversion of macrophages from an M2 to an M1 phenotype should result in enhanced proinflammatory signaling. Conversion of M2 macrophages to an M1 state is induced by LPS, which results in the induction of cytokines including IL-12 and IL-23. STAT3 is a negative regulator of this cytokine expression network, and therefore we tested whether STAT3 inhibition in the presence of LPS could further enhance the production of proinflammatory cytokines. M2-polarized human macrophages were treated with 4 μM free STAT3 ASO, 4 μM STAT3 Exo-ASO, 4 μM scrambled Exo-ASO, native exosomes, or C188-9, a small molecule inhibitor of STAT3. After 24 h, the medium was replaced with medium containing 10 ng / ml LPS, and the supernatant was isolated 24 h later. As shown in Figure 12, LPS induced the secretion of IL-12 and IL-23 (LPS 10 ng / ml group vs. no LPS group). Treatment with STAT3 Exo-ASO but not free STAT3 ASO further enhanced the expression of each cytokine, suggesting that Exo-ASO may more potently promote the M1 phenotype in response to relevant immunoregulatory signals.
[0255] Dysregulation of STAT3, STAT6, and other macrophage regulatory pathways results in widespread changes in gene expression patterns. To understand the differentiated global effects of Exo-ASO treatment, NanoString mRNA analysis was performed on human M2 macrophages at steady state and in response to treatment with unmodified exosomes (EV only) and concentration-matched ASO and Exo-ASO. Normalized mRNA counting using the nCounter® Human Myeloid Innate Immune Panel demonstrated that STAT3 transcripts were reduced after both free ASO and Exo-ASO treatment (Figure 13A). Downstream markers CD163 (Figure 13D), TGFβ (Figure 13C), and STAT6 (Figure 13D) were all strongly downregulated after ASO treatment.
[0256] Robust suppression of TGFβ (<85%) is a key regulator of M2 macrophage polarization (Yang and Zhang Journal of Hematology & ... Oncology (2017) 10:58). The impact of STAT3, STAT6, and CEBP / β Exo-ASO treatment on TGFβ expression was examined. Human M2-polarized macrophages were treated with exosomes loaded with ASOs against STAT3 (both MOE and LNA chemistry), STAT6 (MOE chemistry), and CEBP / β (MOE chemistry). In all cases, TGFβ levels were dramatically reduced after treatment with submicromolar levels of ASO (Figure 14). These results demonstrate that exosome-mediated delivery of ASOs against multiple macrophage polarization regulators can result in robust and stable dysregulation of cellular programs that may have therapeutic implications for multiple cancers. Importantly, each of the macrophage targets, including the novel recognition of KRAS as a regulator of this process, are well recognized for their role in disease and other cellular processes, yet have been characterized as "undruggable" targets, in that safe and effective treatments have eluded classical approaches to drug discovery.
[0257] Example 4: Inhibition of wild-type KRAS results in increased macrophage polarization and reduced tumor size in vivo in an orthotopic mouse model of pancreatic cancer. method: Production and isolation of KRAS exosomes: Electroporation methods are used to insert KRAS siRNA constructs into exosomes without functionally damaging the exosomes. Exosomes are isolated from human embryonic kidney (HEK) 293SF suspension cells grown in chemically defined medium using established ultracentrifugation methods (Kahlert et al., 2014). Exosome purity and homogeneity (particles 80-150 nm in diameter) are verified by Nanosight™ measurements, transmission electron microscopy, and CD9 immunogold labeling. Sucrose gradient ultracentrifugation and qPCR are also used to identify KRAS exosomes. A test was performed to verify the presence and abundance of siRNA. Scrambled siRNA containing exosomes were also generated.
[0258] RNAi strategy. The KRAS siRNA sequence targeted against mouse wild-type KRAS contains TT nucleotide overhangs to promote silencing efficiency. The RNAi is also labeled with Alexa Fluor® 647 fluorophore at the 3' end of the sense strand to track its delivery.
[0259] Mice and imaging methods. Female athymic nu / nu mice (Charles Rivers), 4-6 weeks of age, are housed in individually ventilated cages with a 12-h light / dark cycle at 21-23 °C and 40%-60% humidity. Mice are allowed free access to irradiated food and sterile water. Under general anesthesia, tumorigenic human pancreatic PANC-1 (Kras asp12 (Rejiba et al., 2007; Sun et al., 2001)) cells or BXPC-3 cells (10 6 , resuspended in 10 μl of PBS) are injected into the tail of the pancreas using a 27-gauge syringe. For orthotopic tumor size / volume analysis, Living Image version 4.4 (Caliper Life Sciences) is used to quantify all tumor measurements. A circular region of interest (ROI) around the pancreas and tumor is defined and set as a standard to compare all images within the same experimental group. In addition, exposure conditions (time, aperture, stage position, binning) are kept identical for all measurements in all experimental groups. Subsequent tumor measurements (p / sec / cm) are then recorded. 2 / sr) are obtained under the same conditions for all experimental groups. Mice are imaged periodically and randomly divided into groups for treatment. Mice are injected intraperitoneally with 2 × 10 8 Exosomes are electroporated with 2 μg of siRNA and washed with PBS prior to injection.
[0260] Histology, histopathology, and immunohistochemistry. Tissues are fixed in formalin and processed for paraffin embedding. 5 μm thick tissue sections are cut and stained for hematoxylin and eosin (H&E) and Masson's trichrome (MTS) (Leica). For histopathological scoring, H&E stained slides were scored based on the morphological stage of pancreatic cancer: normal, pancreatic intraepithelial neoplasia (PaNIN) and pancreatic ductal adenocarcinoma (PDAC). For each tissue section, the percentage scores of each of the three stages (normal, PaNIN, PDAC) were obtained manually in a blinded manner by an expert in pancreatic histology and then averaged to give an overall score out of 100 for each cohort. The average of these percentage scores is then taken for each mouse in each cohort. Tumor tissue sections will also be stained for macrophages (pan-macrophage markers such as F4 / 80 antibody and / or M2 and M1 specific cell markers for detection of tumor-resident macrophages).
[0261] Assay for macrophage phenotype characterization. Blood and tumor samples are collected from mice. Macrophages are isolated and stained for analysis of M1 and M2 markers by flow cytometry. Macrophages are stained for pan-macrophage markers as well as M2 phenotype cell surface markers (e.g., YM1, FIZZ1, Dectin-1, and / or MGL) and M1 phenotype cell surface markers. M2 and M1 macrophages are then counted and selected for further analysis such as quantitative PCR to detect cytokines and / or miRNA expression of miRNAs associated with either M1 and / or M2 phenotypes.
[0262] Results from xenograft experiments and orthotopic tumor volume analysis confirmed that exosomes containing KRAS wild-type siRNA effectively reduced the size of pancreatic tumors and increased the number of M1 phenotype tumor-associated macrophages compared with exosomes carrying scrambled siRNA, indicating that administration of exosomes containing inhibitory RNA targeting human wild-type KRAS is effective in treating cancer. surface
Table 0
Table 1-1
Table 1-2
Table 2-1
Table 2-2
Table 2-3
Table 2-4
Table 2-5
Table 2-6
Table 2-7
Table 2-8
Table 2-9
Table 2-10
Table 2-11
Table 2-12
Table 2-13
Table 2-14
Table 2-15
Table 2-16
Table 2-17
Table 2-18
Table 3-1
Table 3-2
Table 3-3
Table 3-4
Table 3-5
Table 3-6
Table 3-7
Table 4-1
Table 4-2
Table 4-3
Table 5-1
Table 5-2
Table 5-3
[0263] The present invention has been described with respect to representative examples which are considered exemplary embodiments, not limiting the scope of the invention, which is defined solely by the claims. All references to publications, including scientific publications, treatises, textbooks, patent applications, and issued patents, are incorporated herein by reference for all purposes.
Claims
[Claim 1] The invention described in the specification.
